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1. INTRODUCTION 
  
 Special-needs children is a wall to wall term those who have both physical and mental 
disabilities caused by neuronal damage. The percentage of disabled children in developing 
countries is generally higher than in developed countries, it is estimated that 6 to 10% of 
children in India are born disabled. Developmental disabilities are some of our intent to 
develop a series of items that would reflect both positive and negative parent appraisals. The 
most common developmental disorder is Mental retardation, cerebral palsy, Autism spectrum 
disorder etc. Although there are many physical disabilities in children, but Autism are most 
common mental disabilities in childhood with unknown aetiology nowadays.  
  The Word Autism comes from the Greek word ―Autos‖ which means self. It 
describes condition in which a person removed from social interaction. In other words, he 
becomes an ―isolated self‖. Eugen Bleuler, a swiss psychiatrist was the first person to use this 
term. Autism spectrum disorder is a group of complex neurodevelopmental disorders 
characterized by repetitive and characteristics patterns of behaviour and difficulties with 
social communication and interaction
 [1]
.  
 The latest analysis from the centres for Disease control and prevention estimate that 1 
in 68 has ASD. The Early signs of ASD can be seen by above 18 months after birth. The 
prevalence of autism is on the alarming rise, with some studies suggesting the increase of 
10% to 17% annually in the last several years.  Also, autism is far more likely to affect boys 
than girls, a fact that is still unexplained. In the all over the world, it is believed that    1 in 42 
boys and 1 in 189 girls are suffering from it .This surveillance study identified 1 in 68 
children. That represents a tenfold rise in the past 40 years. In India, more than 10 million 
children suffer from autism. We found about 1 to 1.5 % autistic children  between ages 2-9 
years says Dr. N.K. Arora, Executive director of the international clinical epidemiology 
network trust which led the study. That means the prevalence rate is 23 children of every 
10,000 children in India
. 
In Tamil nadu, the prevalence rate is 1:116 and in Chennai, that is 
1:100
[2]
. 
  
  Presently, Supportive therapies for training the children with ASD like occupational 
therapy, Behavioural therapy, Speech therapy, Psychotherapy etc. are being used certain 
medication like Antipsychotic drugs are also used in severe condition, till now its quite 
challenge to manage the children with ASD existing therapy.  At this juncture, our Siddha 
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management procedures (Internal and external) would be an invaluable service to this 
children In India, Siddha system of medicine owes its origin to medicinal ideas and practices 
of a class of Tamil sages. In the Siddha system of medicine, herbs, minerals, metals and salts 
all have been used for paediatric population. Siddha system of medicine includes Mind–body 
interventions, Biological based therapies such as drug formulations and diets, Manipulative 
and body based methods such as thuvalai and pugai. 
   In our siddha paediatric text, the definition for ஫ந்தம் & சன்னி respectively ஫ந்தம் 
என்பது அருவ நிலய஬ில் அகக்கருவி஬ாகி஬ ஫னம், புத்தி, அகங்கா஭ம், சித்ததிலும் 
஫ந்தம் & சன்னி என்பது அமிவு கயக்கம், வாய் பிதற்மல், இலை விைா஫ல் அயறுதல்.  
The symptoms of ஫ந்த சன்னி are nearly correlated with Autism Spectrum Disorder 
 (ASD)
 [3]
. 
 Thus the aim and objectives of the present study were to test the efficacy of the 
Siddha medicines/methodologies in ASD children. In order to the drugs chosen for the 
project included Kuruver Kudineer  as internal medicine
[4]
, Sambrani Thuvalai for thuvalai
[5] 
and Mysatchi Pugai
[3]
 for fumigation therapy as external, all of which have been used in the 
Siddha system of medicine for many centuries either singly or in various combination. All the 
ingredients in both Internal and External medicines are herbal. Hence we have choosen the 
Siddha management therapy and it showed safe and efficacies in treating ASD children. 
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2. AIM AND OBJECTIVES 
 
2. Aim 
 To evaluate the Siddha therapeutic management and to analyse the clinical            
 assessment of Mantha sanni (Autism Spectrum Disorder) with Experimental 
 formulations and procedures 
 
2.1. Primary objectives 
 To calibrate the resemblance and the equivalence of Mantha Sanni with Autism 
Spectrum Disorder 
 To explore the siddha therapeutic management in Autism children 
 
2.2Secondary objectives  
 To evaluate the physicochemical, biochemical analysis and pharmacological activities 
of the trail drug 
 To Collect authentic measures and review the ideas mentioned in the ancient siddha 
literature about the disease mantha sanni 
 To study the clinical features, diagnosis, Investigations and treatment of mantha sanni 
from various siddha literatures. 
 To Study the disease Mantha sanni on the basis of mukkutram and the associated 
changes in the physiological functions of the human body as per siddha literature. 
 To Study the disease Mantha sanni on the basis of age, sex, economical status, 
envagai thervu, udalthathukal, Nerkuri and neikuri. 
 To study the clinical parameters of Mantha sanni for the assessment of Social 
relationship, Emotional responsiveness, Communation skills, Behavioural patterns 
and sensory aspects.  
 To make the correlative study of signs and symptoms of the disease Mantha sanni 
with Autism spectrum disorder. 
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3. REVIEW OF LITERATURE 
3.1. SIDDHA ASPECT 
khe;jk; 
,ay;;; 
     ‗ke;j ,ay;GilaJ khe;jk;‘[3] 
 ke;jk; vd;gJ cUtepiyapy; cly;epiyapy; ke;jk;;. 
 mUtepiyapy; mff;fUtpahfpa kdk;>Gj;jp>mfq;fhuk; rpj;jj;jpYk; ke;jk; 
 vd;Wk; caHepiyapy; ke;jk; vd;Wk; tpupj;Jf;nfhs;syhk;.  
-ghythflk;. 
cz;l czT nrupahkhy; tapw;wpy; Gspj;J>tapWg;gp ,iue;J ke;jj;ij      
 cz;lhf;fp the;jpiaAk;>fopr;riyAk;> cz;lhf;fp Jd;gj;ij Vw;gLj;Jk; Neha.;                                                                                                 
        - gps;isgpzp ghfk; 2. 
 Foe;ijfSf;F ghy;> md;dk;> nea;> goq;fs;> tpj;Jf;fs;> gapW> Njq;fha;> 
 thiof;fha; Mfpa mlu;j;jpahd khg;nghUl;fs;> nfhOg;Gg;nghUl;fs; kw;Wk; 
 rPuzpf;ff; fbdkhdjhd gjhu;j;jq;fs; cl;nfhs;sg;gLk;NghJ Ruk; Vw;gl;L 
 Fwpg;ghf fhy; Fspu;e;jhy; khe;jNeha;f;F milahsk; MFk;.                                                                       
        -ghythflk; - ghyNuhfepjhdk;. 
NtWngau; 
 ke;jk;> myrk;> myrfk;.[6] 
-gps;isg;gpzp ghfk; 2. 
Neha; vz; 
 ghythflk;         - khe;jk; 21> 10> 8[3]. 
 gps;isgpzp kUj;Jtk;    - khe;jk; 43[7]. 
 Fk;gKdp ghythflk;  - khe;jk; 13[8]. 
 gjpndz;rpj;ju;fs; itj;jpa rpy;yiuf;Nfhit - khe;jk; 8[9]. 
Neha;tUk; gUtq;fs; 
 Kjyhz;L Kjy; %d;whz;Lfs; njhlUk;. 
 ―Mz;nlhd;iwj; njhl;Nl afy;%d;wh khz;lsTk; 
 jhz;LNk khe;jNeha; jhd;‖.  
 mit jhyg;gUtk;> Kj;jg;gUtk;> rg;ghzpgUtk;> tUifgUtk;. 
-ghythflk; 
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 khe;jk; 3 khjk; Kjy; 12 taJ tiu tuf;$baJ. 
 ghy;kl;Lk; Fbf;Fk; gUtk;> ghYk; NrhWk; cz;Zk; gUtk;> NrhWkl;Lk; 
 cz;Zk; Mfpa %d;W gUtq;fspYk; khe;jk; Vw;gLk;. 
                                        -gps;isgpzp ghfk; 2. 
Neha;tUk; top  
       Foe;ij gpwe;j gpd;Gk; jhaplj;jpy; cw;gj;jpahFk; ghiy cz;Nl mJ 
tsUfpd;wJ. mjdhw; Foe;ij ngw;wjha; cz;Zk; cztpd; rf;jpiag; nghWj;Nj 
jhag;;ghypd; jd;ikAk; ,Uf;Fk;. Foe;ij tsu;r;rpf;F ,ilA+W nra;af;$ba rpy 
nghUs;fisj; jha; tpyf;f Ntz;Lk;. mt;tpjk; tpyf;fhky; jd; czthfr; Nru;j;J 
cz;lhy; mjpypUe;E fpilf;f$ba Cl;lr;rj;jhdJ Kf;Fw;w kpFFiw epiw 
epiyapy; Foe;ijapDila cly;epiyiag; ghjpf;Fk;. mjdhy; Foe;ijf;F khe;jk; 
Vw;gLfpwJ. 
      Foe;ij gpwe;j xU Mz;bw;Fs;  ePu;epiyfspy; gOj;J cjpu;e;j rUFfs; 
tpOe;J mOfpUf;Fk; ePiuf;Fbg;gjhYk;> vUikg;ghy;> Gspj;j vUik Nkhu;> vUik 
nea;> thiog;gok;> khk;gok;> Njq;fha;> ,sePu;> fliy> nty;yk;> khtpdhw;nra;ag;gl;l 
nghUs;> thAg;nghUl;fs;>
 
NrhW ,itfis mjpfkhf cz;gjhYk;> 
       ghfw;fha;> fs;> Cd;> ngupa cSit kPd;> thiskPd;> gd;wp> tuhy;kPd;> 
nfz;ilkPd; ,itfis cz;gjhYk;> Rukbj;jy; vd;Dk; gy fhuzq;fshy; jha;f;F 
kyr;rpf;fy; Vw;gl;L> mtsJ cly; fdj;J Jd;gg;gLk;NghJ Foe;ijahdJ 
mj;jhapdp;lk; ghy;Fbj;jhy; kapu;$r;rj;Jld; $ba fha;r;ry; cz;lhFk;. mj;Jld; 
kpff; fopr;ry; Vw;gl;L khe;jNeha; cz;lhFk;. 
                                      -ghythflk;. 
 
khe;jj;jpd; nghJf;FwpFzq;fs;[3] 
         ―tha;e;j gytit tOj;jy; Nfsha; 
          Foe;ij Alyq; nfhs;sy; fdjp 
          tpioe;J Nehjy; Ntu;j;jy; Nrhu;e;J 
          fplj;jy; fha;jy; fpsuo dhw;wk; 
          gLjiy kaf;fk; ghu;it Nrj;jy; 
          fz;fs; Royy; fz;fs; Fopjy; 
          fz;Z Kfk;gy thf ntSj;Jg; 
          gz;Z nkhspjuy; gfu;Fu who;jy; 
          jpz;th Ayuy; Nru;Kiy Az;zh 
          njz;Zk; the;jp Naw ntLj;jy; 
          grpap uhik gyepw Ngjp  
          frpAQ; rPjK kyKq; fhzy; 
          nfl;l ghy;Nghy; fpsu;jz; zPu;Nghy; 
          tpl;l Ngjp tpjkha;f; fhzy; 
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          iffhy; gpd;dy; iffhy; Fspuy; 
          ifapw; wq;fhf; fyq;fpj; Js;sy; 
          vd;D kpitNa nad;wdu; 
          kd;dpa Kd;D}y; khz;Gil NahNu‖  
                                     
1. Foe;ijapd; clk;G fdj;jpUf;Fk;> Nehjy; cz;lhFk;. 
2. kpFjpahd tpau;it cz;lhFk;> tplhj RukpUf;Fk;. 
3. Foe;ijf;F RWRWg;G ,y;yhky; Nrhu;e;J ,Uf;Fk;. 
4. clk;gpypUe;J xU tpj ntg;Gehw;wk; cz;lhFk;. 
5. kaf;fk; cz;lhFk;> fz;tpop FoptpOe;J fhzg;gLk;. 
6. Kfk; ntSj;J xUtif kq;fpa xsp fhZk;. 
7. Fuy; jho;e;J fhzg;gLk;> tha; cyUk;. 
8. jhapdplk; ghy; cz;zhJ.mbf;fb the;jp cz;lhFk;. grp Vw;glhJ. 
9. rPjKk; kyKkhfTk;> nfl;Lg;Nghd ghy; NghyTk;> jz;zPu; NghyTk;>      
gyepwkhfTk; NgjpahFk;. 
10. iffhy; gpd;dpf;nfhs;Sk;> iffhy;fs; #L ,y;yhky; Fspu;e;J NghFk;. 
11. Foe;ij ifapy; jq;fhky; mOtNjhL Js;Sk;. 
                                      -ghythflk;. 
 ke;jkJ tuyhW nrhy;yf; Nfspu 
 khjNuhL ghyfU  kUe;Je; jPdp 
 Nru;e;jnjhU ghy;jdpy; tpre;jhd; nfhz;L 
 rpWtUf;F cjuj;jpy; ke;jk; gw;wp 
 Cu;j;njOe;j jpiuapdhy; tpuzq;nfhz;L 
 cs;tpuzk; gyNehT cwtjhfp 
 rhu;e;j kyk; rpf;fpajpy; NjhrKz;zha; 
 jhndOk;Gk; khe;jtif rhw;WNtNd 
                           -gps;isgpzp ghfk; 2 
 
khe;jNeha; tiffs; 
 1.tsp 
 2.moy; 
 3.Iak; 
 4.tplk; 
 5.Nghu; 
 6.thiy 
 7.Ruk; 
 8.ePu; 
          9.nrupahik 
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 10.fl;L 
 11.ghy; 
 12.vup 
 13.Jiy 
 14.jiy 
 15.fzk; 
 16.typg;G 
 17.Rop 
 18.Kf;F 
 19.re;ep 
 20.Cjy; 
 21.tPf;fk; 
          -ghythflk;.
 
 
kUj;Jt mwpQu;fs; $Wk; 10 tiffs; 
 1.cg;gy; 
 2.the;jp 
 3.twl;rp 
 4.jpl;L 
 5.cis 
 6.mf;fuk; 
 7.Nga; 
 8.ePu;fzk; 
 9.Njhlk; 
 10.fUg;gk;. 
           –ghythflk;. 
vz;tif khe;jk; 
 1.nghJkhe;jk; 
 2.nrupahkhe;jk; 
 3.jiykhe;jk; 
 4.Nghu;khe;jk; 
 5.fl;Lkhe;jk; 
 6.tplkhe;jk; 
 7.ePu;khe;jk; 
 8.fopkhe;jk;. 
                      –ghythflk;. 
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Fk;gKdp ghythflk;  - 13tif khe;jk; 
 1.thjkhe;jk; 
 2.nghUky;khe;jk; 
 3.tus;khe;jk; 
 4.gpj;jkhe;jk; 
 5.rpNyw;gkhe;jk; 
 6.eLf;Fkhe;jk; 
 7.Fspu;khe;jk; 
 8.Nghu;khe;jk; 
 9.ghy;khe;jk; 
 10.tp\khe;jk; 
 11.,iukhe;jk; 
 12.nghJkhe;jk; 
 13.rf;jpkhe;jk;. 
 
gps;isgpzp kUj;Jtk; 2 - 43tif khe;jk; 
 1.milkhe;jk; 
 2.ml;rmf;fukhe;jk; 
 3.moy;khe;jk; 
 4.ms;Skhe;jk; 
 5.,Og;Gkhe;jk; 
 6.cg;gy;khe;jk; 
 7.cg;Gkhe;jk; 
 8.ciskhe;jk; 
 9.CJkhe;jk; 
 10.vupkhe;jk; 
 11.Iakhe;jk; 
 12.fl;Lkhe;jk; 
 13.fzkhe;jk; 
 14.fu;g;gkhe;jk; 
 15.fizkhe;jk; 
 16.fy;khe;jk; 
 17.fopkhe;jk; 
 18.rf;jpkhe;jk; 
 19.re;epkhe;jk; 
 20.re;epghjkhe;jk; 
 21.Rukhe;jk; 
 22.Ropkhe;jk; 
 23.nrupahkhe;jk; 
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 24.jiykhe;jk; 
 25.jpl;Lkhe;jk; 
 26.ePu;fzkhe;jk; 
 27.Jiskhe;jk; 
 28.Njh\khe;jk; 
 29.ePu;khe;jk; 
 30.ghy;khe;jk; 
 31.Gy;khe;jk; 
 32.Ngjpkhe;jk; 
 33.Nga;khe;jk; 
 34.Nghu;khe;jk; 
 35.kybkhe;jk; 
 36.Kf;Fkhe;jk; 
 37.typg;Gkhe;jk; 
 38.tspkhe;jk; 
 39.twl;rpkhe;jk; 
 40.the;jpkhe;jk; 
 41.thy;khe;jk; 
 42.tplkhe;jk; 
 43.tPf;fkhe;jk;. 
 
Re;ep khe;jk[3]; : 
gj;jpaj; jho;thy; khe;jk; 
gifnrAk; tpjq;fs; nkj;j 
Rw;wpa kaf;f Kz;lha;r; 
Nrhy;nyhzhr; re;ep naa;Jk; 
Kw;wpa   RuKe;  jhf 
Kjph;e;jpL ehtpd; Ks;S 
Gj;jpAq; fyq;fpf; fz;Zk; 
NghjNt jhOe; jhNd 
 
cUf;FQ; re;ep khe;jFzk; 
Xah jyWk; tha;gpjw;Wk; 
xUfz; jpwe;J nkhUfz;iz 
AUl;b tpopj;Jg; ghh;j;JkOk; 
JUf;F %rp Nghy;fOj;J 
Jts nehe;Nj Alynkyhk; 
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ngUf;f euk;Ge; jhd;njwpj;Jg; 
gpopAk; ghrp Nghy;topNa 
md;wpAk;> 
  njhiytpy; jhfK kaf;fK kwpTnjhe; jpj;jy; 
    jiyG ul;ly;fhy; Fsph;e;jpl dhtpy;Ks; jbj;jy; 
  kiyT nra;ntWk; the;jpA Nkg;gKk; typg;Gk; 
rpiyE jw;fNz re;epkhe; jk;nkdr; nrg;Ng. 
 
khk;kNk Nfhgpj; jf;fy; 
tapWNgh Kg;gpf; nfhs;Sk; 
khe;jNk Nfhgpj; jf;fhy; 
tha;jid ntUtpr; rPWk; 
khe;jNk Nfhgpj; jf;fhy; 
kaq;fpNa Fsph;e;J fhZk; 
 
khe;jNk Nfhgpj; jf;fhy; 
……………………………… 
fhe;jy; Nghy; Nkdp jhDk; 
fUfpNa ntUtpr; NrUk; 
Nrh;e;jNjhH gr;ir nts;is 
rpte;JNky; kyKe; jPAk; 
the;jpNa gz;Zq; fz;lha; 
typg;Gld; re;ep jhNd. 
FwpFzq;fs;:  
mwpT fyf;fk; 
,il tplhky; myWjy; 
Tha; gpjw;wy; 
fz; jho;T 
xU fz; jpwe;jpUf;f kw;nwhU fz;iz cUl;b ghHj;jy; 
clk;ngy;yhk; typ vLj;jy; 
if fhy; rpy;nyd;W ,Uj;jy;  
the;jp> Vg;gk; 
ehtpd;Ks; 
typg;G 
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MANTHA SANNI AND AUTISM SPECTRUM DISORDER: 
 
 
gpzp mwpAk; Kiwfs;;;; (Diagnosis)[10] 
                       “ Neha;ehb Neha;Kj dhbaJ jzpf;Fk; 
           tha;ehb tha;g;gr; nray;‖.    -jpUf;Fws;. 
 
Siddha system has a very unique method for diagnosis. This is based upon three 
principles.
[10] 
      1.nghwpahywpjy; (Inspection) 
      2.Gydhwpjy; (Palpation)  
   3.tpdhjy; (Interrogation) 
 
1. nghwpahywpjy; ( poriyall arithal) 
                  Porigal means the five sense organs. These are eyes, ears, nose, tongue and skin. 
Poriyall arithal is examining the five sense organ of the patient by the five sense organ of the 
physician. 
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    In Mantha sanni, 
Mei (skin)  - normal 
Vaai (tongue) -normal 
Kan (eye)  -normal 
Mookku (nose) -normal 
Sevi (ear)  -normal  
 
2. Gydhwpjy; (Pulanaal arithal) 
                  Pulan means sense of perception from the five sense organs. That means 
understanding by the sense objects.     
 In Mantha sanni  
Ooru (sensation)   – normal 
Oosai (sound)       – normal 
Oli (vision)           – normal 
Suvai (taste)          –normal 
Naatram (smell)   – normal 
  
3. tpdhjy; ( Vinaathal ) 
                 Vinaathal means, the physician knows about the patients name, age, occupation, 
family history, socio-economic status, diet and habits, complaints relevant to disease in his 
family by asking questions. 
 
rpj;j kUj;Jtj;jpy; Nehapid fzpf;f gad;gLk; Kiwfs;[10] 
1. jpiz 
2. fhyq;fs; 
3. Rit 
4. capu;j;jhJf;fs; 
5. clw;fl;Lfs; 
6. vz;tifj;Nju;T 
 
1. jpiz 
    jpiz vd;gJ epyk;> G+kp> jiu> ,lk;. kz; vd gy ngau;fshy; toq;fg;gLk;. 
jpiz -5 tifg;gLk; 
FwpQ;rp – rpNyj;Jk Neha; cz;lhFk;. 
Ky;iy – gpj;jNeha; cz;lhFk;. 
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nea;jy; - thjNeha; cz;lhFk;. 
kUjk; - ve;jtpj Neha;fSk; cz;lhfhJ. 
ghiy – thj> gpj;j> fgNeha;fs; cz;lhFk;. 
                          -Neha;ehly; Neha;Kjdhly; 
 
2. fhyq;fs; 
    gd;dpuz;L jpq;fs; nfhz;l Xu; Mz;il MW gpupTfshfg; gpupf;f> xt;nthU 
gpupTk; ,uz;Luz;L jpq;fisf; nfhs;Sk;. ,uz;L jpq;fisf; nfhz;l xt;nthU 
gpupTk; fhyk; (m) gUtk; vdg;gLk;. Mit 
 
1. fhu;fhyk; - Mtzp> Gul;lhrp 
2. $jpu;fhyk; - Ig;grp> fhu;j;jpif 
3. Kd;gdpf;fhyk; - khu;fop> ij 
4. gpd;gdpf;fhyk; - khrp> gq;Fdp 
5. ,sNtdpw;fhyk; -rpj;jpiu> itfhrp 
6. KJNtdpw;fhyk; -Mdp> Mb 
                             -rpj;j kUj;Jthq;fr; RUf;fk;. 
 
      Nkw;$wpa fhyq;fspy; tsp> moy;> Iak;> %d;wpy; VNjDk; xd;W my;yJ gy 
jd;dpiy> jd;dpiy tpUj;jp> Ntw;Wepiy tsu;r;rp vDk; epiyia miltjpdhy; ehb 
eil khw;wkile;J VO clw;jhJf;fspy; Ntw;Wik cz;lhFk;. 
 
1. tsp 
jd;dpiyailjy; - $jpu;fhyk; 
jd;dpiy tsu;r;rp – KJNtdpw;fhyk; 
Ntw;Wepiy tsu;r;rp – fhu;fhyk; 
2. moy;  
jd;dpiyailjy;  - Kd;gdpf;fhyk; 
jd;dpiy tsu;r;rp – fhu;fhyk; 
Ntw;Wepiy tsu;r;rp – $jpu;fhyk;  
3.Iak; 
jd;dpiyailjy; - KJNtdpw;fhyk; 
jd;dpiy tsu;r;rp – gpd;gdpf;fhyk; 
Ntw;Wepiy tsu;r;rp – ,sNtdpw;fhyk; 
                           -Neha;ehly; Neha;Kjdhly;. 
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3.Rit 
 ,uz;buz;L G+jq;fspy; $l;Lwtpdhy; Rit gpwf;fpd;wJ. 
,dpg;G – kz;   + ePu; 
Gspg;G – kz; + jP 
cg;G  - ePu;  + jP 
ifg;G – fhw;W +  tpz; 
fhu;g;G – fhw;W + jP  
Jtu;g;G – kz; + fhw;W. 
  
Kj;Njhlq;fis  kpFjpgLj;Jk;  Ritfs; 
 
―GspJtu;tpQ; Rq;fwpahw; G+upf;Fk; thjk; 
          xspAtu;ifg; Ngwpy; gpj; Jr; rPWk; - fpspnkhopNa 
    fhu;g;gpdpg;G tpQ;rpw; fgk;tpQ;RQ; rl;bujr; 
                   Nrug;Gzu; NehaZ fhNj‖. 
  
Kj;Njhl kpFjpiar; rkdQ; nra;Ak; Ritfs; 
 
                                           ―thj Nkypl;lhy; kJuk; GspAg;G 
                    NrjKwQ; nra;Ak; rpiwAk; -Xjf;Nfs; 
                    fhue; Jtu;frg;Gf; fhl;Lk; Ritnay;yhk; 
                    rhug; gupfhuQ; rhw;W‖.; 
 
―gpj;j kjpfupg;gpd; NgRk; gupfhuk; 
        Rj;jj; JtNuhL nrhy;ypdpg;Gr; - rj;jhFk; 
 ifg;Gr; RitNa fUjtjd; tPW 
 va;g;gilA nkd;Wiuj;jh upq;F‖. 
                            -fz;Zrhkpak;. 
 
4. capu;jhJf;fs; 
               capu;jhJf;fyhfpa tsp> moy;> Iak; Mfpa Kf;Fw;wq;fNs 
vy;yhg;gpzpf;Fk; fhuzkhFk;. 
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5.Kf;Fw;wq;fspd; nghJFzk; 
1. Vali (thjk;); 
 Site of vatham in body (thjk; thOkplk;) 
                        Abaanan, faces, idakalai, below the umblical region, spermatic cord, pelvic 
bones, skin, nerve plexus, joints, hair follicle, muscle, alimentary tract, bones, ear and thighs. 
NkYk;  
        ―mwpe;jpLk; thj klq;Fkyj;jpdpy;‖  
                              -jpU%yu;. 
     ―ehnkd;w thjj;Jf; fpUg;gplNk Nfsha; 
     ehgpf;Ff; fPnod;W etpy yhFk;‖.  
                            –A+fp Kdptu;. 
 
vd;gjhy; kyKk;> ehgpf;F fPoplKk; thjkpUf;Fkplq;fs; vd nfhs;syhk;. 
Vatham consists of 10 types 
[10] 
1. Praanan (Uyirkaal) 
                 This controls knowledge, mind and five sense organs, which are useful for 
breathing and digestion. In Mantha sanni, praana vaayu is affected leading to sleep 
distubances, Poor appetite, Indigestion and aggressiveness. 
 
2. Abaanan (Keezhnokkukaal)  
                This responsible for all downward movement such as passing urine, stools, semen 
and menstrual flow. Abaanan vaayu is affected in mantha sanni leading to constipation. 
 
3. Samaanan (Nadukkal) 
               This aids in proper digestion and controls other vaayus.In Mantha sanni, this vaayu 
is altered leading to poor appetite, Indigestion and cannot control the other vaayus. 
 
4. Viyaanan (paravukaal) 
               This is responsible for all movement of all parts of the body and distribution of 
saaram. This vaayu is not affected in mantha sanni. 
 
5. Uthaanan (melnokkukaal)  
                 Responsible for all upward visceral movements such as vomiting and nausea.Then 
distributes the saaram equally to all tissues. This vaayu is not affected in mantha sanni. 
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6. Naagan                            
     Responsible for opening and closure of eye lids and is not affected in Mantha sanni 
 
7. Koorman 
               Responsible for vision and yawning. Koorman is not affected in Mantha sanni 
 
8. Kirukaran  
               This is responsible for salivation, nasal secretion, sneezes, coughs and maintains the 
appetite. In mantha sanni, this vaayu is affected because poor appetite present. 
 
9. Devathatthan 
                   This is responsible for tiredness, anger and emotional expression. This vaayu is 
affected in mantha sanni because of aggressiveness, frustuation, hyperactivity and impaired 
emotional skills.  
 
10. Dhananjeyan 
                   It produces swelling of the body after death. It escapes on the third day after 
death bursting out of the cranium. 
 
B. Azhal (gpj;jk; ) 
Sites of pitham in body (gpj;jk; thOkplk; ) 
                   Pinkalai, praanavayu, urinary bladder, moolakkini, heart, head, umblical region, 
stomach, sweat, saliva, blood, saaram, eyes and skin.  
  NkYk; 
    ― gpupe;jpLk; gpj;jk; Nguhk; ryj;jpdpy;‖.    
                                 -jpU%yu;. 
 
         ―Nghnkd;w gpj;jj;Jf; fpUg;gplNk Nfsha; 
     Nguhd fz;lj;jpd; fPo jhFk;‖.  
                            – A+fp Kdptu;. 
 vd;gjdhy; rpWePUk;> fz;lj;jpd; fPoplKk; gpj;jk; ,Ug;gplkhFk;. 
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Pitham consists of 5 types
 [10] 
1. Anal pitham 
           It promotes appetite and helps in digestion.In Mantha sanni, this pitham is affected due 
to poor appetite and indigestion 
 
2. Ranjagam 
          It gives colour to the blood. In mantha sanni, some childrens are anaemic. 
 
3. Saadhagam 
         It is important for day today activities with the help of mind and brain .In Mantha sanni, 
this Pitham is affected because of Poor social and communication skills, impaired emotional 
status, Hyperactivity an attention deficit. 
 
4. Prasagam 
       It gives complexion to skin.In Mantha sanni it is normal. 
 
5. Aalosagam  
         It brightens eyes and responsible for clear vision .In mantha sanni it is affected due to 
poor eye to eye contact 
 
C.Iyyam ( fgk;)[10] 
Sites of kabam in body (  fgk; thOkplk; ) 
          Kabam (or) kapham is located in samanavaayu, suzhumunai, sperm, head, tongue, 
uvula, fat, bonemarrow, blood, nose, chest, nerve, bone, brain, large intestine, eyes, joints and 
also present in throat, stomach and pancreas. 
 
Kabam consists of five types  
 
1. Avalambagam  
       It lies in the lungs. It controls the heart and other four kabam. In mantha sanni,it is 
normal. 
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2. Kilethagam 
       It lies in the stomach and gives moisture to food material and also helps for digestion. In 
mantha sanni, it is affected due to indigestion 
 
3. Pothagam 
          It lies in tongue and responsible for taste sensation.It is not affected in mantha sanni. 
 
4. Tharpagam 
         It is present in the head and responsible for coolness of both eyes. It is affected in 
mantha sanni due to poor eye to eye contact. 
 
5. Santheegam 
        It is present in joints and responsible for lubrication and free movement of joints .It is 
not affected in mantha sanni. 
 
5. Udar kattugal (7)
[10] 
1. Saaram 
2. Senneer 
3. Oonn 
4. Kozhuppu 
5. Enbu 
6. Moolai 
7. Sukkilam/suronitham 
          When the seven udar kattukal increase or decrease from the normal level, the normal 
functions of the body will be affected. 
 
In Mantha sanni  
1. Saaram: Normal 
2. Senneer: Normal 
3. Oonn:  Normal 
4. Kozhuppu: Normal 
5. Enbu: Normal  
6. Moolai: Normal 
7. Sukkilam/suronitham: Normal. 
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Eight tools of diagnosis
 [10] 
                       Envagai thervugal is the basic diagnostic principles and the uniqueness of the 
siddha system of medicine. The following lines are said about this. 
            ―nka;f;Fwp epwe;njhdp tpop ehtpUkyk; iff;Fwp‖ 
                                                         -rpj;jkUj;Jthq;fr; RUf;fk;. 
               ―ehbg;guprk; ehepwk; nkhoptpop 
       kyk;%j;jpukpit kUj;Jt uhAjk;‖  
                                                   -Neha;ehly; Neha;Kjy;dhly;. 
           The diagnostic value of Enn vagai thervugal is the unique concept of siddha system of 
medicine. 
Enn vagai thervugal are  
1. Naadi (Uyir thathu) 
2. Sparisam (Touch feel sensation) 
3. Naa (Tongue) 
4. Niram (Colour of the skin) 
5. Mozhi (Quality and character of speech) 
6. Vizhi (Eye)
 
7. Malam (Stools) 
8. Moothiram (Urine) 
 
a) Naadi (Uyir thathu) 
[10] 
―   ,Lnkd;w ehbfs;ghh;f;Fk; tifiaf; NfS 
Vd;dntd;why; eLtpuy; ePtpg;gpd;Nd 
 mLnkd;w mLj;jtpuy; Nkhjpukhk; tpuiy 
 mg;gNd ,Sj;jgpd;G Rz;LtpuypSj;jJ 
cLnkd;w J}z;LtpuypSj;J mg;ghy; 
          cj;jnjhU mq;Fl;l LtpuiyeP tpf;fyj;jpy; 
gLnkd;w rPNahjp mq;FyNkh js;sp  
  ghh;jtpl %d;Wjuk; Ruk;ghh;f;Fk; tifNa 
tifvd;d thjkJ xz;ziuahk; gpj;jk; 
  tsiknahd;W ma;aq;fhy; tskha;epw;fpy;  
gifapy;iy ehbfSe; njhe;j kpy;iy 
       gz;ghd;RfnuhrU&gf; $Wnrhd;Ndd; 
                          -mfj;jpah; fdf kzp 100  
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 clypy; capu;jupj;jpUg;gjw;F fhuzkhd rf;jp vJNth mJNt  jhJ my;yJ 
ehb vdg;gLk;. 
                Otherwise known as uyir thathu,is the principle method for diagnosis in siddha 
system.. It is responsible for existence of life in the physical body. 
 
Naadi nadai in Mantha sanni             
            ―Nghfpa jtis ghk;G Nghythk; Nrj;Jke;ehd;‖ 
                            -Neha;ehly; Kjy; ghfk; 
           The prime factor, kabam is involved in Mantha sanni and is accompanied with vatham 
or pitham and produce clinical symptoms of mantha sanni. 
 
b) Sparisam (Touch feel sensation) 
[10] 
  NjaKlNd thjj;jpd; Njre;jhDk; 
             Neu;ikaha;f; Fsph;e;J rpy tplj;jpNy jhd; 
khaKlD l;lzKe; JbJbg;G  
       kWTjyhk; gpj;jj;jpd; Njfe;jhDk; 
       NjhaNt Tl;lzkjhapUf;Fk; njsptha; 
          Nrj;Jkj;jpd; NjfkJ Fsph;e;jpUf;Fk; 
 Gha njhe;e NjfkJ gythwhFk; 
             Ghpe;J njhl;Lj; Njfj;ijg; ghh;j;Jg; NgNr 
-fz;Zrhkp 
           Identify the heat or coldness of the body, pain and skin nature. In mantha sanni, It may 
be over sensitive of touch 
. 
c) Naa (Tongue)
 [10]
 
gykhd UrpawpAk; ehtpd; $w;iwg; 
 gfh;fpd;Nwd; thjNuhfp apd;wd; ehT 
fykhf ntbj;J fWj;jpUf;F kl;Nghy; 
  fz;L nfhs;tha; gpj;jNuhfp apd;wd; ehT 
eyLq rpte;J gr;nrd;wpWf;Fk; el;gpyh 
rpNyj;JkNuhfp apd;wd; ehT 
jykjdpYw;wKjp Nahh;fs; nrhd;d  
  jd;ikab jbj;J ntSj;jpUf;Fk; ghNu. 
                -fz;Zrhkp 
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  It is noted for colour of the tongue local lesion (ulceration, redness), coating 
deposition of tongue and dryness of the tongue. 
      In Mantha sanni, some children have ulceration and dryness of tongue. 
 
d) Niram (Colour of skin)
 [10]
 
%d;whFk; thjgpj;j rpNyj;J kj;jhy; 
 kpFr;jKwj; njhe;jpj;j Nuhfp Njfk; 
Njhd;whj rPja T];zq; fhy%d;Ee; 
  njhFj;Njd;ahd; jpNufj;jp dpwj;ij NfS 
Cd;whj thjTly; fWj;Jf; fhZk; 
  Cupagpj;j Kly; rptg;Gg; gRikfhZk; 
Nghd;whj itaTly; ntd;ik Njhd;Wk; 
   nghUe;Je; njhe;j NuhfTlw; fptw;iw nahf;Fk; 
                                  -fz;Zrhkp guk;giu itj;jpak;  
  Colour of skin, conjunctiva, teeth, nail bud and hair are note. In Mantha sanni, it is normal 
 
e) Mozhi (Quality and character of speech)
 [10]
 
ghh;g;gjd; thjNuhfp apd;wd; thh;j;ij 
gf;Ftkha;r; rkrj;j khapUf;Fk;  
   Nrh;g;gJjhd; gpj;jNuhfp apd;wd; thh;j;ij 
 Nrg;gf;Nfhs ngyj;JNk Swj;jpUf;Fk; 
Vw;gJjhd; fhNuhfp apd;wd; thh;j;ij 
    Naspjhfr; rpWj;jpUf;Fkpay;gjhFk; 
Nfrw;fNt apk; %d;We; Njhe;jkgfpy; 
$rhkw; gytpjkha; NgRthNu 
                              -fz;Zrhkp 
  Observation of speech and voice.This is said in Agasthiar vallathi. 
                     ―thu;j;ijiag; ghu;‖ 
   In mantha sanni, it is affected due to difficulty in speech or slurred speech present. 
 
f)Vizhi (Eye) [10] 
cz;ikaha; fz;Fwpg;gijf; Nfs; thjk; 
      cw;wtpop fWj;J nehe;J ePWq; fhZk; 
jz;ikapyhg; gpj;jNuhfp apd;wd; fz;fs; 
rhh;ghf gRikrptg; NgWq;fhZk; 
tz;ikapyh itaNuhfp tpopfs; jhDk; 
 tskhd ntz;ikepw Nkjh ehjk; 
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    jpz;ikapyhj; njhe;jNuhfp apd;wd; fz;fs; 
 jPl;Ltha; gyepwnkd; wiwa yhNk. 
                              -fz;Zrhkp 
        By this examination, colour 0f eye (redness, pallor), tears, excreta of eye,disease of eyes 
are noted. 
        In mantha sanni, it is affected because of poor eye to eye contact. 
 
g) Malam (Stools)
 [10]
 
  xf;FNk thj Neha; kyj;ij ghh;f;fpy; 
       cfe;j kyk; fWkpNa fWj;jpUf;Fk; 
  kpf;fgpj;j Neha;kyj;ij cw;W ghh;f;fpy; 
kpFe;j rptg;Gld; gRik jhDk; 
ikFtis khNdNf isa Nuhfk;  
    kykJjhd; ntz;zpw khapUf;Fk; 
gf;Ftkh apk;%d;We; njhe;jpg; ghfpy; 
        gfUkpd; epwq;fs; tif gupe;J fhZk; 
                                    -fz;Zrhkp  
        Consistenccy of stool (hard or semisolid),diarrhoea, undigested food, fluid resembling 
the meat washed water, colour ,frothy, dysentery ,bloody, pus, mucus, smell, frequency of 
defeacation, constipation, quantity of stool are noted.  In mantha sanni, patient may be having 
the symptoms of constipation. 
 
h) Moothiram (Urine)
 [10]
 
  Xq;fpa thjj;Njhh;f;F ePh;tpOq; Fze;jh E}iuf;fpd;w 
   G+q;nfhb fWj;J nehe;H rpWj;Jkd; ngWkp tPOk; 
ghq;Fld gpj;jNjhh;f;Fk; grpa ePh; rpte;J fhl;b 
Vq;fNt fWf;fjhf vupj;Jld; fLj;J tPOk; 
tPONk rpNyw;gdj;Njhh; ePh;f;Fzk; tpsk;gf; Nfsha; 
     ehSnk ntSj;Jiue;J eyk;ngw tPOq; fz;lha; 
ths;tpop khNdnjhe;j Nuhfkhdplh;f;Fk; jhNd 
jhSePh; gyepwe;jh nddNt rhw;wp NdhNk 
                               -fz;Zrhkp 
          Colour of urine (yellow, black white copper colour, mixed colour.Then smell of urine 
(smell of fire, honey, sweet odours, fruity odour) frothy or not, frequency of urination and 
quantity of urine are noted.   In mantha sanni, there is no specific feature related to the colour 
of urine. 
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Neer nira kuri and Nei kuri
 [10]
 
          This method of urine examination is unique in Siddha medicine. 
 
ePu;epwf;Fwp 
―mUe;JkhwpujKk; mtpNuhjkjha; 
      Mf;fy; myu;jy; mfhyT+d; jtpu;e;jow; 
Fw;wstUe;jp cwq;fp itfiw 
Mbf;fyrj; jhtpNa fhJ nga; 
   njhUK$u;j;jf; fiyf;Fl;gL ePupd; 
     epwf;Fwp nea;f;Fwp epUkpj;jy; flNd‖ 
        –Neha;ehly;  Kjy;ghfk;.    . 
 
tpsf;fk; 
       ePu;f;Fwp ghu;f;Fk; Kjy; ehs; ,uT ed;F czT cz;L cwq;f Ntz;Lk;. 
gpd; tpbaw;fhiy gbfghj;jpuj;jpy; ePupidg; gpbj;J mjd; ePu;Fwp kw;Wk; epwf;Fwpapid 
fz;lwpjy; Ntz;Lk;. 
 
Collection of sample urine  
       The urine is collected on the dawn of the day in a pure glass container and closed 
immediately to prevent contamination. This specimen must be examined within one and half 
hours from the collection.  
 
nea;f;Fwp 
― epwf;Fwpf; Fiuj;j epUkhz ePupw; 
      rpwf;f ntz;nza;Nahu; rpWJsp eLtpLj; 
  njd;Wwj; jpwe;njhyp Vfhjikj;jjp 
 dpd;wjptiy Nghk; newptpopawpTk; 
 nrd;wJ GfYe; nra;jpia AzNu‖ 
                                                               –Neha;ehly; Neha;Kjdhly;. 
             A drop of gingelly oil is dropped on a wide glass vessel containing the urine to be 
tested which is kept under sunlight in a calm place. The derangement of three dhoshas can be 
diagnosed by the mode of spread of gingelly oil on the surface of urine. 
            In mantha sanni, the results of neikuri is pearl like oil floating on urine in  patients .                              
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kUj;Jtk; 
1. Ntw;wepiy tsu;r;rpaile;j gpj;jj;jpid jd;dpiyg;gLj;j Ntz;Lk;. 
2. jd;dpiy  tsu;r;rpaile;j Iaj;jpid rkg;gLj;j Ntz;Lk;. 
3. gpj;jf;Fw;wj;jhy; ghjpg;gile;Js;s thjj;jpidAk; rupgLj;j Ntz;Lk;. 
4. td;ikapoe;j clw;fl;Lfis td;ik milar;nra;Ak; tifapy; kUe;jspf;f           
Ntz;Lk;.    
 
Line of treatment  
             Siddha treatment is not only for complete cure but also for prevention and 
rejuvenation. Saint Thiruvalluvar says about the duty of the physician as follows. 
         “  Neha;ehb Neha; Kjy;ehb mJ jzpf;Fk; 
          tha;ehb tha;g;gr; nray;‖. 
                            -jpUf;Fws;. 
        From the above verse, it is essential to know the aetiology of the disease, the nature of 
patients, severity of the illness, the seasons and the time of occurrence the disease and the 
treatment of the disease must be observed clearly. Line of treatment is as follows 
1. Kaappu(Prevention) 
2. Neekkam(Treatment) 
3. Niraivu(Restoration)  
 
1. Kaappu (Prevention) 
          Prevention is the main aims of siddha system. Siddhars have described general 
preventive measures and special measures. 
         Especially in Balavagadam, special preventive measures are explained for prevention of 
the diseases of the child. It starts from the conception and goes on as the child grows in 
intrauterine life and after delivery.ie, diet of pregnant women, habit, medicine to take  during 
every month of pregnancy, psychological and environmental conditions. 
 
2. Neekkam (Treatment) 
The aim of treatment is based on 
To bring the three thodams into normal equilibrium state. 
To treat the patients according to the symptoms with internal medicine KURUVER 
KUDINEER. 
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1) Anupanam in siddha system 
         ―mDghdj;jhNy atpo;jk; gypf;Fk;   
     ,dpjhd Rf;F fd;dy; ,Q;rp – gpDKjfhy;  
            NfhNkak; ghy; Kiyg;ghy; Nfhnea; Njd; ntw;wpiy ePu; 
     Mkpij ahuha;e;J nra;ayhk; ”.                     
                                                                          -   Njiuau; ntz;gh.  
          Siddha system considers anupanam as an important factor. It is otherwise known as 
―Thunai marunthu‖, it can be termed as vehicle, adjuvant and supporting to drug therapy. 
Without anupanam, sureness in the treatment is mostly not possible. In mantha sanni, Palm 
Jaggery is anupanam. 
 
2) Pathiyam: 
         During the course of treatment, the patients were advised to follow certain restrictions 
regarding diet and physical activities. 
        This type of medical advice termed as pathiyam, Importance of pathiyam is said by 
Siddhars Theraiyar as follows, 
                  “gj;jpaj;jpdhNy gyDz;lhFk; kUe;J   
        gj;jpaq;fs; Nghdhy; gyd; NghFk; - gj;jpaj;jpy;    
        gj;jpaNk ntw;wpjUk; gz;bju;f;F Mjypdhy;    
        gj;jpaNk cj;jpnad;W ghu;”.     
                                                                   -Njiuau; ntz;gh. 
   The patient with mantha sanni is advised to avoid gluten, casein food, night shade 
vegetables, sweets, creamy items, cool drinks, cold water and exposure to chill weather and 
allergens. 
 
3) Niraivu: (restoration)  
Resonance of disease recovery was given to all patients. 
All the patients are advised to prepare for lifestyle changes that provide a disease free life 
 
i)Diet 
      Siddhars advise the diet regiments for patients. They are explained below, 
         “ fj;jupNga;Gly; tiuapUghfy; gUq;fhsh fz;lfhup 
    mj;jpf;fha;fSk; tUf;ifkhgaw;iw fiuahy; gPu;f;fUk; - gpQ;RNtu;   
          nkha;j;j#uzq; fjypj; jz;Lfisg; G+Ksq;fp KUf;fUk;Gk; 
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    mj;jpg;G+rzpf; fhaUs;sp ts;spAq; fgj;Njhu;f; fhzhNk .”     
      - gjhu;j;j Fz rpe;jhkzp. 
      ― Ntis kzj;jf;fhsp nkd;rPij rf;futu;j;jp 
    gPis triy Rf;F ngz;rzq;fs;-Ntisapy; 
    nre;jspu; fisf;fPiu nra;tu; fgNjfu;epjk; 
    te;jspAzj;jhd; kfpo;e;J‖.   
                           -gjhu;j;j Fz rpe;jhkzp. 
 
 
fha;fwpfs; 
  fj;jup> Nga;Gly;> mtiu> fz;lq;fj;jup> mj;jpf;fha;> gPu;f;F> thioj;jz;L> 
KUq;if> ghfy;> G+rzp ,itfis jtpu;f;fTk;. 
 
Ntu;fpoq;Ffs; 
   Ks;sq;fp> <Us;sp ,itfis jtpu;f;fTk;. 
  
fPiufs;  
   kzj;jf;fhsp> rpWfz;gPis> triy> rpWfPiu> nghd;dhq;fz;zp> rf;futu;j;jpfPiu> 
Rf;FfPiu Mfpaitfis cztpy; Nru;j;Jf;nfhs;s Ntz;Lk;. 
 
  ii) Diet restrictions 
 Siddhars advised to avoid certain food items during diseased conditions. 
They are,  
  “fLF ew;wpyj; njz;nza; $o;ghz;lq; fliy 
  tLtjhfpa njq;Fkh tUf;if ew;fha  
  kLtp yhjnts; Ss;Snfhs; Gifapiy  
  kJngz; ,lWghfNt gfj;jp ePu;flypr; rhgj;   
      -gjhu;j;j Fzrpe;jhkzp                         
Prevention Methods 
               The patients were advised to find out which avoid them, 
Avoid Gluten and casein food products 
Avoid chill and cold weather  
Avoid cool drinks and ice creams. 
Avoid contaminated food and water. 
Take highly nutritious diet to get their immunity developed. 
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3.2. MODERN ASPECTS 
Autism Spectrum Disorder  
In early 1900‘s Autism has referred to the range of neuropsychological conditions.Individuals 
with autism are generally withdrawn from social and emotional interaction giving rise to the 
term.   Autism is an umbrella term for Autism spectrum disorder which is charscterised by 
Constant problem with social communication and interactions across a variety of contexts such as 
Early onset of symptoms (typically in the first two years of life), Repetitive, restricted patterns of 
behaviour, Activities and interests, Symptoms that cause major impairment in social, educational and 
other important area of functioning. It is called a spectrum because of the wide range of 
symptoms and impairment level in children can have. Some are only mildly affected by their 
symptoms, while the other children are severely disabled 
[11] 
The Basis of ASD: 
1. Genetic factors: may be the most significant cause for ASD spectrum disorders. Early
studies of twins had estimated heritability to be over 90%, meaning that genetics explains
over 90% of whether a child will develop ASD.
2. A common hypothesis: is that ASD is caused by the interaction of a genetic
predisposition and an early environmental insult. Several theories based on
environmental factors have been proposed to address the remaining risk.
3. Epigenetic: mechanisms may increase the risk of ASD. Epigenetic changes occur as a
result not of DNA sequence changes but of chromosomal histone modification or
modification of the DNA bases.
4. Prenatal environment: The risk of ASD is associated with several prenatal risk factors,
including advanced age in parent, diabetes, bleeding, and use of psychiatric drugs in the
mother during pregnancy.
5. Infectious processes: Prenatal viral infection has been called the principal non genetic
cause of ASD. Prenatal exposure to rubella or cytomegalovirus activates the mother's
immune response and greatly increases the risk for ASD.
6. Teratogens: are environmental agents that cause birth defects. Some agents that are
theorized to cause birth defects have also been suggested as potential ASD risk factors.
7. Thyroid problems: that lead to thyroxin deficiency in the mother in weeks 8–12 of
pregnancy have been postulated to produce changes in the foetal brain leading to ASD.
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Thyroxin deficiencies can be caused by inadequate iodine in the diet, and by 
environmental agents that interfere with iodine uptake or act against thyroid hormones. 
8. Diabetes in the mother: during pregnancy is a significant risk factor for ASD; a 2009 
meta-analysis found that gestational diabetes was associated with a twofoldincreased 
risk. 
9. Locus coeruleus–noradrenergic system: This theory hypothesizes that autistic 
behaviours depend at least in part on a developmental deregulation that results in 
impaired function of the locus coeruleus–noradrenergic (LC-NA) system. 
10. Amygdala neurons: This theory hypothesizes that an early developmental failure 
involving the amygdala cascades on the development of cortical areas that mediate social 
perception in the visual domain
 [11]
. 
 
Symptoms of ASD
 [12]
  
The signs and symptoms of autism spectrum disorder vary widely, as do its effects. Some 
autistic children have only mild impairments, while others have more obstacles to overcome. 
However, every child on the autism spectrum has problems, at least to some degree, in the 
following three areas: 
 1. Communicating verbally and non-verbally. 
 2. Relating to others and the world around them. 
 3. Thinking and behaving flexibly. 
 4. Some children with autism spectrum disorders start to develop communication 
skills and then regress, usually between 12 and 24 months. This should be taken very 
seriously, as regression is a major red flag for autism. 
 
Diagnosis of ASD: 
 Monitor your child’s development: Autism spectrum disorder (ASD) involves a variety 
of developmental delays (social, emotional, and cognitive). 
 Take action if you’re concerned: Every child develops at a different pace, but if your 
child is not meeting the milestones for his or her age, or you suspect a problem, share it 
with your doctor. 
 Don’t accept a wait-and-see approach. Waiting is the worst thing you can do. You risk 
losing valuable time at an age where your child has the best chance for improvement. 
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 Trust your instincts. Sometimes, even well-meaning doctors miss red flags or 
underestimate problems. Listen to your gut if it‘s telling you something is wrong, and be 
persistent. 
 
Early Signs of Autism in Babies and Toddlers (0-18 months): 
Inability to relate to other children or adults 
Poor speech or Lack of speech 
Inappropriate laughter or crying  
Oversensitive or under sensitive to sound 
Inappropriate playing with toys 
Difficulty dealing with changes in routine 
Oversensitive or under sensitive to touch 
 
The Following Delays Warrant an Immediate Evaluation By Your Child’s 
Paediatrician:  
By 6 months:   No big smiles or other warm, joyful expressions. 
By 9 months:    No back-and-forth sharing of sounds, smiles, or other facial expressions. 
By 12 months: Lack of response to name, No babbling or ―baby talk‖, No back-and-forth 
         Gestures, such as pointing, showing, reaching, or waving. 
By 16 months: No spoken words. 
By 24 months: No meaningful two-word phrases that don‘t involve imitating or repeating. 
 
Signs and Symptoms of Social Difficulties in ASD: 
 Appears disinterested or unaware of other people or what‘s going on around them. 
 Doesn‘t know how to connect with others, play, or make friends. 
 Prefers not to be touched, held, or cuddled. 
 Doesn‘t play "pretend" games, engage in group games, imitate others, or use toys in 
  creative ways. 
 Has trouble understanding or talking about feelings. 
 Doesn‘t seem to hear when others talk to him or her. 
 Doesn't share interests or achievements with others (drawings, toys). 
 Basic social interaction can be difficult for children with autism spectrum disorders. 
 Many kids on the autism spectrum seem to prefer to live in their own world, aloof and 
 detached from others. 
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Common Self-Stimulatory Behaviours: 
 1. Hand flapping. 
 2. Rocking back and forth. 
 3. Spinning in a circle. 
 4. Finger flicking. 
 5. Head banging. 
 6. Staring at lights. 
 7. Moving fingers in front of the eyes. 
 8. Flicking light switches on and off. 
 9. Repeating words or noises. 
 
Educational Interventions
 [13]
: 
1. Applied Behavioural Analysis (ABA): works to systematically change behaviour based 
on principles of learning derived from behavioural psychology and encourages positive 
behaviour as well teaching new skills. 
 
2. Speech Therapy: with a licensed speech-language pathologist is important in helping to 
improve a person‘s communication skills, allowing better expression. Some individuals with 
ASD are nonverbal, so the use of gestures and sign language are useful. 
 
3. Occupational Therapy (OT): used as a treatment for the sensory integration issues 
associated with ASDs. Improves the individual‘s quality of life and ability to participate fully 
in daily activities. 
 
4. Physical Therapy (PT): to improve gross motor skills and handle sensory integration 
issues, particularly those involving the individual‘s ability to feel and be aware of his body in 
space. 
 
Medical Management
 [13]
: 
1. Pharmaceutical treatments can help ameliorate some of the behavioural symptoms of 
ASD, including irritability and aggression such as, Risperidone and Aripriprazole. 
2. Medications should be prescribed and monitored by a qualified physician. However, 
medications may have adverse effects. 
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3. Stem cell therapy is a new effective approach to treating ASD and is based on the unique 
ability of stem cells to influence metabolism, immune system and restore damaged cells. 
 
Stem Cell Therapy Targets Several Aspects of Concern: 
1. Immunity. 
2. Metabolism. 
3. Communication ability. 
4. Learning capacity, memory, and thinking. 
 
 Improvement is reached through restoration of the lost (impaired) neuron connections 
and formation of the new neuron connections, speeding up brain reactions through 
improvement of synaptic transmission and development of the new neuron connections. 
 
Improvements in ASD after the Stem Cell Therapy 
[13]
: 
 
1. Better tolerance of different foods and improved digestion. 
2. Easier contact with the child (first of all, eye contact). 
3. More adequate behaviour at home and outside. 
4. Less or no fear of loud noises, strangers and bright colours (gradual improvement). 
5. Improved verbal skills. 
6. Writing skills improvement or development. 
7. Improved self-care skills. 
8. Improved attention span and concentration. 
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3.3. REVIEW OF DRUG LITERATURE 
 
3.3.1. Vettiveria zizanoides. (Linn)Nash (ntl;bNth;)[15] 
 Vettiveria zizanoides .(Linn)Nash (Family :  Poaceae) is known as ntl;bNth; (m) 
FUNth; and commonly Known as Cuscus grass, Khas- khas, Khus-Khus .The Holy herb 
Vettiver is derived from Vettivert in Reunioun Island . It has been Introduced from India 
through Indonesia .Its name etched the Bhagavat Gita as the Hindu holy book where lord 
Krishna says ― I am the fragrance of soil‖ [18] .Vettiver  grows wild and found in India.It is 
also distributed in Mysore, Chottanagapur, Bay of Bengal, Rajput and throughout the tropical 
and sub-tropical plains
[19]
. Vettiver is a fast growing perineal herb and can grow upto 150cm 
height. The Leaves are long, thin and rigid. The stems are tall, erect and stiff. The flowers are 
brownish purple colour. This aromatic tuft grasses are spreading horizontally. It has a Mat 
like root system and grows downward 2m to 4m in depth
 [20]
. This grass has no stolen nor 
rhizomes. Above all the characteristics, it is highly drought tolerant which protect the soil 
against sheet erosion
 [21]
.  
 
Chemical Constituents:  
The major chemical constituents in vettiver oil are alpha and beta vetivones, vetivenol 
and vetivenyl vetivenate. The powdered fresh roots on extraction with petroleum ether yield 
khusino, isokhushinol, khushinic acid and epikhusenic acid
 [22]
. 
 
 gpj;jtp jhfk; rfpfh kpyq;fiwg; gpj;jkdw; 
 wj;jpL Fl;lQ; rpuNeha; fskb jhJel;l 
 kj;jk dw;Gz; ldg;Gz;td; %h;r;ir thptpopNeha; 
 tpj;jpu Nkfj;jpd; fl;bAk; Nghk; ntl;b NthpDf;Nf[14]. 
 
Rit: ,dpg;G > jd;ik: jl;;gk; gphpT: ,dp;g;G 
nra;if: cukhf;fp> ntg;gKz;lhf;fp> ,rptfw;wp> Tpah;itg;ngUf;fp> rpWePh;ngUf;fp> 
UJTz;lhf;fp, ntg;gfw;wp> 
 
Phytochemical Activites: 
 From extensive literature review that regarding the traditional uses or phytochemical 
properties of vettiver are Evaluation of Antioxidant Activity (Hyun-Jin Kim)
 [23]
, 
Hepatoprotective activity (Suaib Luqman) [24], Anti tuberculosis activity (D Saikia) [23]. 
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Recent researches of Vetiveria zizanoides  
 Jha Prajna et al., HPLC Quantification of Phenolic Acids from Vetiveria zizanioides 
(L.) Nash and Its Antioxidant and Antimicrobial Activity. Extraction procedure was 
standardized and for the soluble, glycoside, and wall-bound fractions of phenolic acids from 
Vetiveria zizanioides. The compounds p-coumaric acid, p-dihydroxybenzoic acid, and ferulic 
acid were detected in the acidic extracts by HPLC analysis. Dania Cheaha et al., Modification 
of sleep-waking and electroencephalogram induced by vetiver essential oil inhalation   
Essential oils (EOs) have been claimed to modulate mental functions though the most of data 
were obtained from subjective methods of assessment. Direct effects of EO on brain function 
remained largely to be confirmed with scientific proof
 [25]
. 
 
3.3.2. Plectranthus vettiviroides (Jacob) Singh &Sharma- tpyhkpr;R[15]. 
 Plectranthus vettiviroides (Family:  Lamiaceae) is Know as tpyhkpr;R and 
commonly known as White cus cus grass. The Etymology of word Cus cus grass which is 
derived from Sanskrit name Hrivera. It is distributed in endemic to South India and now it is 
extinct in the wild. It has been seen only under cultivation at Shiyali, Tanjore district, Palani 
in Madura district Canjeevaram in Chengalpattu district etc. It is a aromatic grass usually 
grows in the flower garden
 [26]
. The Leaves are long, thin and rigid. The stems are tall, erect 
and stiff. The flowers are brownish purple colour. This aromatic tuft grasses are spreading 
horizontally. It has a Mat like root system and grows downward 2m to 4m in depth. 
 
Chemical Constituents:  
 The Major chemical consituents of White cus cus grass are carbohydrates, steroids, 
proteins, amino acids, phenolic compounds, tannins and alkaloids in various extracts
 [27]
. 
  
 Nkfk; tpopnahpr;ry; tPwpuj;j gpj;jnkhL; 
 Jhfkj %h;r;irgpj;je; jd;kaf;fk;- NrhfQ; 
 rpuNeha; ,itNaFQ; nra;atpyh kpr;Rf; 
 nfhpRuKk; ,y;iy apir. [14]. 
 
Rit: ifg;G > jd;ik: jl;gk; gphpT:,dpg;G 
nra;if: Fsph;r;rpAz;lhf;fp> gpj;jklf;fp  
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Phytochemical Activites: 
From extensive literature review that regarding the traditional uses or phytochemical 
properties of the White cus cus grass are Anti oxidant activities (Nisheeda), Analgesic              
( Hussain), Cns Depressants ( Rehman)
 [28]
.. 
 
Recent researches of Plectranthus vettiveroides: 
 Subdra ganapathy et. al., The efficacy of Plectranthus vettiveroides against various 
cancer cell lines showed that the incubation of cancer cells reduced the viability of all cancer 
cell lines and the dead cells were significantly increased with high extract concentration. 
Hence hydro alcoholic extract of Plectranthus vettiveroides exhibited high cytotoxicity. Also 
the extract showed potent antioxidant activity against all the three tested methods. Even at 
very low concentration Plectranthus vettiveroides showed high efficacy. In conclusion 
Plectranthus vettiveroides possess significant antioxidant activity and anticancer activity
 [29]
. 
 
3.3.3. Zingiber officinalae (Rf;F) [15] 
 Zingiber officinalae (Family: Zingiberaceae) is known as chukka and commonly 
known as dry ginger. The Etymology of the word Ginger comes from old French (Gingibre), 
Sanskrit (Sringavera: Sringa- Horn, Vera – body or Root) and was altered to Latin Gingiber, 
in Greek it is zingeberries
 [30]
. The Nativity of Ginger was Southern Asia and quite popular in 
Carribean Island. In this Island, It is called as Jamaican Ginger and it is the world most 
supplier followed by India, Africa and China
 [31]
.It is a flowering plant and slender perennial 
herb which is usually annually grows. It is undergroundstem and thickened branched 
rhizome. It grows in both tropical and sub tropical regions
 [32]
.  
 
Chemical Constituents: 
 The chemical constituents are zingiberene, β-bisabolene, α-farnesne, β-
sesquiphellandrene, monoterpene hydrocarbons which are α-curcumene and phenolic 
compounds which are gingerol and shogaol in methanol and n-hexane respectively
 [33]
. 
  
 #iyke;jk; neQ;nrhpg;G NjhlNkg; gk;koiy 
 %yk; ,iug;gpUky; %f;FePh;- thyfg 
 Njhlkjp rhue; njhlh;thj Fd;kePh;j; 
 Njhlk;M kk;Nghf;FQ; Rf;F[14].. 
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Rit: fhh;g;;G > jd;ik: ntg;gk; gphpT: fhh;g;G 
nra;if: ntg;gKz;lhf;fp> mfl;Ltha;tfw;wp> grpj;jPJhz;b 
 
Phytochemical Activites: 
From extensive literature review that regarding the traditional uses or phytochemical 
properties of the dried Ginger plants are Antioxidant activity (Stoilova)
 [34]
 , Anxiolytic 
activity (Vishwakarma)
 [35]
, CNS depressant activity ( Kim cooper)
 [36]
,  selective serotonin 
reuptake inhibitors (SSRIs) (Chopra)
 [37]
. 
Recent researches of Zingiber officinalae:  
 Buldun et.al; the main pharmacological actions of ginger and compounds isolated 
therefrom include immuno-modulatory, anti-tumorigenic, anti-inflammatory, anti-apoptotic, 
anti-hyperglycemic, anti-lipidemic and anti-emetic actions
 [38]
. Ginger is a strong anti-oxidant 
substance and may either mitigate or prevent generation of free radicals. It is considered a 
safe herbal medicine with only few and insignificant adverse/side effects. More studies are 
required in animals and humans on the kinetics of ginger and its constituents and on the 
effects of their consumption over a long period of time
 [39]
. Wilson et.al, Limited data suggest 
that ginger may accelerate recovery of maximal strength after eccentric resistance exercise 
and reduce the inflammatory response to cardiorespiratory exercise. Major limitations to the 
research include the use of untrained individuals, insufficient reporting on adverse events, 
and no direct comparisons with NSAID ingestion. While ginger taken over 1–2 weeks may 
reduce pain from eccentric resistance exercise and prolonged running, more research is 
needed to evaluate its safety and efficacy as an analgesic for a wide range of athletic 
endeavours
 [40] 
. 
 
3.3.4. Hedyotis corymbosa (Linn.) Lam – gw;ghlfk; [15] 
 Hedyotis corymbosa (Family:  Rubiacea) is known as gw;ghlfk; (m) rPjk; and 
commonly known as Fever plant and parpat. The Etymology of word Heyotis plant which is 
derived from two Greek. Hedys ―Sweet‖ and Otos ―Ear‖ [41]. It was frequently occurs in 
cultivated fields and waste places in sandy oil. It is widely naturalized weed through the 
tropics and subtropics regions
 [42]
. It is widespread through Africa, Arabia, and Asia to new 
guniea. It grows as erect plant and slightly branched and measures 20 to 40 cm high.The stem 
is full and slender. The leaves are simple, opposite and decussate.The flowers are solitary and 
the seeds are conical, black in colour
 [43]
. 
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Chemical Constituents: 
 The chemical constituents are ten compounds have been isolated and elucidated as 
geniposide, 6 alpha-hydroxygeniposide, scandoside methyl ester (6 beta-hydroxygeniposide), 
asperulosidic acid, deacetylasperuloside, asperuloside, 10-O-benzoylscandoside methyl ester, 
10-O-p-hydroxybenzoyl scandosidemethyl ester, lyoniresinol-3 alpha-O-beta-
glucopyranoside, and rutin
 [44]
.   
 rPjth jr;RuKt; jPuhj jhfKk;Nghk; 
 NghjtpU fz;FspUk; ngha;ayNt – Gjyj;Js; 
 tw;ghh; gapj;jpaK khgpj;j Ke;njhiyAk; 
 gw;ghl fj;ijAd;dpg;(ghh;) [14] 
Rit: ifg;G > jd;ik: ntg;gk; gphpT: fhh;g;G 
nra;if: kykpsf;fp> grpj;jPJ}z;b > mOfyfw;wp> ntg;gfw;wp> tpah;itg;ngUf;fp 
 
Phytochemical Activites: 
 From extensive literature review that regarding the traditional uses or phytochemical 
properties of the Parpat plant are Antioxidant (Senthamil Selvan)
 [46]
, Antimicrobial (Zahir 
Hussain)
 [47]
, Anti depressant activity (Anil T Pawar)
 [47]
, Hepatoprotective (Gajakosh)
 [47]
. 
 
Recent researches of Hedyotis corymbosa: 
 Jagathala Mahalingam Sasikumar et, al., the methanolic extract of the aerial part of 
Hedyotis corymbosa (L.) Lam. (Rubiaceae) was screened for antioxidant activity using 1,1-
diphenyl-2-picryl hydroxyl (DPPH) quenching assay, 2,2'-azinobis-3-ethylbenzothiozoline-6-
sulfonic acid (ABTS) cation decolorization test, ferric reducing power (FRP), scavenging 
capacity towards hydroxyl ion (OH*) radicals and nitric oxide (NO) radical inhibition activity 
using established assay procedures. Total phenolics and total flavonoid contents were also 
determined
 [48]
. Susi Endrini et, al., the research was conducted to determine the 
anticarcinogenic properties of ―rumput mutiara‖ (Hedyotis corymbosa (L.) Lam) and 
―pohpohan‖ (Pilea trinervia (Roxb.) Wight), By the microculture tetrazolium salt (MTT) 
assay on the human breast carcinoma dependent-hormone (MCF-7) cell lines. The 
preliminary results showed that the ―rumput mutiara‖ extract displayed the cytotoxic effects 
against MCF-7 with IC50-value of 22, 67 µg/ml. However, the ―pohpohan‖ extract did not 
show the IC50- value against MCF-7 cell lines. The antioxidative activities of the extracts 
which could contribute to their cytotoxic properties were also studied. The ―rumput mutiara‖ 
extract was found to have higher antioxidant activity compared with ―pohpohan‖ extract. The 
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strong cytotoxic properties of the ―rumput mutiara‖ extract could be due to its high 
antioxidant activity
 [49]
. 
 
3.3.5. Clerodendrum serratum (Linn) Moon (rpWNjf;F) [15]  
 Clerodendrum serratum (Family: Verbenaceae) is known as rpWNjf;F (m) 
fz;Lghuq;fp and commonly known as beetle killer, blue flowered glory tree and blue 
fountain bush in English  and barangi in Sanskrit (Barangi means glorious)
 [50] 
 . It is a woody 
shrub with blunty quadrangular stems and branched. Flowers are blue in colour. So it is 
called blue flowered glory tree
[51] 
 .The Native of  Bettle Killer are tropical and warm 
temperate regions of East India and Malasia. Also distributed throughout in forest of Srilanka 
and India
 [52] 
. 
 
Chemical Constituents: 
 The major Chemical Constituents are Glucose, D-Mannitol, Hydrolysis of crude 
saponin, Oleanic acid, queretaroic acid, Serratagennic acid, B-Sitostirol and phytosterol
 [53]
 
        
     fhr Rthrq; fjpj;j\a ke;jkdy; 
     tPRRuQ; rd;dp tpisNjhlk;- MRWq;fhy; 
     ,j;jihA zpw;fh vhpfhhQ; NrHf;fz;lq; 
     fj;jphpAz; lhkhfpw; fhz;;;; [14] 
 
Rit: fhHg;G> jd;ik: ntg;gk; gphpT: fhh;g;G 
nra;if: Nfhioafw;wp> rpWePh;ngUf;fp> mfl;Ltha;tfw;wp. 
 
Phytochemical Activites: 
 From extensive literature review that regarding the traditional uses or phytochemical 
properties of Bettle Killer plants are Inhibition of serotonin activity ( Ismail shareef), Wound 
healing Activity (Vidhya), Anticarcinogenic activity (Prasant kumar),Bronchodialator 
activity (Praveen kumar)
 [54] 
 , Antiulcer activity( AnilGupta), Reduction of pschycological 
stress (Manoj sarma), Antioxidant (Bhujibal SS), CNS depressant (Kajaria divya), 
Antidiabetic (Trupti R Swain),Vasorelaxant (Mihor K Kar)
 [55]
. 
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Recent researches of Clerodendrum serratum:  
 Kajaria D K et al. The studies on steroidal and anti- platelet aggregation factor were 
performed in Swiss albino rats. Finally Bharangyadi compound has no endogenous 
steroidogenesis effect. It has any role in platelet aggregation inhibition. There is no 
significant change in the weight of adrenal gland with the drug after two week treatment; it 
concluded that the anti-inflammatory effect of the Bharangyadi compound is not due to 
increase synthesis of steroids
 [56]
. Thalla et al., Mast Cell Stabilization the disruption of mast 
cells of the rat mesentery due to the Saponin and the maximum effect was formed in thirty 
minutes
 [57] 
.Gupta AK et al., The Clerodendrum serratuam alcoholic root extract of 100 
and200 mg/kg shows antiasthamatic activity used in ovalbumin lured experimental mice. Due 
to cyclooxygenase inhibitors, the antiasthamatic activity is acting through inhibition of 
inflammatory mediators like histamine, serotonin and prostaglandins
 [57] 
 .  
 
3.3.6. Styrax benzoin – rhk;gpuhzp[15]   
 Styrax benzoin (Styraceae) is known as rhk;gpuhzp> ngz; FikQ;rhd;> J}gk;> 
kyhf;fhr; rhk;gpuhzp and commonly known as gum benzoin, Benzoin, Indian olibanum 
tree. The Benzoin is obtained from the tree of Indonesia from middle French benzoin 
whichcomes via Spanish, portuguse, Arabic luban jawi ―Incense of jawa‖ It is grown on the 
tropical island of Sumatra
 [58] 
. It is shruby, deciduous tree, gray bark, simple leaves and short 
raceme of fragrance, bell shaped white flowers. This tree produces a yellowish, balsamic 
resin called benzoin or gum Benjamin
 [59]
. 
 
Chemical Constituents: 
 The chemical constituents of Benzoin are23% free balsamic acids contains mainly 
cinnamic acid, 70-80% resin consisting triterpenoids acid, Siaresinolic acid and 
Sumaresinolic acid at hydroxyl group. Vanillin, Sterol, and phenyl propyl cinnamita 
responsible for the aromatic smell
 [60]
. 
  
 thjrP jq;fz;Nzha; khwhj; jiytypAk; 
 XjKW gPdrKk; Xl;Lq;fhz;- Gjyj;jpy; 
 Ntk;gpJjhd; vd;d kpFfrg;ig tha;f;fspf;Fk; 
 Rhk;gpuhzp vd;Dk; ruf;F[14]   
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Rit: fhh;g;G  jd;ik: ntg;gk; gphpT: fhh;g;G  
nra;if: ntg;gKz;lhf;fp>NfhiOafw;wp> jbg;Gz;lhf;fp> rpWePh;g;ngUf;fp 
 
Phytochemical Activites: 
 From extensive literature review that regarding the traditional uses or phytochemical 
properties of the Antifungal, Antibacterial (Patrícia M)
 [61]
, Antioxidant (Ragav same)
 [62] 
    , 
and Antidepressant (Sahif)
 [63] 
  . 
Recent Researches of Styrax benzoin 
 Pauline Burger et, al., the phytochemical characterisation of both the volatile and non-
volatile fractions of benzoin balsams and the quantitation of some of the major components 
by gas and liquid chromatography techniques. Four coniferyl and two morinol derivatives 
were characterised for the first time in Benzoe tonkinensis Laos. Finally, two liquid 
chromatographic methods used to easily discriminate Siam from Sumatra balsam (also 
known as Benzoe sumatranus Indonesia) were developed
 [64]. Seema et, al., α-
Hydroxyketones were prepared in appreciable yields at a very high speed, (by the benzoin 
condensation) under microwave irradiation using a catalytic amount of thiamine 
hydrochloride, from various aromatic as well as heteroaromatic aldehydes. They can be used 
as intermediates in NCE synthesis
 [65]
. 
 
3.3.7. Clatropis gigantea (Linn) - vUf;F[15]   
 Clatropis gigantea(Linn)(Family : Asclepedaceae) is known as vUf;F(m) mUf;fd; 
and commonly known as  crown flower, Mudar, Gigantic, Swallow wort.In Ancient times, it 
is a poisonous plant and used as a It is used as an arrow poison, cattle poison , rarely for 
suicide and homicide and mostly an accidental poison
[66] 
. It is native to Cambodia, Indonesia, 
Malaysia, the Philippines, Thailand, Sri Lanka, India, China, Pakistan, Nepal, Booc Booc in 
Somalia and tropical Africa
 [67]
. It is a fast-growing, attractive, evergreen flowering shrub or 
small tree that grows about 5 metres tall, occasionally to 10 metres. It is much branched at the 
base, with stems up to 20cm in diameter. 
 
Chemical Constituents: 
  The Chemical constituents are methyl β-carboline-1-carboxylate dehydrovomifoliol, 
pleurone, calotropagenin, and calotoxin
 [68] 
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  Nts;nsUf; fpd;Gw NtUkpg; gbnra;J  
 Nfhs;sNt tpUr;rpff; $l;lkhe; Njl;Fy 
 Kidj;jpDf; Fq;nfhLj; jUsyh Kz;ikNa[14]   
 
Rit: ifg;G> fhh;g;G> ,dpg;G> jd;ik: ntg;gk; gphpT: fhh;g;G 
nra;if: ntg;gKz;lhf;fp> tpah;itngUf;fp> clw;Nww;wp 
 
Phytochemical Activites: 
 From extensive literature review that regarding the traditional uses or phytochemical 
properties of the Antibacterial Activity (Kalpesh B. Ishnava)
 [69]
, Antimicrobial activity 
(Nagy Mahmoud Morsy)
 [70]
, Antioxidant (Namrata Singh)
 [71]
 and anxiolytic activity (Irfan 
Newaz Khan)
 [72] 
  
 
Recent researches of Calatropis giganteae: 
 Irfan Newaz Khan et, al., the crude ethanolic extract exhibited a significant decrease 
of motor activity and exploratory behavior in whole cross and open field tests. The extract 
also markedly increased both the number of visits to and time spent in the corners of the open 
field. The extract treated rats spent more time in the open arm of elevated plus-maze, 
showing its antianxiety activity. There was a decrease in the locomotor activity. Namrata 
Singh et, al., Antioxidants play an important role to protect human against infections and 
degenerative diseases. The aim of this study is to verify the In-vitro antioxidant properties 
and to calculate the total polyphenol contents, total tannins, and flavonoid contants of 
hydroalcohlic extract. The powdered crude drugs were extracted with hydro-alcoholic solvent 
(70:30) by double maceration process. Phytochemical tests of hydro-alcoholic extract reveal 
the presence of carbohydrate, alkaloid, flavonoid, steroids, protein, amino-acids and tannins. 
It is concluded that, this study is to verify the antioxidant properties of hydroalcohlic extract, 
and to define the total polyphenol contents, flavonoids and tannins in Calotropis gigantea 
leaves
 [72]
.  
 
3.3.8. Azadiracta indica .A.Jess – Ntk;G[15]    
  Azadiracta indica (Family; Meliaceae) is also kown as Ntk;G> mupl;lk;> Jj;ij 
epk;gk;> ghhpgj;jpuk;> thjhhp> Ntg;G and commonly known as Neem, Indian lilac, Margosa 
tree. The word Neem comes from Latin and Azadiracta indica which is derived from Persian. 
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Azad means ―Free‖ and diracta Means ―Tree‖ Hence it literally means ―Free tree of India‖ 
[73]
. It is a fast-growing tree that can reach a height of 15–20 metres (49–66 ft), rarely to  
35–40 metres (115–131 ft) [73]. It is evergreen, but in severe drought it may shed most or 
nearly all of its leaves. The branches are wide and spreading. Typically growing in tropical 
and semi-tropical regions
 [74]
. Neem trees now also grow in islands in the southern part of 
Iran. It is considered to be native to dry areas in Afghanistan, Pakistan, India, Sri Lanka, 
Bangladesh, Myanmar and China. It is cultivated as well as naturalized in Thailand, Malaysia 
and Indonesia
 [75]
.  
 
Chemical Constituents: 
  The Major chemical constituents are three flavonoids and one flavone glycoside, 
isomeldenin, nimbin, nimbinene, 6-desacetyllnimbinene, nimbandiol, immobile, nimocinol, 
quercetin, and beta-sitosterol 
[76]
. 
 
  fpUkpFl;l khe;jq; nfLtplQ;R uq;fs; 
     nghUkpak; Rupifapd; Gz;fs; - xUkpf;f 
  epk;gj; jpiyapUf;f ePLyfpy; ePq;fhky; 
  fk;gj; jpiyapUf;ff; fhz[14]  ; 
 
Rit: ifg;G> jd;ik: ntg;gk; gphpT: fhh;g;G 
nra;if: ntg;gKz;lhf;fp> GOf;nfhy;yp 
   
Phytochemical Activites: 
  From extensive literature review that regarding the traditional uses or phytochemical 
properties of the Neem tree are Antimicrobial, Cytotoxic, Analgesic, Anti-Inflammatory 
(Talha Bin Emran) an antioxidant activity (Sree Lakshmi)
 [77]
. 
 
Recent researches of Azadiracta indica 
 Raj Kumar et, al., Pre-clinical research work done during the last decade has fine-
tuned our understanding of the anticancer properties of the crude and purified products from 
this plant. The anticancer properties of the plant have been studied largely in terms of its 
preventive, protective, tumor-suppressive, immunomodulatory and apoptotic effects against 
various types of cancer and their molecular mechanisms. This review aims at scanning 
scattered literature on ―the anticancer biology of A. indica,‖ related toxicity problems and 
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future perspectives. The cogent data on the anticancer biology of products from A. indica 
deserve multi-institutional clinical trials as early as possible. The prospects of relatively 
cheaper cancer drugs could then be brighter, particularly for the under-privileged cancer 
patients of the world
 [78]
. Ayon Bhattacharya et, al., The analgesic activity using the Neem 
Seed Oil (NSO) has already been done but not the Neem Leaf Extract (NLE). Hence the 
present study is done to evaluate the analgesic effect of NLE on albino rats. It is a 
randomized control study. The analgesic effect of Neem Leaf Extract (NLE) was assessed by 
the experimental pain model of tail flick response to thermal stimulation. The results were 
statistically analyzed by applying the chi-square test .NLE in all doses enhanced the Tail flick 
Latency (TFL) and showed a dose dependent increase in effect. The Neem Leaf Extract 
(NLE) exhibited analgesic activity showing its central analgesic action
 [79] 
  
 
3.3.9. Shorea robusta, Gaertn.f.-Fq;Fypak; [15]   
  Shorea robusta (Family: Dipterocarpaceae) is known as Fq;Fypak;> 
Fq;fpypfk;>rUturk;>Ff;fpy; and commonly known as Sal tree. The word sal comes from 
Sanskrit Ashton (1998). "Shorea robustawhich means house. In Hindu tradition, the sal tree is 
said to be favoured by Vishnu
 [80]
. It is found in Assam, Nepal, and Bengal and on the bank of 
the Yamuna River. In Haryana Sal can be found in the Morni Hills and the Kalesar forests. 
Sal tree grows in North East and Central India up to 1700 meter elevation. It is widely grown 
in the foothills of the Himalayas. It requires well drained, moist and sandy loam soil. is a 
large sub deciduous tree. It is up to 30 meter high. Sal tree is seldom completely leafless. It 
has large leathery leaves and yellowish flowers. They have tough texture. Young trees have a 
linear crown, which becomes rounder and flatter with aging. The sapwood is whitish in 
colour, thick and is less durable. The heartwood becomes dark brown to black in colour on 
exposure. The wood pores are filled with resin
 [81]
.  
 
Chemical Constituents: 
The chemical constituents have an oleoresin, which contains triterpenoids, the 
derivatives of ursonic, oleanane and a triterpene acid. These chemical constituents give Sal 
Tree its therapeutic benefits
 [82]
. 
 ngUk;ghL Nkfk;Nghk; Nguh Jlypy;  
 mUk;gpa Gz; zhWkpit ay;yhky; - FUk;ghk; 
 vYk;GUf;fp Gz;rPOk; VFk; cyfpy;  
 ryk;gUFq; Fq;fpypaj; jhy; [14]  
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Rit: ifg;G> fhh;g;G jd;ik: ntg;gk; gphpT: fhh;g;G 
nra;if: ntg;gKz;lhf;fp> Nfhioafw;wp> rpWePh;ngUf;fp 
 
Phytochemical Activites:  
From extensive literature review that regarding the traditional uses or phytochemical 
properties of the sal tree are Anti bacterial, antioxidant (Raphael R. Marandi)
 [83] 
 ,Anti fungal 
activity (K. Sri Rama Murthy)
 [84] 
, Analgesic activity (Wani TA)
 [85]
 and  Wound healing 
activity (Mukherjee.H.)
 [86]
. 
 
Recent researches of Shorea robusta: 
 Sushma Vashishtha et, al., the methanolic extract of the resin of Shorea robusta was 
subjected to investigate its antioxidant and antibacterial properties its utility in free radical 
mediated diseases including diabetic, cardiovascular, cancer etc. The methanol extract of the 
resin was tested for antioxidant activity using scavenging activity of DPPH (1,1-diphenyl-2-
picrylhydrazil) radical method, reducing power by FeCl3 and antibacterial activity against 
gram positive and gram negative bacteria using disc diffusion method. The phytochemical 
screening considered the presence of triterpenoids, tannins and flavoniods. Overall, the plant 
extract is a source of natural antioxidants which might be helpful in preventing the progress 
of various oxidative stress mediated diseases including aging. The half inhibition 
concentration (IC50) of resin extract of Shorea robusta and ascorbic acid were 35.60 µg/ml 
and 31.91 µg/ml respectively. The resin extract exhibit a significant dose dependent 
inhibition of DPPH activity. Antibacterial activity was observed against gram positive and 
gram negative bacteria in dose dependent manner
 [87]
. Chattopadhyay Debprasad et,al., to 
evaluate the anti-inflammatory and analgesic activities and the possible mechanism of action 
of tender leaf extracts of Shorea robusta, traditionally used in ailments related to 
inflammation. The acetic-acid-induced writhing and tail flick tests were carried out for 
analgesic activity, while the anti-inflammatory activity was evaluated in carrageenan-and 
dextran- induced paw edema and cotton-pellet-induced granuloma model. The acetic-acid-
induced vascular permeability, erythrocyte membrane stabilization, release of 
proinflammatory mediators (nitric oxide and prostaglandin E2), and cytokines (tumor 
necrosis factor-α, and interleukins-1β and -6) from lipopolysaccharide-stimulated human 
monocytic cell lines were assessed to understand the mechanism of action. The results 
revealed that both aqueous and methanol extract (400 mg/kg) caused significant reduction of 
writhing and tail flick, paw oedema, granuloma tissue formation, vascular permeability, and 
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membrane stabilization. Interestingly, the aqueous extract at 40 μg/mL significantly inhibited 
the production of NO and release of PGE2, TNF-α, IL-1β, and IL-6. Chemically the extract 
contains flavonoids and triterpenes and toxicity study showed that the extract is safe. Thus, 
our study validated the scientific rationale of ethnomedicinal use of S. robusta and unveils its 
mechanism of action. However, chronic toxicological studies with active constituents are 
needed before its use
 [88]
. 
 
3.3.10. Aquillaria agallocha Roxb- mfpw;fl;il[15]   
 Aquillaria agallocha (Family: Thymelaeaceae) is known as mfpw;fl;il (m) 
fhfJz;lk; and commonly known as Aloe tree, Eagle tree and Sweet scented tree. The 
Etymology of word Aloe tree which is derived from Sanskrit name Aguru. It was popular in 
Rome, Greece, Arabia, Persia, Egypt, India, and China in ancient times. At first it was used in 
embalming and many historical records continues to use in some Middle Eastern areas such 
as Yemen. Some numerous Islamic text references shows about Aloe tree
 [89]
. The habitats of 
Aloe wood tree are humid, subtropical climate with rainfall 1800-3500 mm annually. They 
are distributed in Himalayan mountain region, Assam, Butan, Asia
 [90]
. 
 
Chemical Constituents: 
  The chemical constituents are aquilochin, liriodenine (an alkaloid), agarol (novel 
sesquiterpenes), chromone derivatives (Agarospirol) and the essential oils yields a number of 
agarofurans, sesquiterpene alcohols and spirosesquiterpene alcohols 
[91]
. 
 
 Ehrp ailg;G etputpb jhSNeha; 
 tPR eikg;Gilg;Gfs; tpl;NlFk;- Ngrpy; 
 RfU kaq;Fe; JizKiyaha; ey;y 
 mfU kuj;jh ywp[14]   
 
Rit: ifg;G> fhh;g;G>rpW ,dpg;G > jd;ik: ntg;gk; gphpT: ,dpg;G 
nra;if: ntg;gKz;lhf;fp> gpj;jePh;g;ngUf;fp> tPf;fKUf;fp 
 
Phytochemical Activites: 
 From extensive literature review that regarding the traditional uses or phytochemical 
properties of the Aloe tree had Antispasmodic, Antiemetic, Constipative, Stomachic, 
Sedative, Tonic, nutritive, tissue-builder .  
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Recent Researches of Aquillaria acallocha 
 P.B. Miniyar et, al., Traditionally, the bark, root and heartwood are used for their 
medicinal properties as a folk medicine to treat infl ammation, arthritis, vomiting, cardiac 
disorders, cough, asthma, leprosy, anorexia, headache and gout. Th e present study was 
carried out to investigate the antioxidant activity of ethyl acetate extract of Aquilaria 
agallocha (EAA). EAA was tested in vitro at diff erent concentrations for inhibitory effect on 
nitrite-induced oxidation of haemoglobin in human blood haemolysate. Results indicate a 
strong antioxidant effect of EAA in a concentration range of 500-3500 μg/ml. However pro-
oxidant activity was observed at higher concentrations of these compounds. Radik naiyar 
et,al., studies have shown that agarwood leaves had mild depressant and antioxidant actions. 
We, therefore, interested in screening the actions of Aquilaria subintegra (AS) leaves extract 
on the central nervous system (CNS) function and learning and memory in an animal model 
of Alzheimer‘s disease. Sixty aged female rats were used. Fifty rats were subjected to 
bilateral ovariectomy and ten rats were served as control sham. These rats were divided into 5 
groups as 1) control 2) sham (non-ovariectomized) .After a single dose administration, rats 
were subjected to behavioral tests. We found that the AS-treated groups exhibited 1) a 
reduction in spontaneous locomotion, 2) an increase of anxiolytic index, 3) an increase of 
nociceptive threshold, and 4) marked potentiation of thiopental induced anesthesia. 
Additionally, rats received AS leaves extract for 2 months showed a significant improvement 
in both object recognition and spatial memories when compared to the control group. 
Altogether, the results suggest that agarwood leaves extract has the potential to be developed 
as herbal beverage and may be used for reducing stress and anxiety, and for the treatment of 
mild cognitive deficits
 [92] 
. 
 
3.3.11 .Nigella sativa .Linn – fUQ;rPufk; (m) re;ep ehafk; [15]   
 Nigella sativa (Family: Ranunculaceae) is also known as fUQ;rPufk;> muzk;> 
cgFQ;rpif> re;ep ehafk; and commonly known as Black cumin, small fennel seeds. The 
Etymology of nigella contains an element meaning black in reference to the unusually dark 
colour of the seeds. It was robably Western Asia. Although nigella is not mentioned in the 
common Bible translations, there is good evidence that an obscure plant name mentioned in 
the Old Testament means nigella; if true, this would indicate that nigella is cultivated since 
far more than two millennia
 [93]
. It is an annual flowering plant, native to south and southwest 
Asia. It grows to 20–30 cm (7.9–11.8 in) tall, with finely divided, linear (but not thread-like) 
leaves. The flowers are delicate, and usually coloured pale blue and white, with five to ten 
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petals. The fruit is a large and inflated capsule composed of three to seven united follicles, 
each containing numerous seeds which are used as spice, sometimes as a replacement for 
original black cumin
 [94]
.  
 
Chemical Constituents: 
The major Chemical Constituents of seeds contain numerous esters of structurally 
unusual unsaturated fatty acids with terpene alcohols (7%); furthermore, traces of alkaloids 
are found which belong to two different types: iso-chinoline al-kaloids are repre-sented by 
nigellimin and nigellimin-N-oxide, and pyrazol alkaloids include nigellidin and nigellicin. In 
the essential oil thymo-quinone was identified as the main component besides p-cymene, α-
pinene, di-thymo-quinone and thymo-hydroquinone. Other terpene derivatives were found 
only in trace amounts: Carvacrol, carvone, limonene, 4-terpineol, and citronellol. 
Further-more, the essential oil contains significant (10%) amounts of fatty acid ethyl esters. 
On storage, thymo-quinone yields di-thymo-quinone and higher oligo-condensation products 
(nigellone). The seeds also contain a fixed oil rich in unsaturated fatty acids, mainly linoleic 
acid (50 – 60%), oleic acid (20%), eicodadienoic acid (3%) and dihomo-linoleic acid (10%) 
which is charac-teristic for the genus. Saturated fatty acids (palmitic, stearic acid) amount to 
about 30% or less. Commercial nigella oil (Black Seed Oil, Black Cumin Oil) may also 
contain parts of the essential oil, mostly thymo-quinone, by which it acquires an aromatic 
flavour
 [95]
.  
 
 fUQ;rP ufj;jhd; fug;gndhL Gz;Zk; 
 tUQ;rPuha;g; gPerK khw;Wk; - mUe;jpdhy; 
 fha;r;ry; jiytypAq; fz;typAk; NghKyfpy; 
 tha;r;r kUe;njdNt it[14]  . 
 
Rit: ifg;G> jd;ik: ntg;gk; gphpT: fhh;g;G 
nra;if: mfl;Lthafw;wp> rpWePh;ngUf;fp> UJTz;lhf;fp> grpj;jPJ}z;b> ghw;ngUf;fp 
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Phytochemical Activites: 
 From extensive literature review that regarding the traditional uses or phytochemical 
properties of the Black cumin seeds are Antioxidant, Antimicrobial, anti inflammatory           
( Mohesan kaseme), Anti diabetic (Desai S D), Anti depressant (Ehab S. Elkhayat)
 [96]
. 
Recent researches of Nigella sativum: 
 Amin F. Majdalawieh et, al., the major signaling pathway utilized by N. sativa to 
manifest its anti-cancer activity is the iNOS signaling pathway. This review underscores the 
recent developments that highlight an effective therapeutic potential of N. sativa to suppress 
tumor development, reduce tumor incidence, and ameliorate carcinogenesis. In sum, 
experimental findings reported in the last two decades strongly suggest that N. sativa 
fractions could serve, alone or in combination with known chemotherapeutic drugs, as 
effective agents to control tumor initiation, growth, and metastasis, and hence, treatment of a 
wide range of cancers
[97] 
. Mohammad Hayatul Islamet, et, al., All tested extracts of N. sativa 
during different phases of germination (especially 5th day germination phase) showed 
significant anxiolytic effect in comparison to control. Diazepam reduced locomotor activity 
in control (unstressed) rats but did not show affect in stressed rats while N. sativa extracts 
from germination phases significantly reduced locomotor activity in unstressed as well as 
stressed animals
 [98]
. All the extracts of N. sativa from different germination phases exhibited 
significant reduction in various phases of epileptic seizure on comparison with the reference 
standard (diazepam). During antidepressant test, N. sativa extracts exhibited a slight 
reduction in the immobility of rats
 [99]
. 
  
3.3.12. Cleome viscosa .Linn. – ey;Ntis[15]   
  Cleome viscosa (Family:  Capparaceae) is also known as ey;Ntis (m) eha;Ntis 
and commonly known as Dog mustard. It occurs in northern tropical Africa, from Cape 
Verde and Senegal to Egypt, Ethiopia and Zanzibar; it is absent in southern Africa, but 
present in Madagascar and other Indian Ocean islands. Outside Africa it is widespread in 
peninsular Arabia, tropical Asia, Australia and tropical and subtropical America. Annual, 
erect, branched herb up to 1 m tall, with yellowish, glandular hairs, viscid, with a strong 
smell when bruised; stem angular-striate, sometimes becoming woody at base. Leaves 
alternate, digitately compound with 3–5 leaflets; petiole up to 6 cm long; leaflets obovate-
lanceolate, 1–5.5 cm × 0.5–2 cm, gradually becoming smaller in higher leaves. The seeds 
have no dormancy and germinate readily after shedding. Plants start flowering 3–4 weeks 
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after germination and the life cycle is about 3 months. The flowers are ephemeral, opening in 
the morning and closing in the afternoon
 [100]
.  
Chemical Constituents: 
  The major chemical constituents are obtained from the seeds is rich in linoleic acid 
and other fatty acids such as palmitic, stearic, oleic,and linolinic acids. Cleomiscosin A, 
cleomiscosin B, cleomiscosin C, cleomiscosin D
[101] 
 . 
   
  rpuNeha; typFilr;ry; jPuhr; rapj;jpak; 
  cuNeh apitf nshopAk; - cuNkTk; 
  tpy;Ntisf; fhAk; tpopaha; grpnfhLf;Fk; 
  ey;Ntis jd;id etpy;[14]   
 
Rit: ifg;G> jd;ik: ntg;gk; gphpT: fhh;g;G 
nra;if: mfl;Lthafw;wp> tpah;itg;ngUf;fp> ,rptfw;wp  
 
Phytochemical Activites: 
  From extensive literature review that regarding the traditional uses or phytochemical 
properties of the Dog mustard significant activities such as s anthelmintic, antimicrobial, 
analgesic, antiinflammatory, immunomodulatory, antipyretic, psychopharmacological, 
antidiarrheal, and hepatoprotective activities (Ravindra G. Mali)
 [102] 
  
 
Recent researches of Cleome viscosa: 
  Nishant Kumar Gupta et, al., the test material was found effective as hepatoprotective, 
through in vivo and histopathological studies. The extract was found to be effective in 
shortening the thiopental induced sleep in mice poisoned with CCl 4. The hepatoprotective 
effect of ethanolic extract was comparable to that of silymarin, a standard hepatoprotective 
agent. B. Parimla Devi et, al., a study was undertaken to evaluate the effect of a methanol 
extract of the entire plant Cleome viscosa L. (CVME) (Family; Capparidaceae) for its anti-
diarrheal potential against some of the experimental models of diarrhea in rats. CVME 
showed significant inhibitory activity against castor-oil-induced diarrhea and PGE2- induced 
enteropooling in rats. The extract also showed a significant reduction in gastrointestinal 
motility in the charcoal meal test in rats. The results obtained establish the efficacy and 
substantiate the folklore claim as an anti- diarrheal agent
 [103]
. 
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3.3.13. Trianthema potulacastrum .Linn. – rj;jprhuiz[15]   
 
  Trianthema potulacastrum (Family: Aizoaceae) is also known as rj;jpr;rhuiz (m) 
nts;isr;rhuiz and commonly known as Desert Horse Purslane, Giant pigweed, Horse-
Purslane.It is a weed found throughout the tropical and subtropical countries. It occurs in 
wastelands, roadsides, lawns, gardens, cultivated crops, and in paddy fields if the water 
supply is low. Stems are prostrate or rising, somewhat succulent, up to 50 cm long or more, 
smooth or sparsely velvety. Leaves are flat, elliptic to obovate or spade-shaped, 1-2 cm long, 
0.4-2 cm wide, margins entire, tip blunt, base rounded to wedge-shaped. Leaf stalks are 0.5-
2.5 cm long, expanded into a sheath joined with opposing leaf base to form a cup. Pink 
flowers are borne solitary, stalkless, largely hidden in leaf axils. Petals (perianth lobes) are 
linear to narrowly deltate, 4-5 mm long, inner surface pink or white, sparsely velvety 
externally; ovary cylindrical; style about 2 mm long
 [104]
. 
 
Chemical Constituents: 
  The major chemical constituents are ecdysterone and the other constituents are 
trianthenol, 3-acetylaleuritolic acid, 5,2‘-dihydroxy-7-methoxy-6,8-dimethylflavone, 
leptorumol, 3,4-dimethoxy cinnamic acid, 5-hydroxy-2-methoxybenzaldehyde, p-
methoxybenzoic acid, and beta cyanin
[105] 
. 
 
Phytochemical Activites: 
  From extensive literature review that regarding the traditional uses or phytochemical 
properties of the Desert Horse Purslane are Analgesic, anti inflammatory activity , Hepato 
protective, Antioxidant, Antidiabetic,Antimicrobial, Anti carcinogenic and wound healing 
property (R.Geethalakshmi)
 [106] 
 
 
 Recent researches of Trianthema decandra: 
  Sree lakshmi K et,al., Urolithiasis is the third most common disorder, which results 
from combined influence of dietary, geographical, biochemical &genetic risk factors. 
Hyperoxaluria was induced by administration of Ethylene glycol (EG) 0.75% and 
Ammonium chloride (AC) 1% in drinking water for 28 days. EG feeding results in 
hyperoxaluria induced oxidative stress as well as increased excretion of calcium, oxalate, and 
phosphate in serum levels. The present study was focused on evaluation of ethanolic extract 
of leaves of Trianthema portulacastrum Linn. (EETP) and Gymnema sylvestre R.Br (EEGS) 
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on experimentally induced urolithiasis. Cystone, a polyherbal formulation is used as a 
reference standard. Parameters like urinary volume, urine analysis (calcium, oxalate, 
phosphate, magnesium, and phosphate), serum analysis (calcium, creatinine, uric acid, BUN) 
and antioxidant studies were performed to access the activity. Treatment with ethanolic 
extract of Trianthema portulacastrum and Gymnema sylvestre at both the doses (200 mg/kg 
and 400 mg/kg) showed a significant restoration of urinary and serum parameters on EG&AC 
induction. The extracts at both doses (200 mg/kg and 400 mg/kg) showed significant increase 
in antioxidant enzymes activity &decrease in MDA levels. From all the protective findings of 
both extracts EEGS showed more potent antilithiatic activity when compared to EETP
 [107]
. 
Jason Yamak et, al., Emerging studies demonstrate that crude extracts as well as bioactive 
phytoconstituents of T. portulacastrum exhibit potent antioxidant, anti-infective, analgesic, 
and anti-inflammatory activities. A growing number of in vitro and in vivo studies 
demonstrate various biological and pharmacological activities, including prevention and 
amelioration of hepatotoxicity, nephrotoxicity, hyperglycemia, hyperlipidemia, infectious 
diseases and cancer. This review aims to present and analyze available literature to 
understand the full potential of T. portulacastrum in health promotion and disease prevention. 
Current limitations and future directions of research on this medicinal and dietary plant are 
also critically discussed
 [108]
. 
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3.4. CLINICAL ASSESSMENT PARAMETERS 
 
Social relationship and reciprocity 
 Persons with Autism generaiiy remain aloof, socially withdrawn and do not interact 
with other people. They have difficulty in understanding another person‘s feelings such as 
pain or sorrow.They have problems in maintain eye contact and do not develop age 
appropriate peer relationships 
 
 Eye contact – Individuals with Autism avoid looking people in the eye. They are 
unable to maintain eye contact as expected. 
 Social smile – Individuals with Autism do not smile when meeting people or in 
reciprocation. A smile that reflectssocial response and recognition cannot be elicited 
from such persons 
 Solitary and repetitive activities - Individuals with Autism may remain alone most 
of the item or prefer solitary activites. They avoid playing with otheras and may not 
engage in group oriented activities or tasks at all. 
 Social interaction – Individuals with Autism don not comprehend the significance of 
taking turns in reciprocal interaction with others. They do not wait until their turn 
comes or others turn ends 
 Peer relationship - Individuals with Autism do not develop age appropriate 
friendships. They may not engage in age appropriate peer relationship as it is socially 
expected. 
 
Emotional responsiveness 
 Individuals with Autism do not show the expected feelings in a social situation. 
Emotional reactions are unrelted to the situation and may show anxiety or fear which is 
excessive in nature without apparent reason. They may show inappropriate emotional 
reponse. 
 
 Inappropriate emotional response – Persons with Autism do not show the expected 
feeling in a social situation. They express iappropriate emotional reponse like 
laughing when scolded or spanked and inappropriate degree of responses like 
excessive crying or laughing that is unwarranted. 
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 Exaggerated emotions - Persons with Autism may show anxiety or fear which is 
excessive in nature and which may be triggered off which is excessive in nature and 
which may be triggered off without an apparent reasons. At times, it may be 
exaggerated or atypical. 
 Self-stimulating emotions - Persons with Autism may engage in self talk that is 
inappropriate for their age. The Autistic individual may smile to self without any 
apparent reason.  
 Fear for danger - Persons with Autism may not show fera of hazards or dangers 
which other of the same age would show or know 
 Excited for no apparent reasons - Persons with Autism may show excitement, over 
activity or agitation that is both excessive and unwarranted. The Autistic child moves 
around brisk energy and may difficult to control. 
Speech: language and communication 
 Individuals with Autism have problems in speech development.They find it difficult 
to express their needs verbally and non verbally and may also have difficulty in 
understanding the non verbal language of others. People with Autism often have echolalia 
and may repeat a word, phrase or sentence out of context. 
 
 Non-verbal language to communicate the others - Persons with Autism find it 
diffict to express their needs non verbally and may also have difficulty in 
understanding the non verbal language of others, instead of gesturing or pointing, they 
may lead others to desire object by dragging or pulling the latter‘s hand 
 Stereotyped and repetitive use of language - Persons with Autism may repeat a 
word, phrase or sentence out of context. They repeat the same statement many times. 
 Unusual noises - Persons with Autism May sueal make bizarre, noises and produce 
unintelligible speech like sound. They may produce speech like sounds that lack 
meaning. 
 Meaningless words - Persons with Autism may use strange or meaningless words 
which convey no meaning 
 Understand the meaning of communication - Persons with Autism have difficulty 
in understanding the true intent of speech of others. They may not understand the 
pragmatics of speech communication 
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Behavioural patterns 
 Persons with Autism may engage in self- stimulatory behaviour in the form of 
flapping hands and using as object for this purpose. They insist on following routine and may 
resist change. Some Autistic children may be restless and exhibit aggressive behaviour. 
 
 Hyperactivity and restlessness - Persons with Autism Amy be restless with 
boundless energy which makes it difficult for others to control them. The 
hyperactivity interferes with their learning and performance tasks. 
 Aggressive behaviour - Persons with Autism may show unprovoked aggression and 
socially inappropriate behaviour such as htting, kicking and pinching. 
 Attachment to inanimate objects - Persons with Autism may be staunchly attached 
to certain inanimate objects which they insists on keeping with themselves such as 
string , rock , pen, stick, toy, bottle . 
 Self-injurious behaviour - Persons with Autism may indulge in self injurious 
behaviour like bitting, hitting or mutilating self. Such individuals have to be 
constantly supervised to prevent injuring themselves. 
 Temper tantrums - Persons with Autism may show the outburst of emotions like 
whining, crying to screaming, kicking, hitting and breath holding. 
 
Sensory aspects 
 Persons with Autism are usually sensitive to sensory stimuli. Amajority of them are 
eitherhypo or hyper sensitive to light, sound, smell and other external stimulation. Some 
Autistic children explore their environment by smelling, touching or tasting objects. 
 
 Unusual visions - Persons with Autism may be able to observe tiny details which 
may not apparent to others. Such individuals focus their attention on some 
insignificant part of an object that is generally ignored by others. 
 Stares into space for long periods of time - Persons with Autism may stare at some 
distant spot or space for long periods of time. They seemto be unaware of 
surroundings when thus occupied. 
 Insensitive to pain - Persons with Autism may hardly react to pain. They seem not to 
be distressed or cry when hurt. They seem to have high thresholds for pain. 
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 Responds to object - Persons with Autism may go around exploring their 
environment by smelling, touching, or tasting objects. Some of them may not show 
appropriate use of objects or toys. 
 Tracking objects - Persons with Autism may difficulty in tracking objects or persons 
in motion. They are unable to follow or fix their gaze on moving objects or persons 
for the required period of time. 
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4. MATERIALS AND METHODS 
 
4.1. Preparation of Experimental Formulations 
     The trial drugs were purchased from a well reputed country shop in Tambaram and 
the raw drug were authenticated by the Medical Botanist of National Institute of Siddha. 
After process the medicine was proper purification and prepared in Gunapadam lab of NIS. 
The Prepared medicine was stored in glass container authenticated by the concerned guide for 
its completeness.    
 
4.1.1. Kuruver kudineer (Internal Medicine): 
 
Vernacular/ Tamil name Botanical Name  Parts Used Part 
Vettiver Vettiver Zaizanoids Root 1/4 palam 
Vilamichu Plectranthus vettiveroids Root 1/4 palam 
Chukku Zingiber officinalae Dried rhizome 1/4 palam 
Parpadagam Hedyotis corymbosa Root 1/4 palam 
Siruthaeku Clerodendrum serratum Root 1/4 palam 
 
Purification: 
வவட்டிவவர்  ( Vettivera zizanoides)   : Cut into a small pieces and dried at day time 
வியா஫ிச்சு (Plectranthes vettiveroides ) :  Cut into a small pieces and dried at day time    
சுக்கு (Zingiber officinalae ) : 
   Add 2 part of sunnakkal 1 part of Zingiber officinalae for 3 hours, wash it and then 
dried. After that external skin should be peeled off. 
பற்பைாகம் ( Hedyotis corymbosa ) :  
 Remove the dust materials then washed into pure water and then dried. 
சிறுவதக்கு ( Clerodendrum seratum  ) :  
 Cut into a small pieces and dried at day time    
 
Preparation method: 
               Ingredients mentioned above are made as a coarse powder and then soaked it in a 
vessel containing  of water 1 படி and heat till it comes to 1/8 th of its volume, twice a day. 
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Duration: 90 days 
Dispensing:    
          Prepared medicine will be given as decoction 
 
4.1.2. External medicine I-Sambrani thuvalai 
   
Vernacular/ Tamil name Botanical Name  Parts Used Part 
Vellerukan samoolam Calatropis giganteae All parts 1 Kg 
Sambirani Styrax benzoin Gum 1 Kg 
Veapa ennai Azadiracta indica oil 2 litres 
 
Method: 
               Take all the above ingredients in equal quantity except neem oil and make it as a 
decoction then boiled with neem oil. After the oil is apply over whole body like a thuvalai 
once in a day. 
Duration: 90 days 
 
4.1.3. External Medicine- II Mysatchi pugai 
 
Vernacular/ Tamil name Botanical Name  Parts Used Part 
Mysatchi Shorea robusta gum 1/2 Kg 
Sambirani Styrax benzoin gum resin 1/2 Kg 
Agirkattai Aquillari agalocha wood 1/2 Kg 
Sanninayagam Nigella sativum Seeds 1/2 Kg 
Velai ver Cleome viscosa Root 1/2 Kg 
Sathisaranai Ver Trianthema decandra Root 1/2 Kg 
 
 Method: 
            Take1- 4 ingredients mentioned above in equal quantity make as a powder and then 5-
6 ingredients make it as a flamed substances. After that fumigate once in a day.  
Duration: 90 days            
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Kuruver Kudineer (Internal Medicine) 
 
 
Vettivera Zaizanoides 
 
Plectranthus vettiveroides 
 
Zingiber officinalae 
 
Hedyotis corymbosa 
Clerodenrum serrattum 
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I.Sambirani Thuvalai (External medicine) 
 
 
 
 
Calatropis giganteae 
 
Styrx benzoin 
 
 
 
 
 
Azadiracta indica 
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II.Mysatchi pugai (External medicine) 
  
 
Aquillaria agalocha 
 
Nigella sativa 
 
Cleome viscosa 
 
Trianthema decandra 
 
 
                            Styrax benzoin                                               Shorea robusta 
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Thvalai (Oleation therapy)
 [109]
: 
 Thuvalai is also kown as oleation therapy in the field of Siddha. It is basically a type 
of lubrication system for the human body. It works by administrating the fatty products 
externally. This is used prior to the detox therapy. This process of the body makes use of the 
oils and ghees by consuming them or use of the oils and ghees by consuming them or using 
them externally as well. 
 
Purpose of oleation therapy 
1. Helps in eliminating the toxic materials from the body of the individuals. 
2. Detoxifies the body and its various vital organs 
3. Provides a wounderful lubrication of the various parts of the body  
 
Procedure: 
 A day prior to liquid food must be consumed. The next day morning is suggested to 
consume the light food like porridge in empty stomach. Then it is essential to wait for the 
proper digestion of the entire thing. Once it is digested, go for this therapy. Afterwards, the 
medicated oil is applied all over the body. 
 
Fumigation (Pugai)
 [101] 
 Fumigation denotes the artificial impregnation of the atmosphere, with the fumes or 
the smoke of any vegetable or aromatic substance. Fumes are also used as inhsalation 
therapy. Many times apart from herb, animal products including snake, birds and dropping of 
elephant, donkey and other animal dung are used. 
  
Indications: 
1. Fume inhalation therapy is as effective treatment for respiratory conditions such as 
sinusitis, bronchitis, allergies, dental caries and asthma 
2. Fumigation can be considered an integral medicine and given even for an unconscious 
patient 
3. Fumigation is done in hysteria probably the pleasabt and sharp aroma elevates the 
mood 
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 Do’s and Dont’s: 
1. Fumigation should not be done in empty stomach and it has to be done in inorganic 
substances. 
2. Curd should be avoided 
3. Fumigation with toxic substances is not advised in newborn, infants, pregnany and 
lactating mothers, people under influence of alcohol, suffering from the head injury. 
4. A strict diet restriction is advised during treatment. The restriction includes avoiding 
sour food like tamarind, salt and spicy food. 
5. Oil bath with application of omam paste on the vertex is suggested after the treatment 
period. 
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4.2. Preclinical Studies 
4.2.1Physicochemical analysis of the Trial drug based on PLIM 
4.2.2. Phytochemical analysis 
4.2.3. Biochemical analysis 
4.2.4 Pharmacological Study – Anxiolytic activity of the trial drug 
 
4.21PHYSICOCHEMICAL ANALYSIS OF KURUVER KUDINEER CHOORANAM 
  The prepared medicine were analysed of Physicochemical based on PLIM done in   
Tamil Nadu Dr.MGR medical university, Guindy. 
 
1. Loss on drying: 
 An accurately weighed 2g of Kuruver Kudineer chooranam formulation was taken in 
a tarred glass bottle. The crude drug was heated at 105°C for 6 hours in an oven till a constant 
weight. The percentage moisture content of the sample was calculated with reference to the 
shade dried material. 
 
2. Determination of total ash: 
 Weighed accurately 2g of Kuruver Kudineer chooranam formulation was added in 
crucible at a temperature 600°C in a muffle furnace till carbon free ash was obtained. It was 
calculated with reference to the air dried drug. 
 
3. Determination of acid insoluble ash: 
 Ash above obtained, was boiled for 5min with 25ml of 1M Hydrochloric acid and 
filtered using an ash less filter paper. Insoluble matter retained on filter paper was washed 
with hot water and filter paper was burnt to a constant weight in a muffle furnace. The 
percentage of acid insoluble as was calculated with reference to the air dried drug. 
 
4. Determination of water soluble ash: 
 Total ash 1mg was boiled for 5min with 25ml water and insoluble matter collected on 
ash less filter paper was washed with hot water and ignited for 15 min at a temperature not 
exceeding 450°C in a muffle furnace. The amount of soluble ash is determined by drying the 
filtrate. 
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5. Determination of water soluble extractive: 
 5gm of air dried drug, coarsely powered Kuruver Kudineer chooranam was macerated 
with 100ml of distilled water in a closed flask for twenty- four hours, shaking frequently. The 
solution was filtered and 25 ml of filtered was evaporated in a tarred flat bottom shallow dish, 
further dried at 100°C and weighed. The percentage of water soluble extractive was 
calculated with reference to the air dried drugs. 
 
6. Determination of alcohol soluble extractive: 
 2.5mg of air dried drugs coarsely powered Kuruver Kudineer chooranam was 
macerated with 50ml alcohol in a closed flask for 24 hrs. With frequent shaking, it was 
filtered rapidly taking precaution against loss of alcohol.10ml of filtrate was then evaporated 
in a tarred flat bottom shallow dish, dried at 100°C and weighed. The percentage of alcohol 
soluble extractive was calculated with reference to air dried drug. 
 
4.2.2PRELIMINARY PHYTOCHEMICAL SCREENING KURUVER KUDINEER 
CHOORANAM 
The prepared medicine were analysed of phytochemical screening done in Tamil Nadu 
Dr.MGR medical university, Guindy. 
The preliminary phytochemical screening test was carried out for each extracts of Kuruver 
Kudineer Chooranam as per the standard procedure. 
 
1. Detection of alkaloids: 
Extracts were dissolved individually in dilute Hydrochloric acid and filtered. 
 
a) Mayer’ Test: Filtrates were treated with Mayer‘s reagent (Potassium Mercuric 
Iodide). Formation of a yellow colored precipitate indicates the presence of alkaloids. 
b) Wager’s Test: Filtrates were treated with Wagner‘s reagent (Iodine in Potassium 
Iodide). Formation of brown/reddish precipitate indicates the presence of alkaloids. 
c) Dragendroff’s Test: Filtrates were treated with Dragendroff‘s reagent (Solution of 
Potassium Bismuth Iodide). Formation of red precipitate indicates the presence of 
alkaloids. 
d) Hager’s Test: Filtrates were treated with Hager‘s reagent (Saturated picric acid 
solution). Presence of alkaloids confirmed by the formation of yellow colored 
precipitate. 
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2) Detection of carbohydrates:
Extracts were dissolved individually in 5 ml distilled water and filtered. The filtrates were 
used to test for the presence of carbohydrates. 
a) Molisch’s Test: To 2ml of plant sample extract, two drops of alcoholic solution of α-
naphthol are added. The mixture is shaker well and few drops of concentrated sulphuric acid 
are added slowly along the sides of test tube. A violet ring indicates the pressure of 
carbohydrates. 
b) Benedict’s test: Filtrates were treated with Benedict‘s reagent and heated gently.
Orange red precipitate indicates the presence of reducing sugars. 
3. Detection of glycosides:
Extracts were hydrolyzed with dil.HCL, and then subjected to test for glycosides. 
a) Modified Borntrager’s Test: Extracts were treated with Ferric chloride solution and
immersed in boiling water for about 5 minutes. The mixture was cooled and extracted with 
equal volumes of benzene. The benzene layer was separated and treated with ammonia 
solution. Formation of rose-pink color in the ammonical layer indicates the presence of 
anthranol glycosides. 
b) Cardiac glycoside (Keller-Killiani test): Extract was shaken with distilled water (5
mL). To this, glacial acetic acid (2 mL) containing a few drops of ferric chloride was added 
followed by H2SO4 (1mL) along the side of the test tube. The formation of brown ring at the 
interface gives positive indication for cardiac glycoside and a violet ring may appear below 
the brown ring. 
4. Detection of saponins:
a) Froth Test: Extracts were diluted with distilled water to 20ml and this was shaken
in a graduated cylinder for 15 minutes. Formation of 1 cm layer of foam indicates the 
presence of saponins. 
b) Foam Test: 0.5 gm of extract was shaken with 2 ml of water. If foam produced
persists for ten minutes it indicates the presence of saponins. 
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5. Detection of phytosterols:
a) Salkowski’s Test: Extracts were treated with chloroform and filtered. The filtrates
were treated with few drops of Conc. sulphuric acid, shaken and allowed to stand. 
Appearance of golden yellow color indicates the presence of triterpenes. 
6. Detection of phenols Ferric Chloride Test:
Extracts were treated with 3-4 drops of ferric chloride solution. Formation of bluish 
black color indicates the presence of phenols. 
7. Detection of tannins Gelatin test:
The extract is dissolved in 5 ml of distilled water and 2 ml of 1% solution of Gelatin 
containing 10% NaCl is added to it. White precipitate indicates the presence of phenolic 
compounds. 
8. Detection of Flavonoids:
a) Alkaline reagents test: Extracts were treated with few drops of sodium hydroxide
solution. Formation of intense yellow color, which becomes colorless on addition of dilute 
acid, indicates the presence of flavonoids. 
b) Lead acetate test: Extracts were treated with few drops of lead acetate solution.
Formation of yellow color precipitate indicates the presence of flavonoids. 
9. Detection of proteins and amino acids:
a) Xanthoproteic test: The extracts were treated with few drops of Conc.Nitric acid.
Formation of yellow color indicates the presence of proteins. 
b) Ninhydrin test: To the extract, 0.25% w/v Ninhydrin reagent was added and
boiled for few minutes. Formation of blue color indicates the presence of amino acids. 
67 
 
10.  Detection of diterpenes copper Acetate test: 
 Extracts were dissolved in water and treated with 3-4 drops of copper Acetate 
solution. Formation of emerald green color indicates the presence of diterpenes. 
 
11.  Gum and Mucilage: 
 To 1 ml of extract add 2.5 ml of absolute alcohol and stirring constantly. Then the 
precipitate was dried in air and examine for its swelling properties. Swelling was observed 
that will indicate preence of gum and Mucilage. 
 
12.  Test for fixed oils and fats: 
 a) Spot test: A small quantity of extract is pressed between two filter papers. Oil stain 
on the paper indicates the presence of fixed oils. 
 
13. Test for Quinones: 
 Extract was treated with sodium hydroxide blue or red precipitate indicates the 
presence of Quinones. 
 The preliminary phytochemical studies of aqueous extract of Kuruver Kudineer 
Chooranam were done using standard procedures. The results were presented in tables. The 
present study reveals that the bioactive compounds were present in all the extracts of 
Kuruver Kudineer Chooranam. 
 
4.2.3. BIOCHEMICAL ANALYSIS OF KURUVER KUDINEER 
             Chemical analysis of Kuruver Kudineer was done at the Biochemistry lab at National 
Institute of Siddha, Chennai by the method of Kolkate. 
 
Preparation of Extract 
             5ml of sample was taken in a 250ml clean beaker and added with 50ml of distilled 
 Water .Then it is boiled well for about 10 minutes. Then it is cooled and filtered in a 100ml  
Volumetric flask and made up to 100ml with distilled water. This preparation is used for the  
Qualitative analysis of acidic| basic radicals and biochemical constituents in it. 
 
Procedure 
a) Test for Silicate 
      2ml of the sample was shaken well with distilled water. 
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b) Action of Heat
2ml of the sample was taken in a dry test tube and heated gently at first and then strong.
c) Ash Test
A filter paper was soaked into a mixture of extract and dil. Cobalt nitrate solution and
introduced into the Bunsen flame and ignited. 
1. Test for Acid Radicals
1.1Test for Sulphate 
     2ml of the above prepared extract was taken in a test tube to this added 2ml of 4% 
dil.ammonium oxalate solution. 
1.2Test for Chloride 
     2ml of the above prepared extract was added with 2ml of dil.HCL is added until the 
effervescence ceases off. 
1.3Test for Phosphate 
     2ml of the extract were treated with 2ml of dil.ammonium molybdate solution and 2ml of 
con.HNO3. 
1.4Test for Carbonate 
      2ml of the extract was treated with 2ml of dil.magnesium sulphate solution. 
1.5Test for Nitrate 
      1gm of the extract was heated with copper turning and concentrated H2SO4 and viewed 
the test tube vertically down. 
2. Test for Basic Radicals
2.1. Test for Lead 
        2ml of the extract was added with 2ml of dil.potassium iodine solution. 
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2.2 Test for Copper 
        One pinch (25mg) of extract was made into paste with con.HCLin a watch glass and 
introduced into the non-luminuous part of the flame. 
2.3. Test for Aluminium 
       To the 2ml of extract dil.sodium hydroxide was added in 5 drops to excess. 
2.4. Test for Iron 
a. To the 2ml of extract add 2ml of dil.ammonium solution.
b. To the 2ml of extract 2ml of thiocyanate solution and 2ml of con.HNO3 is added.
2.5. Test for Zinc 
       To 2ml of the extract, dil.sodium hydroxide solution was added in 5 drops to excess and 
dil.ammonium chloride is added. 
 2.6. Test for Calcium 
       To 2ml of the extract was added with 2ml of 4% dil. Ammonium oxalate solution. 
2.7. Test for Magnesium 
        To 2ml of extract dil.sodium hydroxide solution was added in drops to excess. 
2.8. Test for Ammonium 
      To 2ml of extract 1ml of Nessler‘s reagent and excess of dil.sodium hydroxide solution 
are added. 
2.9. Test for Potassium 
       A pinch (25mg) of extract was treated of with 2ml of dil. Sodium nitrite solution and 
then treated with 2ml of dil.cobalt nitrate in 30% dil.glacial acetic acid. 
2.10. Test for Sodium 
       2 pinches (50mg) of the extract is made into paste by using HCL and introduced into the 
blue flame of Bunsen burner. 
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2.11. Test for Mercury 
       2ml of the extract was treated with 2ml of dil.sodium hydroxide solution. 
2.12. Test for Arsenic 
       2ml of the extract was treated with 2ml of dil. Sodium hydroxide solution. 
3. Miscellaneous
3.1. Test for Starch 
        2ml of extract was treated with weak dil.Iodine solution. 
3.2. Test for reducing sugar 
        5ml of Benedict‘s qualitative solution was taken in a test tube and allowed to boil for 2 
minutes and added 8 to 10 drops of the extract and again boil it for 2 minutes.The colour 
change are noted. 
3.3. Test for the Alkaloids 
1. 2ml of the extract was treated with 2ml of dil.potassium Iodide solution.
2. 2ml of the extract was treated with 2ml of dil.picric acid.
3. 2ml of the extract was treated with 2ml of dil.phosphotungstic acid.
3.4. Test for Tannic Acid 
        2ml of extract was treated with 2ml of dil.ferric chloride solution. 
3.5. Test for Unsaturated Compound 
        To the 2ml of extract 2ml of dil.potassium permanganate solution is added. 
3.6. Test for Amino acid 
       2 drops of the extract was placed on a filter paper and dried well.20 ml of Burette reagent 
is added. 
3.7. Test for Type of Compound 
     2ml of the extract was treated with 2ml of dil. Ferric chloride solution. 
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4.2.4. Pharmacological activity-Anxiolytic activity (Elevated plus maze method): 
The pharmacological study protocol has got an approval from Institutional ethical 
committee of National Institute of Siddha, Chennai (NIS/IAEC/-IV/04105012017).  
Species/Common name : Swiss albino Mice 
Age / weight / size   : 6 – 8 weeks/20-35g 
Gender :  Male and female 
Route of Administration : Oral 
Room temperature        : 22+2
0
C
Humidity : 40-65% 
Same sex of 3 animals was hused in propylene cages with husk bedding. Ech animal 
has marked in picric acid on the fur for identification (Head, Neck, Body and Base of tail) 
and it was indicated in cage card along with the number.CPCSEA guidelines would be 
strictly adhered . Animals would be monitored for health, food with adequate nutrition 
(Rodent pellets) and water atlibidum etc. for 24 x7 days per week. Animal husbandry would 
be 12-hour light and12-hour dark cycle. Monitoring room temperature   at 22°C (±3°) and 
relative humidity are 30–70%. Polypropylene cages would be used with proper husk bedding. 
Animal excreta would be disposed properly and monitored hygienic condition. All animals 
would be observed for signs of illness, injury or abnormal behaviour treated with veterinary 
surgeon. If any animal die immediately post-mortem would done for observation of autopsy 
changesDiseased animals would be monitored, treated and quarantined in the separate cages 
After the experimental period, animals would be reutilized for another study followed by 
acclimation period or else would be leave independently. 
The Elevated plus maze has been described as simple method for assessing anxiety 
response of rodents. The apparatus used for the elevated plus maze test is in the configure of 
a+  and comprises two arms (25*5*0.5cm) across from each other and perpendicular to two 
closed arms (25*5*16cm) with a centre  platform (5*5*0.5 cm). The open arms have a very 
small (0.5cm) wall to decrease the number of fall, whereas the closed arms have a high 
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(16cm) wall to enclose the arm.  The entire apparatus is 50cm above the floor and is placed in 
empty circular tank to protect the mice that fall or attempt to escape during the experiment 
.The apparatus is made of plastic materials. The platform is white and the walls are 
transparent. There is a variation and colours of the apparatus of elevated plus maze. 
The behaviour testing room is soundproof and the illumination level is maintained at 
100 lux.  A mouse is placed in the centre area of the maze in its head directed toward a closed 
arm.  The elevated plus maze test is observed. The number of entries into each arm and the 
time spent in the open arms are recorded and these measurements serve as an index of anxiety 
like behaviour.  Mice are allowed to move freely about the maze for 10 min. The distance 
travelled the number of entries into each arm, the time spent in each arm and the per cent of 
entries into the open arm are calculated. After each trail, all arms and the centre area are 
cleaned with super hypo chlorous water, that is an efficient odour removal agent and has 
relatively weak odour of itself compared to their cleaning solutions to prevent a bias based on 
olfactory cues. 
Thus we can conduct the tests under controlled condition regarding olfactory cues. A task 
using a y shaped apparatus that include on elevated open alley which produced a strong 
approach avoidance conflict ad and closed assay. The Mice demonstrated the most robust 
avoidance response in the first 5 min after placement in the elevated open alleys. The 
behaviour that is typically observed when rodents are in the elevated plus maze time spends 
and entries made on the open and closed arms. Antianxiety behaviour can be determined 
simultaneously with a measure of spontaneous motor activity and the arm entries made in the 
maximum of an optimal motor activity. 
4.3. Clinical studies: 
A Protocol was prepared and submitted before IEC of National Institute of Siddha. 
The IEC approval number is NIS/IEC/2016/11-19/ 14.10.2016 and my registered CTRI 
number is CTRI/2017/05/008698. After getting the approval from committee, the clinical 
study on Mantha sanni (Autism spectrum disorder) in children and drug of choice was 
Kuruver kudineer carried out as per the protocol. 
       The trial drug ―KURUVER KUDINEER‖ is given for 90 days .For OP patients 
before and after treatment the clinical assessment will be done and prognosis is noted.     
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4.3.1. INCLUSION CRITERIA: 
Children of age group under 3- 12 years                                         
Impaired social interaction                                                              
Mild to Moderate aggressiveness                                                             
Repetitive behaviour                                                                        
Lack of eye contact                                                                          
Babble sound                                                                                  
Clinically diagnosed as a ASD      
    Child will be include 4 or more criteria for this clinical trial study               
 
4.3.2. Exclusion criteria: 
Epilepsy                                                                                         
Severe aggressiveness                                                                    
Cerebral palsy                                                                                 
Congenital heart disease           
 
4.3.3. Withdrawal criteria 
Intolerance to the drug and development of adverse reactions during trial  
Poor patient compliance and defaulters 
Patient turned unwilling to continue in the course of clinical trial     
 
4.3.4. Clinical assessment parameters: 
Social relationship and reciprocity 
 Eye contact 
 Social smile 
 Solitary and repetitive activities 
  Social interaction 
 Peer relationship 
Emotional responsiveness 
 Inappropriate Emotional response 
 Exaggerated emotions 
 Self-stimulating emotions 
 Fear for danger 
 Excited for no apparent reasons  
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Speech: language and communication 
 Non-verbal language to communicate the others 
 Stereotyped and repetitive use of language 
 Unusual noises 
 Meaningless words 
 Understand the real meaning of  communication 
Behavioural patterns 
 Hyperactivity and restlessness 
 Aggressive  behaviour 
 Attachment to inanimate objects 
  Self-injurious behaviour 
 temper tantrums 
Sensory aspects 
 Unusual visions 
 Stares into space for long periods of time 
 Insensitive to pain 
 Responds to object  
 Tracking objects 
 Children were assessed for improvement on 0th, 30th, 60th, 90th day of treatment and the 
results were entered in the assessment forms. The results were analysed by computing the scores 
as 0 score – Never (5), 1 score – Sometimes (10), 2 score – Often (15), 3 score – Mostly (20), 4 
score – Always (25) exhibits the skills in Autism Clinical Assessment Parameters. 
  
4.3.4. Siddha Method of Assessment 
Nilam 
Kaalam 
NeerThathukal  
Udal Thathukal 
Envagai Thervugal 
Neerkuri 
Neikruri 
Autistic child Severe  Moderate to severe Mild to Moderate  Mild  Normal to Mild  
Score Range (125-249) (250-374) (375-499) (500-624) ( >625) 
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Study Enrolment: 
1. In this study, patients reporting at the NIS OPD with three or more clinical symptoms 
were examined clinically for enrolling in this study based on the inclusion and exclusion 
criteria 
2. The patients were enrolled to be informed about the study, trial drug, possible 
outcomes and the objectives of the study in the language and terms understandable to them 
and to their informants. 
3. After ascertaining the patient and informants willingness, informed consent was 
obtained in writing from them in the consent form (Form II). 
4. All these patients were given unique registration card in which patient‘s Registration 
number of the study; Address, Phone number and Doctors phone number etc. were given, so 
as to report easily should any complication arise. 
5. Complete clinical history, complaints and duration, examination findings all were 
recorded in the prescribed Profoma in the history and clinical assessment forms separately. 
Patients were advised to take the trial drug and appropriate dietry advices were given 
according to the patient informant‘s perfect understanding. 
  
Conduct of the study: 
      The trail drug  Kuruver  Kudineer were given continuously for 90 days.After that patient 
will be requested to attend the OPD for clinical assessment and it will be recorded in the 
clinical assessment form and prognosis noted. The patient‘s informants are requested to bring 
back the un-consumed trial drug if any. For IP patients the drug will be provided daily and 
prognosis will be noted. Laboratory investigations will be done on the day before the start of 
my study. After the completion of the treatment, the patient is advised to visit our OPD for 
follow up. 
 
DATA COLLECTION FORMS 
FORM 1 SCREENING AND SELECTION PROFORMA 
FORM 2 CONSENT FORM 
FORM 3 CASE REPORT PROFOMA 
FORM 4 PATIENT‘S INFORMATION SHEET  
FORM 5 DRUG COMPLIANCE 
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FORM 6 WITHDRAWAL FORM  
FORM 7ADVERSE REACTION FORM 
FORM 8 PHARMACOVIGILENCE FORM 
FORM 9 DIETARY ADVICE FORM. 
 
Data Management: 
 After enrolling the patient in the study a separate file for each patient will be opened 
and all forms were filled in the file. Whenever study patient visits OPD during the study 
period, the respective patient file were taken and necessary recordings were made at the 
assessment form or other suitable form.The screening forms were filed separately.The Data 
recordings were monitered for completion all collected data were enterd using MS access 
software onto computer. Investigators were trained to enter the patient data and cross checked 
by SRO. 
 
Adverse effects / serious effect Management: 
      If the trial patient develops any adverse reaction he /she were immediately withdrawn 
from the trial and proper management were given in OPD of NIS and the same were reported 
to regional pharmacovigilance centre.The details of adverse reactions were recorded in 
prescribed Pharmacovigilance centre. 
 
Ethical Issues: 
 To prevent infection, while collecting blood sample from the patient, only disposable 
syringes, disposable gloves, with proper sterilization of lab equipements will be used 
 No other external and internal medicines were used. There were no infringements on 
the rights of patient. 
 The data collected from the children‘s parent /guardians were kept confidentially. The 
patient‘s parent /guardian were informed about the diagnosis, treatment and follow up. 
 After the consent of the patient (through consent form) they were enrolled in the 
study. 
 Informed consent was obtained from the patient‘s parent / guardian explaining in the 
understandable language to his / her for the enrollment of the study. 
 Treatment were provided free of cost 
 In condition of treatment failure, adverse reactions, patients were given alternative 
treatment at the NIS with full care 
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5. RESULT AND ANALYSIS 
Table.5.1. Physico Chemical Analysis of Kuruver Kudineer 
 
Table.5.2.Phytocomponents Result: 
S.No Parameters Percentage 
1 Loss on drying 5.54% 
2 Total ash value 6.82% 
3 Acid insoluble ash 1.81% 
4 Water soluble ash 2.40% 
5 Water soluble extraction 33.23% 
6 Alcohol soluble extraction 10.76% 
S.no Phytochemicals Test Name H2O Extract 
1 Alkaloids 
Mayer‘s Test  +ve 
Wagner‘s Test -ve 
Dragendroff‘sTest -ve 
Hager‘s Test -ve 
2 Carbohydrates 
Molisch‘s Test +ve 
Benedict‘s Test +ve 
3 Glycoside 
Modified Borntrager‘s 
Test 
-ve 
Keller Killaini 
-ve 
 
4 Saponin 
Froth Test +ve 
Foam Test -ve 
5 Phytosterol Salkowski‘s Test -ve 
6 Phenols Ferric Chloride Test -ve 
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   +   Indicates positive 
         -    Indicates Negative 
 
5.3. Biochemical analysis of Kuruver kudineer 
Table.5.3.1.Results of Acid radical’s studies 
7 Tannins Gelatin Test -ve 
8 Flavonoids 
Alkaline Reagent Test +ve 
Lead acetate Test +ve 
9 Proteins and amino acids Xanthoproteic Test -ve 
10 Diterpenes Copper Acetate Test +ve 
11 Gum & Mucilage Extract + Alcohol -ve 
12 Fat & Fixed Oil Spot Test -ve 
13 Quinones NAOH + Extract +ve 
S.NO Parameter Observation Result 
1 Test for Sulphate 
              No Cloudy 
appearance. 
 
Positive 
2 
Test for Chloride 
 
Cloudy appearance    
present 
 
Positive 
3 
Test For Phosphate 
 
No Cloudy  yellow     
appearance  
 
Negative 
 
 
4 
Test For Carbonate   
 
 
- 
 
Negative 
 
 
5 Test For Nitrate 
- 
 
Negative 
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Interpretation 
The acidic radicals test shows the presence of Sulphate, Chloride. 
 
Table 5.3.2: Results of basic radicals studies. 
 
S.NO Parameter Observation Result 
1 Test for Lead 
 
- 
Negative 
2 Test for Copper - Negative 
3 Test For Aluminium 
 
- 
 
Negative 
4 Test For Iron. Red colour appeared Positive 
5 Test For Zinc 
 
- 
Negative 
6 Test for Calcium 
 
- 
Negative 
7 Test For Magnesium - Negative 
8 Test For Ammonium - Negative 
9 Test For Potassium 
 
- 
 
Negative 
6 Test for Sulphide 
 
- 
Negative 
7 
Test For Fluoride &oxalate 
 
 
- 
Negative 
 
 
8 
Test For Nitrite 
 
- 
 
Negative 
9 
Test For Borax 
 
- Negative 
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10  Test For Sodium 
 
- 
Negative 
11 Test For Mercury 
 
- 
Negative 
12 Test For Arsenic 
 
- 
Negative 
 
Interpretation 
The basic radical test shows the presence of Iron, and absence of heavy metals such as lead, 
arsenic and mercury. 
 
Table5. 3.3 .Results of miscellaneous test: 
 
 
Interpretation: 
The Miscellaneous test shows the presence of Alkaloid, Tannic acid, Type of Compounds.  
 
 
 
S.NO Parameter Observation Result 
1 Test for Starch 
 
- 
Negative 
2 
Test for Reducing sugars 
 
- Negative 
3 
Test For Alkaloids 
. 
Yellow colour developed Positive 
4 
Test For Tannic acid 
. 
Blue-black precipitate 
obtained 
Positive 
5 
Test for unsaturated 
compounds 
 
- 
Negative 
6 Test for Amino acid - Negative 
7 
Test For Type of compounds 
 
Blue colour developed. Positive 
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5.4. Anxiolytic activity (Elevated plus maze method) of Kuruver kudineer 
Table 5.4.1 Anxiolytic activity of Kuruver Kudineer 
 
5.5. CLINICAL STUDIES 
 For the clinical study 30 cases with confirmed diagnosis of Mantha sanni were 
selected and treated with Kuruver kudineer with dosage of 30ml BD for 90 days in the 
Outpatient department of P.G Kuzhandhai Maruthuvam, Ayothidoss Pandithar Hospital NIS, 
and Chennai 47. 
Results were observed with respect to the following criteria 
1. Sex  
2. Age 
3. Parent‘s Socio Economic Status 
4. Religion 
5. Family history 
6. Thinaikal 
7. Immunisation history 
8. Diet 
9. Uyirthathukkal 
10. Ezhuudalkattugal 
11. .Envagaithervugal 
12. Neikuri 
13. Clinical features &Clinical assessment parameters 
Average Calculation (n=6) 
Control 
group 
Open arm Closed arm 
Number of entry 5 Number of entry 12 
Spent time 34sec Spent time 1min56sec 
Standard 
group        
(Alprazolom 
IP) 
Open arm Closed arm 
Number of entry 8 Number of entry 11 
Spent time 1min7sec Spent time 2min4sec 
Low Dose                     
(Kuruver 
kudineer) 
Open arm Closed arm 
Number of entry 13 Number of entry 12 
Spent time 1min8sec Spent time 2min5sec 
High Dose                  
(Kuruver 
kudineer) 
Open arm Closed arm 
Number of entry 9 Number of entry 10 
Spent time 1min2sec Spent time 2min9sec 
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Table.5.5.1.Frequency and percentage of patients with Mantha sanni according to 
Gender  
 
S.NO GENDER 
NO OF CASES 
(out of 30 cases) 
PERCENTAGE % 
1 Male child 19 63 
2 Female child 11 37 
3 Total 30 100 
 
 
 
 
Fig:5.5.1.Frequency and percentage of cases according to gender 
 
 
 
Inference: 
       Out of 30 patients 63% were male children and 37% were female children. Though 
63% were male children so there is no related in sex difference and this disease can affect 
either sex. 
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Table 5.5.2.Frequency and percentage of patients with Mantha sanni according to Age  
 
S.NO AGE IN YEARS 
NO OF CASES 
(out of 30 cases) 
PERCENTAGE % 
1 3- 6 years 18 60 
2 7-9 years 9 30 
3 10-12 years 3 10 
4 Total 30 100 
 
 
 
Fig 5.5.2: Frequency and percentage of patients according to Age  
 
 
Inference: 
       Out of 30 patients, 60% of cases were 3-6 years, 30% of cases were 7-9 years, and 
10% of cases were 10-12years. So there is more number of children present at the 3-6 
years age group. 
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Table.5.5.3.Frequency and percentage of patients with Mantha sanni according to 
Parent’s Socio Economic Status. 
 
 
 
Fig5.5.3: Frequency and percentage of patients according to Parent’s Socio 
Economic Status. 
 
   Inference:   
 About 43% patients were under high income group, 37% patients were under middle 
income group, 20%patients were lower income group. The highest incidence was in high 
income group. So there is no related in this disease can affect either income. 
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2 Middle Income Group 11 37% 
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4 Total 30 100 
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Table.5.5.4.Frequency and percentage of patients with Mantha sanni according to 
Religion  
 
S.NO RELIGION NO OF CASES 
(out of 30 cases) 
PERCENTAGE (%) 
1 Hindu 27 90% 
2 Muslim 1 3.30% 
3 Christian 2 6.70% 
4 Total 30 100 
 
 
 
Fig.5.5.4.Frequency and percentage of patients according to Religion 
 
Inference: 
 Out of 30 patients, 90% of the cases were Hindu, 3.30% of the cases were Muslim, 
and 6.70% of the cases were Christian. Though more number of cases were reported to be 
Hindu, there is no relation between the incidence of the disease is respect to religion. 
 
 
 
 
 
0
5
10
15
20
25
30
Hindu
Muslim
Christian
27 
1 
2 
90% 
3.30% 
6.70% 
PERCENTAGE(%)
NO OF CASES
86 
 
Table.5.4.5.Frequency and percentage of patients with Mantha sanni according to 
Thinaigal  
 
S.NO THINAIKAL NO OF CASES 
(out of 30 cases) 
PERCENTAGE (%) 
1 Kurinji 2 6.70% 
2 Mullai 0 0 
3 Marutham 0 0 
4 Neithal 28 93.30% 
5 Paalai 0 0 
6 Total 30 100 
 
 
 
Fig.5.4.5: Frequency and percentage of patients according to Thinaigal 
 
Inference: 
     According to Siddha concept, the people living in marutham lead a disease free life. 
But now days both life style and habits of the people entirely differs from ancestor leading to 
disease .since the study was conducted in neithal nilam and around Chennai. 
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Table .5.5.6.Frequency and percentage of patients with Mantha sanni according to Diet. 
 
 
 
 
 
 
 
 
 
Fig.5.5.6.Frequency and percentage of patients according to Diet. 
 
Inference: 
 Out of 30 patients, 13.30% of the cases were Vegetarian, 86.70% of the cases were 
Non vegetarian.Though more number of cases were reported to be Non vegetarian, and there 
is no relation between the incidences of the disease. 
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Table .5.5.7.Frequency and distribution of patients with Mantha sanni according to 
Immunisation. 
 
 
 
 
 
 
 
 
 
 Fig.5.5.7.Frequency and distribution of patients according to Immunisation. 
 
Inference: 
 Out of 30 patients, 90% of the cases were proper immunisation, 6.70% of the cases 
were improper immunisation and 3.30% of the cases were proper immunisation but time 
lag.Though more number of cases were reported to be proper immunisation history, there is 
no relation between the incidences of the disease. 
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Table 5.5.8.Frequency and percentage of patients according to Uyir Thathukkal 
(Vatham) 
S.NO TYPES OF VATHAM NO. OF CASES  
(OUT OF 30) 
PERCENTAGE % 
1 Praanan 20 66.7 
2 Abaanan 2 6.7 
3 Samaanan 2 6.7 
4 Uthaanan 0 0 
5 Viyaanan 0 0 
6 Naagan 6 20 
7 Koorman 5 16.7 
8 Kirukaran 0 0 
9 Devathatthan 0 0 
10 Dhananjeyan 0 0 
 
 
Fig.5.5.8: Frequency and percentage of patients according to Uyir Thathukkal  
Inference 
       According to vatham, praanan was  affected   in 66.7%  cases  because of   sleep 
disturbances ,abanan was  affected  in 6.7% cases  because constipation, samaanan  was  
affected  in  6.7%  cases  due to derangement of other  vatha‘s, Naagan  was  affected  in   2% 
cases due topoor eye to eye contact ,koorman  was  affected in  16.7% cases  due to eye 
contact. 
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Table.5.5.9: Frequency and percentage of patients with Mantha sanni according to Uyir 
Thathukkal (Pitham). 
 
 
 
 
 
 
 
 
 
Fig 5.5.9: Frequency and percentage of patients according to Uyir Thathukkal 
(Pitham). 
Inference 
      According to pitham, analagam was affected in all cases (100%) because of poor 
appetite, ranjagam was affected 10%   because pallor of the eyes. 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
20 
2 
0 14 
0 
66.7 
6.7 
46.70% 
PERCENTAGE9%)
NO OF CASES(Out of 40)
S.NO TYPES OF  PITHAM NO OF CASES   
(Out of 30) 
PERCENTAGE 
1 Analagam 20 66.7 
2 Ranjagam 2 6.7 
3 Sathagam 0 0 
4 Alosagam 14 46.70% 
5 Prasagam 0 0 
91 
 
Table 5.5.10: Frequency and percentage of patients with Mantha sanni according to 
Uyir Thathukkal (Iyyam). 
 
 
 
 
 
 
 
\ 
 
Fig 5.5.10: Frequency and percentage of patients according to Uyir Thathukkal 
(Iyyam). 
 
Inference 
          According to Iyyam, Tharpagam was   affected in 14 cases (46.7%) due to poor eye to 
eye contact 
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Table.5.5.11.Frequency and percentage of patients with Mantha sanniaccording to 
UdalThathukkal   
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5.5.11: Frequency and distribution of patients with Mantha sanniaccording to 
UdalThathukkal  
Inference 
         According to Udalthathukkal, Saaram was affected 13.4%   due to Anaemic, Senneer 
was affected 6.7% because pallor of the tongue. 
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Table 5.5.12. Frequency and percentage of patients with Mantha sanni according to 
Envagaithervugal. 
S.NO ENVAGAITHERVUGAL 
NO OF CASES 
(out of 30 Cases) 
PERCENTAGE 
(%) 
1 Naa 3 10 
2 Niram 0 0 
3 Mozhi 0 0 
4 Vizhi 14 46.7 
5 Sparism 0 0 
6 Naadi-Kaba vatham 30 100 
7 Malam 0 0 
8 Moothiram 0 0 
 
 
Fig.5.5.12: Frequency and percentage of patients according to Envagaithervugal   
 
Inference 
          In  Naadi  has  been  observed  in 30 cases, 100% of cases had Kabavatha naadi, Naa   
was  affected  in  10 (3%)  cases  as  they  had  Pallor in tongue .vizhi  was affected  in 14 
(46.7%) cases , as the had poor eye to eye contact. 
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Table.5.5.13.Frequency and percentage of patients with Mantha sanni according to 
Neikuri. 
 
 
Fig.5.5.13: Frequency and percentage of patients according to Neikuri   
 
Inference 
       According to Neikuri, Vatham neer was observed in 10% of cases.Pitham neer was 
observed in 6.7% of cases.Kabam neer was observed in 83.3% of cases.  
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Table.5.5.14: Frequency and percentage of patients according to clinical features 
 
S.NO CLINICAL FEATURES 
NO. OF PATIENTS 
(OUT OF 30CASES) 
PERCENTAGE(%) 
1 
Children of age group under 3- 12 
years 
30 100 
2 Impaired social interaction 13 43.4 
3 Mild aggressive 10 33.4 
4 Repetitive behaviour 4 13.4 
5 Lack of eye contact 14 46.7 
6 Blabble sound 8 26.7 
7 Clinically diagnosed as a ASD 30 100 
 
 
Fig.5.5.14: Frequency and percentage of patients according to clinical features 
 
Inference: 
 According to Clinical features, 100% of cases were Children under 3-12 years of age, 
clinicaly diagnosed as ASD, 13% of cases were Impaired social interaction, 14% of cases 
were lack of eye to eye contact, 8% of cases are blabble sound,3% of cases were Mild 
aggressivenessand 4% of cases were repititive behaviour present 
 
 
30 
13 
10 
4 
14 
8 
30 
No. of patients (out of 30cases) 
Children of age group under 3-
12 years
Impaired social interaction
Mild aggressive
Repetitive behaviour
Lack of eye contact
Blabble sound
96 
 
5.5.15. CLINICAL ASSESSMENT PARAMETERS 
SOCIAL RELATIONSHIP AND RECIPROCITY  
Table 5.5.15.1. Frequency and percentage distribution of Eye Contact: 
EYE CONTACT 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 14 46.70% 10 33.30% 6 20% 3 10% 
1 5 16.60% 2 6.70% 5 16.60% 2 6.70% 
2 6 20% 6 20% 5 16.60% 4 13.30% 
3 2 6.70% 5 16.60% 6 20% 9 30% 
4 3 10% 7 23.30% 8 26.70% 12 40% 
Inference: 
 From the above table 46.7% of children had score-0 on 0th day and 10% of children 
had on 90th day. 16.60 % of children had Score-1 on 0th day and 6.70% of children had on 
90th day. 20% of children had Score-2 on 0th day and 13.30% of children had on 90th day. 
6.70% of children had score-3 on 0th day and 30% of children had on 90th day. 10% of 
children had score-4 on 0th Day and 40% of children had on 90th day.  
5.5.15.1.Frequency and percentage distribution of Eye Contact:
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SOCIAL RELATIONSHIP AND RECIPROCITY  
Table 5.5.15.2 Frequency and percentage distribution of Social Smile: 
SOCIAL SMILE 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 16 53.50% 13 43.30% 3 10% 1 4% 
1 6 20.00% 4 13.30% 2 6.60% 2 6.60% 
2 4 13% 4 13% 6 20.00% 3 10.00% 
3 1 3.50% 4 13.30% 7 23% 11 37% 
4 3 10% 5 16.60% 12 40.00% 13 43% 
 
Inference:  
 From the above table 53.50% of children had score-0 on 0th day and 4% of children 
had on 90th day. 20% of children had Score-1 on 0th day and 6.60% of children had on 90th 
day. 13% of children had Score-2 on 0th day and 10% of children had on 90th day. 3.50% of 
children had score-3 on 0th day and 37% of children had on 90th day. 10% of children had 
score-4 on 0th Day and 43% of children had on 90th day.  
Fig 5.5.15.2 Frequency and percentage distribution of  Social Smile: 
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SOCIAL RELATIONSHIP AND RECIPROCITY  
Table 5.5.15.3 Frequency and percentage distribution of solitary and repetitive 
activities: 
SOLITARY AND REPETITIVE ACTIVITIES 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 15 50.00% 11 36.67% 5 17% 2 17% 
1 6 20.00% 4 13.33% 3 10.00% 3 10.00% 
2 5 17% 5 17% 6 20.00% 2 6.67% 
3 2 6.67% 4 13.33% 7 23% 10 33% 
4 2 7% 6 20.00% 9 30.00% 13 43% 
Inference: 
 From the above table 50% of children had score-0 on 0th day and 17% of children had 
on 90th day. 20% of children had Score-1 on 0th day and 10% of children had on 90th day. 
17% of children had Score-2 on 0th day and 6.67% of children had on 90th day. 6.67% of 
children had score-3 on 0th day and 33% of children had on 90th day. 7% of children had 
score-4 on 0th Day and 43% of children had on 90th day.  
Fig 5.5.15.3 Frequency and percentage distribution of  solitary and repetitive activities:: 
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SOCIAL RELATIONSHIP AND RECIPROCITY  
 
Table 5.5.15.4 Frequency and percentage distribution of social interaction: 
SOCIAL INTERACTION 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 15 50.00% 13 43.33% 8 27% 5 17% 
1 7 23.33% 5 16.67% 6 20.00% 3 10.00% 
2 5 17% 6 20% 4 13.33% 3 10.00% 
3 1 3.33% 2 6.67% 6 20% 9 30% 
4 2 7% 4 13.33% 6 20.00% 10 33% 
Inference: 
 From the above table 50% of children had score-0 on 0th day and 17% of children had 
on 90th day. 23.33% of children had Score-1 on 0th day and 10% of children had on 90th 
day. 17% of children had Score-2 on 0th day and 10% of children had on 90th day. 3.33% of 
children had score-3 on 0th day and 30% of children had on 90th day. 7% of children had 
score-4 on 0th Day and 33% of children had on 90th day. 
Fig 5.5.15.4 Frequency and percentage distribution of  social interaction: 
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SOCIAL RELATIONSHIP AND RECIPROCITY  
Table 5.5.15.5 Frequency and percentage distribution of   peer relationship: 
PEER RELATIONSHIP 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 15 50.00% 11 36.67% 5 17% 2 17% 
1 6 20.00% 4 13.33% 3 10.00% 3 10.00% 
2 5 17% 5 17% 6 20.00% 2 6.67% 
3 2 6.67% 4 13.33% 7 23% 10 33% 
4 2 7% 6 20.00% 9 30.00% 13 43% 
 
 
Inference: 
 From the above table 50% of children had score-0 on 0th day and 17% of children had 
on 90th day. 20% of children had Score-1 on 0th day and 10% of children had on 90th day. 
17% of children had Score-2 on 0th day and 6.67% of children had on 90th day. 6.67% of 
children had score-3 on 0th day and 33% of children had on 90th day. 7% of children had 
score-4 on 0th Day and 43% of children had on 90th day.  
Fig 5.5.15.5 Frequency and percentage distribution of   peer relationship: 
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EMOTIONAL RESPONSIVENESS 
Table 5.5.15.6. Frequency and percentage distribution of emotional responsiveness: 
INAPPROPRIATE EMOTIONAL RESPONSIVENESS 
Score 0th day 30th day 60th day 90th day 
N % N % N % N % 
0 12 40.00% 8 26.67% 6 20% 3 10% 
1 6 20.00% 3 10.00% 5 16.67% 2 6.67% 
2 6 20% 4 13% 5 16.67% 4 13.33% 
3 4 13.33% 8 26.67% 6 20% 9 30% 
4 2 7% 7 23.33% 8 26.67% 12 40% 
  
Inference: 
 From the above table 40% of children had score-0 on 0th day and 10% of children had 
on 90th day. 20% of children had Score-1 on 0th day and 6.67% of children had on 90th day. 
20% of children had Score-2 on 0th day and 13.33% of children had on 90th day. 13.33% of 
children had score-3 on 0th day and 30% of children had on 90th day. 7% of children had 
score-4 on 0th Day and 40% of children had on 90th day.  
Fig 5.5.15.6. Frequency and percentage distribution of  emotional responsiveness: 
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5.5.15.7. EMOTIONAL RESPONSIVENESS 
Table 5.5.15.7.Frequency and percentage distribution of exaggerated emotions: 
EXAGGERATED EMOTIONS 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 15 50.00% 13 43.33% 8 27% 5 17% 
1 7 23.33% 5 16.67% 6 20.00% 3 10.00% 
2 5 17% 6 20% 4 13.33% 3 10.00% 
3 1 3.33% 2 6.67% 6 20% 9 30% 
4 2 7% 4 13.33% 6 20.00% 10 33% 
  
Inference:  
 From the above table 50% of children had score-0 on 0th day and 17% of children had 
on 90th day. 23.33% of children had Score-1 on 0th day and 10% of children had on 90th 
day. 17% of children had Score-2 on 0th day and 10% of children had on 90th day. 3.33% of 
children had score-3 on 0th day and 3% of children had on 90th day. 7% of children had 
score-4 on 0th Day and 33% of children had on 90th day.  
Fig 5.5.15.7. Frequency and percentage distribution of   exaggerated emotions: 
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EMOTIONAL RESPONSIVENESS 
Table 5.5.15.8. Frequency and percentage distribution of self-stimulating emotions: 
SELF-STIMULATING EMOTIONS 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 16 53.50% 13 43.30% 3 10% 1 4% 
1 6 20.00% 4 13.30% 2 6.60% 2 6.60% 
2 4 13% 4 13% 6 20.00% 3 10.00% 
3 1 3.50% 4 13.30% 7 23% 11 37% 
4 3 10% 5 16.60% 12 40.00% 13 43% 
 
Inference:  
 From the above table 53.5% of children had score-0 on 0th day and 4% of children 
had on 90th day. 20% of children had Score-1 on 0th day and 6.60% of children had on 90th 
day. 13.3% of children had Score-2 on 0th day and 10% of children had on 90th day. 3.50% 
of children had score-3 on 0th day and 37% of children had on 90th day. 10% of children had 
score-4 on 0th Day and 43% of children had on 90th day.  
Fig 5.5.15.8. Frequency and percentage distribution of self-stimulating emotions: 
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EMOTIONAL RESPONSIVENESS 
Table 5.5.15.9.Frequency and percentage distribution of fear for danger: 
FEAR FOR DANGER 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 16 53.33% 10 33.33% 6 20% 3 10% 
1 8 26.67% 6 20.00% 4 13.33% 2 6.67% 
2 2 7% 4 13% 3 10.00% 3 10.00% 
3 2 7.00% 6 20.00% 9 30% 10 33% 
4 2 7% 4 13.33% 8 26.67% 12 40% 
 
Inference:  
 From the above table 53.3% of children had score-0 on 0th day and 10% of children 
had on 90th day. 26.67% of children had Score-1 on 0th day and 6.67% of children had on 
90th day. 7% of children had Score-2 on 0th day and 10% of children had on 90th day. 7% of 
children had score-3 on 0th day and 33% of children had on 90th day. 7% of children had 
score-4 on 0th Day and 40% of children had on 90th day.  
Fig 5.5.15.9. Frequency and percentage distribution of  fear for danger: 
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EMOTIONAL RESPONSIVENESS 
Table 5.5.15.10 Frequency and percentage distribution of excited for no apparent 
reasons: 
EXCITED FOR NO APPARENT REASONS 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 15 50.00% 11 36.67% 5 17% 2 17% 
1 6 20.00% 4 13.33% 3 10.00% 3 10.00% 
2 5 17% 5 17% 6 20.00% 2 6.67% 
3 2 6.67% 4 13.33% 7 23% 10 33% 
4 2 7% 6 20.00% 9 30.00% 13 43% 
 
Inference:  
 From the above table 50% of children had score-0 on 0th day and 17% of children had 
on 90th day. 20% of children had Score-1 on 0th day and 10% of children had on 90th day. 
17% of children had Score-2 on 0th day and 6.67% of children had on 90th day. 6.67% of 
children had score-3 on 0th day and 33% of children had on 90th day. 7% of children had 
score-4 on 0th Day and 43% of children had on 90th day.  
 
Fig 5.5.15.10Frequency and percentage distribution of   excited for no apparent reasons:
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SPEECH: LANGUAGE AND COMMUNICATION 
Table 5.5.15.11. Frequency and percentage distribution of Non-verbal language to 
communicate the others 
NON-VERBAL LANGUAGE TO COMMUNICATE 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 17 56.67% 14 46.67% 10 33% 8 27% 
1 9 30.00% 6 20.00% 5 16.67% 7 23.33% 
2 1 3% 5 17% 8 26.67% 9 30.00% 
3 3 10.00% 4 10.00% 5 17% 4 13% 
4 1 10% 1 3.33% 2 6.67% 2 7% 
 
Inference:  
 From the above table 56.67% of children had score-0 on 0th day and 27% of children 
had on 90th day. 30% of children had Score-1 on 0th day and 23.33% of children had on 90th 
day. 3% of children had Score-2 on 0th day and 30% of children had on 90th day. 10% of 
children had score-3 on 0th day and 17% of children had on 90th day. 10% of children had 
score-4 on 0th Day and 7% of children had on 90th day.  
Fig 5.5.15.11. Frequency and percentage distribution of  Non verbal language to communicate 
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SPEECH: LANGUAGE AND COMMUNICATION  
Table 5.5.15.12 Frequency and percentage distribution of Stereotyped and repetitive use 
of language 
STEREOTYPED AND REPETITIVE USE OF LANGUAGE 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 13 43.33% 11 36.67% 9 30% 5 17% 
1 9 30.00% 6 36.67% 3 10.00% 4 13.33% 
2 3 10% 5 36.67% 4 13.33% 6 20.00% 
3 2 6.67% 3 10.00% 8 27% 6 20% 
4 3 10% 5 16.67% 6 20.00% 9 30% 
 
Inference:  
 From the above table 43.33% of children had score-0 on 0th day and 17% of children 
had on 90th day. 30% of children had Score-1 on 0th day and 13.33% of children had on 90th 
day. 10% of children had Score-2 on 0th day and 20% of children had on 90th day. 6.67% of 
children had score-3 on 0th day and 20% of children had on 90th day. 10% of children had 
score-4 on 0th Day and 30% of children had on 90th day.  
 
Fig 5.5.15.12Frequency and percentage distribution of   Stereotyped and repetitive use of language: 
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SPEECH: LANGUAGE AND COMMUNICATION 
Table 5.5.15.13 Frequency and percentage distribution of unusual noises: 
UNUSUAL NOISES 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 10 33.33% 8 26.67% 5 17% 3 10% 
1 8 26.67% 7 23.33% 5 16.67% 3 10.00% 
2 4 13% 5 16.67% 7 23.33% 5 16.67% 
3 5 16.67% 6 20.00% 5 17% 9 30% 
4 3 10% 5 16.67% 8 26.67% 10 33% 
 
Inference: 
 From the above table3 3.33% of children had score-0 on 0th day and 10% of children 
had on 90th day. 26.67% of children had Score-1 on 0th day and 10% of children had on 90th 
day. 13% of children had Score-2 on 0th day and 23% of children had on 90th day. 16.67% 
of children had score-3 on 0th day and 30% of children had on 90th day. 10% of children had 
score-4 on 0th Day and 33% of children had on 90th day. 
Fig 5.5.15.13Frequency and percentage distribution of    unusual noises: 
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SPEECH: LANGUAGE AND COMMUNICATION 
Table 5.5.15.14. Frequency and percentage distribution of Meaningless words: 
MEANINGLESS WORDS 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 14 46.70% 10 33.30% 6 20% 3 10% 
1 5 16.60% 2 6.70% 5 16.60% 2 6.70% 
2 6 20% 6 20% 5 16.60% 4 13.30% 
3 2 6.70% 5 16.60% 6 20% 9 30% 
4 3 10% 7 23.30% 8 26.70% 12 40% 
 
Inference: 
 From the above table 46.7% of children had score-0 on 0th day and 10% of children 
had on 90th day. 16.6% of children had Score-1 on 0th day and 6.7% of children had on 90th 
day. 20% of children had Score-2 on 0th day and 13.30% of children had on 90th day. 6.70% 
of children had score-3 on 0th day and 30% of children had on 90th day. 10% of children had 
score-4 on 0th Day and 40% of children had on 90th day 
Fig 5.5.15.14 Frequency and percentage distribution of meaningless words: 
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SPEECH: LANGUAGE AND COMMUNICATION 
Table 5.5.15.15. Frequency and percentage distribution to understand the 
communication: 
TO UNDERSTAND THE COMMUNICATION 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 15 50.00% 13 43.33% 10 33% 8 27% 
1 6 20.00% 5 16.67% 4 13.33% 3 10.00% 
2 4 13% 6 20% 5 16.67% 4 13.33% 
3 2 6.67% 2 6.67% 6 20% 5 17% 
4 3 10% 4 13.33% 5 16.67% 10 33% 
 
Inference: 
 From the above table 50% of children had score-0 on 0th day and 27% of children had 
on 90th day. 20% of children had Score-1 on 0th day and 10% of children had on 90th day. 
13% of children had Score-2 on 0th day and 13.33% of children had on 90th day. 6.67% of 
children had score-3 on 0th day and 17% of children had on 90th day. 10% of children had 
score-4 on 0th Day and 33% of children had on 90th day. 
Fig 5.5.15.15. Frequency and percentage distribution  to understand the communication 
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BEHAVIOURAL PATTERNS 
Table 5.5.15.16 Frequency distribution of hyperactivity and restlessness: 
HYPERACTIVITY AND RESTLESSNESS 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 14 46.70% 10 33.30% 6 20% 3 10% 
1 5 16.60% 2 6.70% 5 16.60% 2 6.70% 
2 6 20% 6 20% 5 16.60% 4 13.30% 
3 2 6.70% 5 16.60% 6 20% 9 30% 
4 3 10% 7 23.30% 8 26.70% 12 40% 
 
Inference: 
 From the above table 46.7% of children had score-0 on 0th day and 10% of children 
had on 90th day. 16.60 % of children had Score-1 on 0th day and 6.70% of children had on 
90th day. 20% of children had Score-2 on 0th day and 13.30% of children had on 90th day. 
6.70% of children had score-3 on 0th day and 30% of children had on 90th day. 10% of 
children had score-4 on 0th Day and 40% of children had on 90th day.  
 
Fig 5.5.15.16 Frequency and percentage distribution of  hyperactivity and restlessness:
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BEHAVIOURAL PATTERNS  
Table 5.5.15.17. Frequency and percentage distribution of aggressive behaviour: 
AGGRESSIVE BEHAVIOUR 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 16 53.50% 13 43.30% 3 10% 1 4% 
1 6 20.00% 4 13.30% 2 6.60% 2 6.60% 
2 4 13% 4 13% 6 20.00% 3 10.00% 
3 1 3.50% 4 13.30% 7 23% 11 37% 
4 3 10% 5 16.60% 12 40.00% 13 43% 
 
Inference: 
 From the above table 53.50% of children had score-0 on 0th day and 4% of children 
had on 90th day. 20% of children had Score-1 on 0th day and 6.60% of children had on 90th 
day. 13% of children had Score-2 on 0th day and 10% of children had on 90th day. 3.50% of 
children had score-3 on 0th day and 37% of children had on 90th day. 10% of children had 
score-4 on 0th Day and 43% of children had on 90th day.  
 
 
Fig 5.5.15.17 Frequency and percentage distribution of aggressive behaviour: 
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BEHAVIOURAL PATTERNS  
Table 5.5.15.18 Frequency and percentage distribution of attachment to inanimate 
objects: 
ATTACHMENT TO INANIMATE OBJECTS 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 15 50.00% 11 36.67% 5 17% 2 17% 
1 6 20.00% 4 13.33% 3 10.00% 3 10.00% 
2 5 17% 5 17% 6 20.00% 2 6.67% 
3 2 6.67% 4 13.33% 7 23% 10 33% 
4 2 7% 6 20.00% 9 30.00% 13 43% 
 
Inference: 
 From the above table 50% of children had score-0 on 0th day and 17% of children had 
on 90th day. 20% of children had Score-1 on 0th day and 10% of children had on 90th day. 
17% of children had Score-2 on 0th day and 6.67% of children had on 90th day. 6.67% of 
children had score-3 on 0th day and 33% of children had on 90th day. 7% of children had 
score-4 on 0th Day and 43% of children had on 90th day. 
Fig 5.5.15.18 Frequency and percentage distribution of  attachment to inanimate objects: 
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BEHAVIOURAL PATTERNS  
Table 5.5.15.19 Frequency distribution of self-injurious behavior: 
SELF-INJURIOUS BEHAVIOR 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 15 50.00% 13 43.33% 8 27% 5 17% 
1 7 23.33% 5 16.67% 6 20.00% 3 10.00% 
2 5 17% 6 20% 4 13.33% 3 10.00% 
3 1 3.33% 2 6.67% 6 20% 9 30% 
4 2 7% 4 13.33% 6 20.00% 10 33% 
 
Inference: 
 From the above table 50% of children had score-0 on 0th day and 17% of children had 
on 90th day. 23.33% of children had Score-1 on 0th day and 10% of children had on 90th 
day. 17% of children had Score-2 on 0th day and 10% of children had on 90th day. 3.33% of 
children had score-3 on 0th day and 30% of children had on 90th day. 7% of children had 
score-4 on 0th Day and 33% of children had on 90th day.  
Fig 5.5.15.19 Frequency and percentage distribution of self-injurious behaviour: 
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BEHAVIOURAL PATTERNS  
 Table 5.5.15.20 Frequency and percentage distribution of temper tantrums: 
TEMPER TANTRUMS 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 15 50.00% 11 36.67% 5 17% 2 17% 
1 6 20.00% 4 13.33% 3 10.00% 3 10.00% 
2 5 17% 5 17% 6 20.00% 2 6.67% 
3 2 6.67% 4 13.33% 7 23% 10 33% 
4 2 7% 6 20.00% 9 30.00% 13 43% 
 
 
Inference: 
 From the above table 50% of children had score-0 on 0th day and 17% of children had 
on 90th day. 20% of children had Score-1 on 0th day and 10% of children had on 90th day. 
17% of children had Score-2 on 0th day and 6.67% of children had on 90th day. 6.67% of 
children had score-3 on 0th day and 33% of children had on 90th day. 7% of children had 
score-4 on 0th Day and 43% of children had on 90th day.  
Fig 5.5.15.20.Frequency and percentage distribution of temper tantrums:
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 SENSORY ASPECTS 
Table 5.5.15.21.Frequency and percentage distribution of unusual visions 
UNUSUAL VISIONS 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 12 40.00% 10 33.33% 8 27% 4 13% 
1 7 23.33% 6 20.00% 5 16.67% 5 16.67% 
2 3 10% 5 17% 7 23.33% 6 20.00% 
3 5 16.67% 4 13.33% 6 20% 5 17% 
4 3 10% 5 16.67% 5 16.67% 10 33% 
 
Inference: 
  From the above table 40% of children had score-0 on 0th day and 13% of children had 
on 90th day. 23% of children had Score-1 on 0th day and 16.67% of children had on 90th 
day. 10% of children had Score-2 on 0th day and 20% of children had on 90th day. 16.67% 
of children had score-3 on 0th day and 17% of children had on 90th day. 10% of children had 
score-4 on 0th Day and 33% of children had on 90th day.  
Fig 5.5.15.22. Frequency and percentage distribution of  unusual visions: 
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SENSORY ASPECTS 
Table 5.5.15.25. Frequency and percentage distribution of stares into space for long 
periods of time 
STARES INTO SPACE FOR LONG PERIODS OF TIME 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 12 40.00% 10 33.33% 6 20% 3 10% 
1 8 26.67% 5 16.67% 3 10.00% 4 13.33% 
2 5 17% 4 13% 5 16.67% 3 10.00% 
3 3 10.00% 5 16.67% 7 23% 9 30% 
4 2 7% 6 20.00% 9 30.00% 11 37% 
 
Inference: 
 From the above table 40% of children had score-0 on 0th day and 10% of children had 
on 90th day. 26.67% of children had Score-1 on 0th day and 13.33% of children had on 90th 
day. 17% of children had Score-2 on 0th day and 10% of children had on 90th day. 10% of 
children had score-3 on 0th day and 30% of children had on 90th day. 7% of children had 
score-4 on 0th Day and 37% of children had on 90th day.  
Fig 5.5.15.25 Frequency and percentage distribution  of stares into space for long periods of time 
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SENSORY ASPECTS 
Table 5.5.15.23.Frequency and percentage distribution of insensitive to pain 
INSENSITIVE TO PAIN 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 15 50.00% 13 43.33% 8 27% 5 17% 
1 7 23.33% 5 16.67% 6 20.00% 3 10.00% 
2 5 17% 6 20% 4 13.33% 3 10.00% 
3 1 3.33% 2 6.67% 6 20% 9 30% 
4 2 7% 4 13.33% 6 20.00% 10 33% 
 
 
Inference: 
 From the above table 50% of children had score-0 on 0
th
 day and 17% of children had 
on 90th day. 23.33% of children had Score-1 on 0th day and 10% of children had on 90th 
day. 17% of children had Score-2 on 0th day and 10% of children had on 90th day. 3.33% of 
children had score-3 on 0th day and 30% of children had on 90th day. 7% of children had 
score-4 on 0th Day and 33% of children had on 90th day. 
Fig 5.5.15.23Frequency and percentage distribution  of  Insensitive to pain: 
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 SENSORY ASPECTS 
Table 5.5.15.24. Frequency and percentage distribution of responds to object 
RESPONDS TO OBJECT 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 14 46.67% 11 36.67% 8 27% 4 13% 
1 5 16.67% 7 23.33% 6 20.00% 2 6.67% 
2 6 20% 5 17% 4 13.33% 3 10.00% 
3 3 10.00% 3 10.00% 6 20% 10 33% 
4 2 7% 4 13.33% 6 20.00% 11 37% 
 
 
Inference: 
 From the above table 46.67% of children had score-0 on 0th day and 13% of children 
had on 90th day. 16.67% of children had Score-1 on 0th day and 6.67% of children had on 
90th day. 20% of children had Score-2 on 0th day and 10% of children had on 90th day. 10% 
of children had score-3 on 0th day and 33% of children had on 90th day. 7% of children had 
score-4 on 0th Day and 37% of children had on 90th day.  
Fig 5.5.15.24. Frequency and percentage distribution  of  responds to object 
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SENSORY ASPECTS 
Table 5.5.15.25.Frequency and percentage distribution of Tracking objects 
TRACKING OBJECTS 
Score 
0th day 30th day 60th day 90th day 
N % N % N % N % 
0 11 36.67% 9 30.00% 8 27% 5 17% 
1 7 23.33% 8 26.67% 6 20.00% 3 10.00% 
2 6 20% 5 17% 4 13.33% 3 10.00% 
3 4 13.33% 5 16.67% 6 20% 9 30% 
4 2 7% 3 10.00% 6 20.00% 10 33% 
 
 
Inference: 
 From the above table 36.67% of children had score-0 on 0th day and 17% of children 
had on 90th day. 26.67% of children had Score-1 on 0th day and 10% of children had on 90th 
day. 20% of children had Score-2 on 0th day and 10% of children had on 90th day. 13.33% 
of children had score-3 on 0th day and 30% of children had on 90th day. 7% of children had 
score-4 on 0th Day and 33% of children had on 90th day.  
Fig 5.5.15.25.Frequency and percentage distribution of Tracking objects 
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5.5.16. ANALYSIS AND INTERPRETATION 
Table.5.5.16.1. Frequency and Percentage of Social Relationship and Reciprocity: 
 
 
Inference: 
 From the above table 8.67% of children had score-0 on 0th day and 1% of children 
had on 90th day. 4.67% of children had Score-1 on 0th day and 2% of children had on 90th 
day. 4% of children had Score-2 on 0th day and 2% of children had on 90th day. 13.33% of 
children had score-3 on 0th day and 7% of children had on 90th day. 1% of children had 
score-4 on 0th Day and 8% of children had on 90th day. 
Score 0th day 30th day 60th day 90th day 
 
N % N % N % N % 
0 13 8.67% 10 6.67% 6 4% 2 1% 
1 7 4.67% 4 4.67% 4 2.67% 3 2.00% 
2 6 4% 6 4% 5 3.33% 3 2.00% 
3 2 1.33% 4 2.67% 7 5% 10 7% 
4 2 1% 6 4.00% 8 5.33% 12 8% 
Fig 5.5.16.1  Frequency And Percentage Of Social Relationship And Reciprocity  
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ANALYSIS AND INTERPRETATION  
 Table5.5.16.2 Frequency and percentage of Emotional Responsiveness 
 
Inference: 
 From the above table 10%% of children had score-0 on 0th day and 2% of children 
had on 90th day. 4.67% of children had Score-1 on 0th day and 1.33% of children had on 
90th day. 2% of children had Score-2 on 0th day and 2% of children had on 90th day. 1.33% 
of children had score-3 on 0th day and 7% of children had on 90th day. 2% of children had 
score-4 on 0th Day and 8% of children had on 90th day. 
Score 0th day 30th day 60th day 90th day 
 N % N % N % N % 
0 15 10.00% 11 7.33% 6 4% 3 2% 
1 7 4.67% 4 2.67% 4 2.67% 2 1.33% 
2 3 2% 5 3% 5 3.33% 3 2.00% 
3 2 1.33% 4 2.67% 6 4% 10 7% 
4 3 2% 6 4.00% 9 6.00% 12 8% 
Fig5.5. 16.2  Frequency And Percentage Of Emotional Responsiveness  
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ANALYSIS AND INTERPRETATION  
Table 5.5.16.3.Frequency and percentage of Speech Language and Communiaction 
Skills 
 
Inference: 
 From the above table 9.33% of children had score-0 on 0th day and 3% of children 
had on 90th day. 4% of children had Score-1 on 0th day and 2.67% of children had on 90th 
day. 3% of children had Score-2 on 0th day and 4% of children had on 90th day. 2% of 
children had score-3 on 0th day and 3% of children had on 90th day. 2% of children had 
score-4 on 0th Day and 3% of children had on 90th day. 
Score 0th day 30th day 60th day 90th day 
 N % N % N % N % 
0 14 9.33% 12 8.00% 8 5% 5 3% 
1 6 4.00% 8 5.33% 4 2.67% 4 2.67% 
2 4 3% 5 3% 6 4.00% 6 4.00% 
3 3 2.00% 1 1.00% 4 3% 5 3% 
4 3 2% 4 2.67% 8 5.33% 10 7% 
Fig 5.5.16.3  Frequency And Percentage Of  Speech Language And Communiaction Skills 
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ANALYSIS AND INTERPRETATION 
Table 5.5.16.4 Frequency and percentage of Behavioural patterns 
 
 
Inference: 
               From the above table 8.67% of children had score-0 on 0
th
 day and 1% of children 
had on 90
th
 day. 4.67% of children had Score-1 on 0
th
 day and 2% of children had on 90
th
 
day. 4% of children had Score-2 on 0
th
 day and 2% of children had on 90
th
 day. 1.33% of 
children had score-3 on 0
th
 day and 7% of children had on 90
th
 day. 1% of children had score-
4 on 0
th
 Day and 8% of children had on 90
th
 day.  
 
Score 0th day 30th day 60th day 90th day 
 N % N % N % N % 
0 13 8.67% 10 6.67% 6 4% 2 1% 
1 7 4.67% 4 4.67% 4 2.67% 3 2.00% 
2 6 4% 6 4% 5 3.33% 3 2.00% 
3 2 1.33% 4 2.67% 7 5% 10 7% 
4 2 1% 6 4.00% 8 5.33% 12 8% 
Fig 5.5.16.4  Frequency And Percentage Of  Behavioural patterns 
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ANALYSIS AND INTERPRETATION 
Table 5.5.16.5. Frequency and Percentage of Sensory aspects 
Inference: 
            From the above table 8.67% of children had score-0 on 0
th
 day and 3% of children had 
on 90
th
 day. 4.67% of children had Score-1 on 0
th
 day and 2% of children had on 90
th
 day. 4% 
of children had Score-2 on 0
th
 day and 2.67% of children had on 90
th
 day. 2% of children had 
score-3 on 0
th
 day and 5% of children had on 90
th
 day. 1% of children had score-4 on 0
th
 Day 
and 7% of children had on 90
th
 day 
Score 0th day 30th day 60th day 90th day 
 N % N % N % N % 
0 13 8.67% 11 7.33% 8 5% 4 3% 
1 7 4.67% 6 4.00% 5 3.33% 3 2.00% 
2 5 3% 5 3% 6 4.00% 4 2.67% 
3 3 2.00% 4 2.67% 5 3% 8 5% 
4 2 1% 4 2.67% 6 4.00% 11 7% 
 
 
 
 
 
 
 
 
 
Fig 16.5  Frequency And Percentage Of  Sensory aspects  
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5.5.17. STATISTICAL ANALYSIS  
                   All collected data were entered into MS Excel software using different columns 
variable and rows as patients. STATA software was used to perform statically analysis .Basic 
descriptive statistics included frequency distribution and cross tabulation were performed. 
Bar diagram, Pie charts were used to describe the value of different variables for pictorial 
representation. The quantity variables were expressed as Mean and Standard deviation and 
qualitative data as percentage. A probability value of less than 0.05 was considered to 
indicate as statistical significance. Paired‘ test was performed for determining the 
significance between before and after treatment. 
 
Table 5.5.17.1.Summary values of Clinical assessment parameters for Autism spectrum 
disorder in Children 
 
Treatment No. of Patients Mean Std Dev Min Max 
0 score (Before) 30 248.33 102.53 125 600 
0 Score (After) 30 503.33 125.55 250 625 
4 Score (Before) 30 49.66 20.50 25 120 
4 Score (After) 30 100.66 25.11 50 125 
Social skills (Before) 30 49.83 21.06 25 120 
Social Skills (After) 30 102.83 25.85 50 150 
Emotional skills (Before) 30 47.16 22.19 25 120 
Emotional skills (After) 30 98.66 26.12 50 125 
Communication Skills 
(Before) 
30 50.66 20.16 25 120 
Communication Skills 
(After) 
30 98 25.37 50 125 
Behaviour Skills (Before) 30 52.66 22.88 25 120 
Behaviour Skills (After) 30 104.5 27.92 50 125 
Sensory Skills (Before) 30 46.83 19.54 25 120 
Sensory skills (After) 30 99.66 25.01 50 125 
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Fig: 5.5.17.1.Summary values of Clinical assessment parameters for ASD 
 
 
Table 5.5.17.2. Statistical significance of treatment on ASD 
 
Treatment t value P value 
0 score (Before & After) 11.46 >1.0000 
4 Score (Before & After) 11.46 >1.0000 
Social skills (Before & After) 10.53 >1.0000 
Emotional skills (Before & After) 11.00 >1.0000 
Communication Skills (Before & 
After ) 
10.36 >1.0000 
Behaviour Skills (Before & After) 10.75 >1.0000 
Sensory Skills (Before & After) 11.73 >1.0000 
 
 
            The  mean and standard deviation of clinical assessment parameters ,before and after 
treatment of 0 score ,4 Score ,Social skills ,Emotional skills ,Communication Skills , 
Behaviour Skills,Sensory Skills were 283.33±102.53, 503.33±125.55, 49.66±20.50, 
100.66±25.11, 49.83±21.06, 102.83±25.85, 47.16±22.19, 98.66±26.12, 50.66±20.16, 
98±25.37, 52.66±22.88, 104.5±27.92, 46.83±19.54, 99.66±25.01 respectively which is 
statistically highly significant (Score 0:t- value - 11.46, P>1.0000, Score 4: t- value – 11.46, 
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P>1.0000,Social skills: t- value – 10.53, P>1.0000, Emotional skills: t- value – 11.00, 
P>1.0000,Communication skills: t- value – 10.36, P>1.0000, Behavioural Skills: t- value – 
10.75, P>1.0000 , Sensory skills: t- value – 11.73, P>1.0000). 
               There is significant difference between before and after treatment on clinical 
assessment parameter score i.e 86% improvement in this score after treatment 
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6. DISSCUSSION 
 
Autism spectrum disorder is extremely controversial. There are 4 main categories of 
controversies may run into in discussion of ASD. There are Cause, Cure, Treatment, and 
Research. 
Causes:   
 Most of them heard of the vaccines controversy surrounding Autism which has been 
thoroughly refused by science. Many scientists say that genes play a role in Autism. It is the 
subject of much debate. When environmental factor plays arolein causes is also hotly 
debated. Many theories heard and spectrum about everything from Autism beingncaused to 
be Vaccines, Gluten, cellphone, Some types of sugar, traumatic births and childhood illness.  
Cure: 
 Still more controversial conversation of the cure. It may wish for a cure for ASDwant 
acceptance for individuals with Autism until such point that a cure is feasible. It is life long 
condition and there is no known but support can improve the quality of life. 
Treatment: 
 Another controversy forASD includes treatments which are based in the 
behaviourism. Therefore someone who believes given certain types of Sugar contributes to 
Autism might put their child in diet free of food as treatment. This move would naturally be 
controversial among there who believes solely genetics 
Research: 
 It is a multifaceted issue. Much research about ASD delves into the cause, cure, and 
treatment of ASD. Towards the later point, the applications of ASD in research, many people 
with Autism fear that research had a course of autism, culminating in prenatal screening of 
ASD, may lead to selective abortions of features who fall on the Autism spectrum disorder. 
 It may cover some of what science has to tell us about the cause, cure, treatment, 
research but for now know that is very controversial 
  In the present study, 30 Mantha sanni (ASD) cases were treated in the Kuzhandhai 
maruthuvam out patient department of Ayothidoss Pandithar Hospital, National Institute of 
siddha. The diagnosis was confirmed according to clinical features mentioned in textbook of 
Balavagadam and managed with the trial drug ―Kurever Kudineer‖ (Internal), Sambrani 
thuvalai and Mysatchi Pugai (External) and the result was clearly observed.       
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                  This study proves the efficacy of ―Kurever Kudineer‖ (Internal), Sambrani 
thuvalai and Mysatchi Pugai (External) in relieving the symptoms of    Mantha sanni and the 
output of this study is discussed as follows 
 In biochemical analysis, the trial medicine Mantha sanni showed the presence of 
Starch, Tanin, Alkaloid and ferrous iron. Ferrous iron is more soluble and therefore more 
readily absorbed 
         In Physicochemical analysis was done as a preliminary evalution of the trial drug 
Kuruver kudineer. Loss on drying (LOD) is a method of measuring the amount of water and 
volatile matters in a sample when the sample is dried. Low moisture content is always 
desirable for higher stability of drugs. In Kuruver kudineer, the loss on drying at 105
o
C was 
found to be 5.54%. So the determination of moisture content shows the good stability of the 
drug Kuruver kudineer 
The total Ash values are helpful in determining the quality and purity of drugs, 
especially in powder form. The total Ash value found to be 6.82%. The minimal level of total 
ash shows the less inorganic residue and purity of the trail drug. So There is no negative 
results found in Kuruver kudineer. 
         Phytochemical analysis was done as a preliminary evalution of the trial drug Kuruver 
kudineer .The report shows positive in Mayers test for alkaloida, Molish test and benedict test 
for carbohydrates, Froth test for saponin,Alkaline reagent test and lead acetate test for 
flavonoids, Naoh test for quinones. 
 In Anxiolytic activity (Elevated plus maze method) shows low dose and high dose of 
kuruver kudineer action were good when compared to control and standard group (I.p. 
Alprazolam). The results were satisfactorily good.  
 In Social relationship and Reciprocity skills - Challenges with social interactions, 
social behavior, and social understanding remain the defining characteristics of Autism 
Spectrum Disorder (ASD). Although young children with autism sometimes seem to prefer to 
be by themselves, one of the most important issues, especially for older children and adults, is 
the development of friendships with peers. It can take a great deal of time and effort for 
people with ASD to develop the social skills needed to interact successfully with others, so it 
is important to start developing social ability early. Furthermore, bullying in middle and high 
school, not to mention at the workplace for some adults, can be a major problem for people 
with autism, and the development of friendships is one of the best ways to prevent it. In this 
research, effective Social relationship score were analysed in children who were enrolled in 
this study. 
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 The clinical parameters such as eye contact, social smile, solitary and repetitive 
activities, social interaction, peer relationship were analysed. The average percentage showed 
there was stadrared decline of behavirol pattern from 0
th
 day to 90
th
 day. If the children 
entrolled with severe pattern changes at the end of the treatment period syptoms significantly 
reduced. 
 In Emotional responsiveness Skills more generic emotional impairments exist in 
people with ASD that cause facial emotion processing deficits, would expect to observe 
emotional impairments in language as well. This article is to provide a systematic review of 
the empirical literature with respect to emotional language in ASD, discuss the implications 
for our understanding of ASD. In this research, effective emotional responsiveness score 
were analysed in children who were enrolled in this study. 
 The clinical parameter such as such as inappropriate emotional response, exaggerated 
emotions, Self-stimulating emotions, fear for danger, Excited for no apparent reasons were 
analysed.The average percentage showed there was stadrared decline of behavirol pattern 
from 0th day to 90th day. If the children entrolled with severe pattern changes at the end of 
the treatment period syptoms significantly reduced. 
 In Speech, language and communication skills Children with ASD are often unable 
to use gestures such as pointing to an object to give meaning to their speech. They often 
avoid eye contact, which can make them seem rude, uninterested, or inattentive. Without 
meaningful gestures or other nonverbal skills to enhance their oral language skills, many 
children with ASD become frustrated in their attempts to make their feelings, thoughts, and 
needs known. They may act out their frustrations through vocal outbursts or other 
inappropriate behaviors. In this research, effective communication skills score were analysed 
in children who were enrolled in this study.  
 The clinical parameters such as Non-verbal language to communicate the others, 
Stereotyped and repetitive use of language, unusual noises, meaningless words, understand 
the meaning of communication were analysed. The average percentage showed there was 
stadrared decline of behavirol pattern from 0th day to 90th day. If the children entrolled with 
severe pattern changes at the end of the treatment period syptoms significantly reduced. 
  In Behavirol pattern, the core features of autism are areas in which difficulties can 
lead to feelings of frustration, confusion, anxiety or lack of control, resulting in behavioral 
responses. Since behavior is often a form of communication, many individuals with autism 
voice their wants, needs or concerns through behaviors, rather than words. This does not 
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mean that they are always knowingly communicating. In this research, effective behavioural 
patterns score were analysed in children who were enrolled in this study.  
 The clinical parameters such as Hyperactivity and restlessness, Aggressive behaviour, 
attachment to inanimate objects, Self-injurious behaviour, and temper tantrums were 
analysed. The average percentage showed there was stadrared decline of behavirol pattern 
from 0
th
 day to 90
th
 day. If the children entrolled with severe pattern changes at the end of the 
treatment period syptoms significantly reduced. 
 In Sensory aspects, Children and adults with autism, as well as those with other 
developmental disabilities, may have a dysfunctional sensory system. Sometimes one or more 
senses are either over- or under-reactive to stimulation. Such sensory problems may be the 
underlying reason for such behaviors as rocking, spinning, and hand-flapping. Although the 
receptors for the senses are located in the peripheral nervous system (which includes 
everything but the brain and spinal cord), it is believed that the problem stems from 
neurological dysfunction in the central nervous system--the brain. In this research, effective 
sensory aspects score were analysed in children who were enrolled in this study. 
 The clinical parameters such as  Unusual visions,Stares into space for long periods of 
time, Insensitive to pain, Responds to object , Difficulty in tracking objects were analysed . 
The average percentage showed there was stadrared decline of behavirol pattern from 0
th
 day 
to 90
th
 day. If the children entrolled with severe pattern changes at the end of the treatment 
period syptoms significantly reduced. 
 The trial medicine chosen for treatment of Mantha sanni was ―Kuruver kudineer‖. 
The ingredients of this drug have the property of managing Mantha sanni. 
Vettiver: Antioxidant, Anxiolytic, CNS depressant 
Vilamichu: Antioxidant, CNS depressant 
Chukku: Anti axidant, Anti inflammatory, Slective serratonin reuptake inhibitors and 
antilipidemic activity 
Parpadagam: Antioxidant, Antideprassant and hepatoprotective activity 
Siruthekku: Antioxidant, Anti depressant and Anti carcinogenic activity 
Distribution according to clinical presentation 
      Out of 30 patients of this clinical trial, all cases under 3-12 years of age group, Impaired 
social interaction, poor eye to eye contact, aggressiveness and blabble sound.  The clinical 
improvement was accurately noted and further follow up was made through assessment form. 
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Onset of disease 
       The mode of the mantha sanni was early onset and fount at the age of after one and half 
years. 
Age 
         Among 30 cases , 60% of  the cases  belongs to the age group 3-6 years,30 % of the 
cases   belongs  to the age group 7-9 years  and  10 % of   the  cases  belongs to the  age 
group 10-12 years. Though 60% of the cases were 3-6 years of Age group so there is no 
related difference in sex distribution and this disease can affect either age. 
Sex  
        Out of 30 patients, 63% patients were male children and 37% patients were female 
children. Though 63 % patient were more in  male children so there is no related difference in 
sex distribution and this disease can affect either sex. 
Food habits  
          Out of 30 patients, 86.7% patients were mixed diet and 13.3% patients were 
vegetarians. Though 86.7% Patient were mixed diet so there is no related in vegetarian and 
mixed diet and this disease can affect any food habits. 
Immunisation 
 Out of 30 patients, 90%patients were proper immunisation, 6.70% patients were 
incomplete immunisation, and 3.30% 1 patient were Complete and time lag. Though 90% 
Patient were proper immunaisation, so there is no related in immunisation and this disease 
can affect any food habits.  
Thinaikal  
 Out of 30 patients, 6.7%patients were in Kurinji thinai, 93.30% patients were Neithal 
thinai, There is no related in thinaikaland disease 
Uyirthathukkal  
 Uyirthathukkal include 3 vital humours namely vatham, pitham, kabam. The 
derangement in any of the above three causes disease. This was noticed in the 30 cases and 
are discussed below. 
 
Vali (Vatham) 
     Out of 30 patients, 
1. Pranan was affected in 66.7% cases due to sleep distubances 
2. Abanan was affected   in 6.7% cases because of  Constipation 
3. Samanan was affected in 100% cases due to derangement of other vatha‘s. 
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4. Nagan was affected in 20% cases due to Social intraction 
5. Koorman was affectedin 46.7% due to lack of eye conatct 
Azhal (pitham)  
Out of 30 patients, 
1. Anaalagam was affected in  66.7% cases due to indigestion 
2. Ranjagam was affected in6.7% cases due to anemic children 
3. Alosagam was affected in 2.8% cases because of impaired communication. 
Iyyam (Kabam) 
Out of 30 patients, 
1. Avalambagam was affected in all cases 100% due to derangement of other Iyya‘s. 
2. Tharpagam was affected in 46.7% cases   due to poor eye to eye contact 
Ezhu udarkattugal 
Out of 30 patients, 
1. Saaram was affected in 13.4%   due to poor appetite. 
2. Senneer was   affected in 6.7 % because of pallor of the eyes. 
3. Envagai thervugal 
4. Naadi has been   observed in  100% of cases had Kabavatha  naadi. 
5. Naa was affected in 10% of cases due to anemia 
6. Mozhi   was affected   in 66.7% cases as they had impaired communication skills 
7. Vizhi was affected in 46% cases due to poor eye to contact. 
8. Malam was affected in 6.7% of the cases and they had contipation 
Neikuri 
      According to Neikuri 
1. Vatham neer was observed in 10% of cases. 
2. Pitham neer was observed in 6.7% of cases. 
3. Kabam neer was observed in 83.3% of cases. 
     Majority of the cases (83.3%) proves that the disease was due to derangement of kabam. 
 
Clinical manifestation 
       Among  the  30 cases , Among  the  30 cases , 100%  of  the  cases  had  Mantha sanni 
(ASD) and  19.3%of   the  cases  had   Social impairment ,20.3% of  the cases  had   
emotional changes, 19.9%of  the cases  had  impaired communication skalls, 19.3% of the 
cases had behavioural problems, 19.6% of the cases had sensory aspects.  
Statistical Analysis: 
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 There is significant difference between before and after treatment on clinical 
assessment parameter score i.e 86% improvement in this score after treatment 
 
 So it is safe to be administrated in children. There is no adverse effect produced by 
the trial drug Kuruver kudineer during the entire course of treatment. The result of this study 
reveals that the trial drug Kuruver kudineer is having a significant effect in the treatment of 
patients with Mantha sanni. Thus clinically there was satisfactory improvement in all the 
cases and no adverse effects were noted. At the end of the treatment all the patients were 
advised to contact the outpatient department of kuzhandhai maruthuvam for further follow 
up. 
Advice –Dietary and Habitual 
The patients were advised  
1. To avoid Gluten foods 
2. To avoid casein foods 
3. To avoid contaminated food and water. 
4. To drink jeera water and almond shake 
5. Increase intake of vitamins and minerals 
      
                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
136 
 
7. SUMMARY 
 A child who has been determined to require special attention is called as Special 
children. Children with multiple disabilities assossiated with impairment in social, cognitive 
skills, communication skills, behavioural changes and sensory issues called Autism spectrum 
disorder. Many Allopatyhic medications like respiridon, valporic acid are widely used for 
ASD. Not all the patients benefit from this treatment. However this drug has to shown 
undesirable side effects. 
 It is in the text that we have undertaken a review of the Siddha formulation which 
could help management of ASD.In the view of the abovde, great efforts have been made to 
find out the Siddha medicine and methologies to improve the life styles of ASD children.  
 The available literature on Manthasanni reveals that this is a disease of Autism 
spectrum disorder. For the purpose of study about Mantha sanni, 30 patients of both sexes 
were selected between the age group of 3-12 years. The study revealed that the incidence of 
the disease is greater in the age group of 3-6 years.  
  The study revealed that.43%of the cases belonged to high socio economic status. 
Regarding unknown aetiology 100% of the cases developed diseases after the age of one and 
half years.  In Uyir thathukkal vatham, pitham, kabam were affected in 100% of cases. 
In Udal thathukkal Saram was affected in 2.6% cases. In Envagai thervugal, Neikuri 
indicated kabaneer (Pearl like shape) in all the cases. 
     Patients attending the kuzhandhai maruthuvam OPD of Ayothidoss 
Pandithar Hospital, NIS having the complaints of Mantha sanni is diagnosed and taken for 
this study. Clinical diagnosis of Mantha sanni is done on the basis of clinical feature 
described in Balavagadam text. 
                 Autism is an umbrella term for Autism spectrum disorder which is charscterised by 
Constant problem with social communication and interactions across a variety of contexts 
Early onset of symptoms (typically in the first two years of life).Repetitive, restricted 
patterns of behaviour, Activities and interests. Symptoms that cause major impairment in 
social, educational and other important area of functioning 
 It is called a spectrum because of the wide range of symptoms and impairment level 
in children can have. Some are only mildly affected by their symptoms, while the other 
children are severely disabled.   Diagnosis has been made based on the specially prepared 
proforma, which includes all clinical signs and symptoms of the disease.A detailed history 
has been taken and recorded.  
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 Clinical studies were carried out after obtaining proper permission from IEC of 
National Institute of Siddha via IEC number NIS/IEC/2016/11-19/ 14.10.2016 and the trial 
was registered in Clinical trial registry of India via CTRI number CTRI/2017/05/008698. The 
authentications of the new drugs are obtained from the Medicinal Botanist of NIS and the 
medicine is prepared in the Gunapadam laboratory of NIS under the guidance and superviser 
of the guide. Physicochemical and Biochemical analysis for the drug has been carried out. 
       In treatment aspect all the 30 cases were treated with Kuruver kudineer internally and 
Sambrani and mysatchi pugai (externally) for an average of 90days.The observation made 
during this study showed that the trial medicine was clinically effective.  
 After the treatment period of 3 months ,the Summary of case study were shown in all 
the 30 ASD children are improved cognitive functions, eye to eye contact and reduced 
hyperactivity behaviour. There was sitting tolerance, enhanced the mind calming activity. 
Able to mingle the other children and try to speak the verbal with limited skills and having 
good sound sleep. So the Siddha internal and external therapies are enhancing the ‗quality of 
life‘ of ASD childrenThe potency of drug was studied by pharmacological, phytochemical, 
physicochemical and biochemical analysis. It showed that the drug has good action. The drug 
also has Anxiolytic activity. All the patients showed very good response. No patients 
developed any adverse effects. The action of trial drug and progress in the patients was 
encouraging 
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8. CONCLUSION 
 In this study, results were found to be improvement  in all the cases.No adverse 
effects were noticed during the treatment.Further follow up of these patients showed good 
recovery and fine improvement.The preparation of the medicine is simple as well as 
economical.The trial drug has anxyiolytic actions. So it is concluded that for the disease 
Mantha sanni, the treatment with Kuruver kudineer is good, in the view of efficacy and 
safety. 
 The Global burden of Mantha sanni (Autism spectrum disorder), increasing 
prevalence and its impact in reducing the quality of life in children has prompted the author 
to choose an efficient and nutritive drug which is believed to good in central nervous system.  
The treatment of Mantha sanni with Kuruver Kudineer has showed good response with no 
adverse effect, very effective and simple to administer.  
 This has, in turn, provided a golden opportunity for new drug established in 
themanagement of Mantha sanni. 
 Our perception of autism has evolved over time. Sixty years ago autism was nothing 
more than an unrecognized developmental delay generally lumped in with mental retardation.  
Today it is recognized as an independent neurologically based disorder of significance, a 
major public health problem, and a topic of much research. So we will overcome this disease 
by regular practice of Siddha treatment and also with help of Role of Families, Educational 
services, Effective Interventions, Public Policies, Personal preparation. 
 Further study is recommended for scientific validation to prove its clinical efficacyin 
multicenter clinical study. 
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9. RECOMMENDATIONS 
 
 As with research work presented in this thesis has answered many questions of Siddha 
medicine and methodologies in clinical parameters however, in doing so it has created even 
more questions and areas for further research. Further research not only must the outcome 
measures to be valid and reliable, but they must be relavant to the child and family 
concerened. 
 
1. Further studies of the efficacy of the combined use of kuruver kudineer as Internal, 
sambrani thuvalai and mysatchi pugai as External in the management of children with 
ASD should use a randomized controlled study design in multicentre which is the 
gold standard for clinical research. 
 
2. We are strongly recommended need for further research as there are not reported 
studies are available on effect of Siddha medicines which focuses on Speech and 
language, Cognition, Social relationship, behavioural patterns and Sensory aspects in 
Children with ASD. This research has shown the value of providing siddha medicines 
with these children and they have developed somescope for further research in above 
aspects. 
 
3. Need to scrutinize and produce the siddha philosophical guidelines towards the 
management of children with ASD which consists of complete full information and 
management of these children with traditional approach for physicians and parents 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
Clinical Evaluation of  Kuruver Kudineer  (Internal Medicine) , Sambrani Thuvalai 
And Mysatchi Pugai ( External Medicine) For Mantha Sanni In Children. 
FORM  I – SCREENING FORM 
 
Principle Investigator:  Dr.G.Dharshini priya 
Clinical trial registry no: CTRI/2017/05/008698    Serial.No: 
 
DATE OP.NO 
/ IP.NO 
NAME AGE / 
SEX 
DATE OF 
ENROLLMENT  
INFORMANT 
 
RELIABLITY 
          
 
 
INCLUSION CRETERIA: 
                 YES               NO                               
Children of age group under 3- 12 years                                       
Impaired social interaction                                                            
Mild to Moderate aggressiveness                                                           
Repetitive behaviour                                                                      
Lack of eye contact                                                                        
Blabble sound                                                                                
Clinically diagnosed as a ASD                                                      
 
Child will be include 4 or more criteria for this clinical trial study 
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EXCLUSION CRITERIA: 
      YES                          NO 
Epilepsy                                                                                       
Severe aggressiveness                                                                  
Cerebral palsy                                                                               
Congenital heart disease                                                               
 
 
ADMITTED TO TRIAL:  YES           NO              
 
 IF YES, SERIAL NO:  
OP NO / IP NO:   
 
                                                            Signature of the Investigator:                            
    Date:                                                                 
                                                                       Signature of the Guide: 
    Station:                                          
                                                                       Signature of the HOD:  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM  
FORM  II – CONSENT FORM 
CERTIFICATE BY INVESTIGATOR 
 I certify that I have disclosed all the details about the study in the terms readily 
understood by the parent/guardian 
Signature  _________________ 
Date   _________________ 
Name  _________________ 
CONSENT BY PARENT 
 I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial, and the nature of drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my son/daughter body functions. 
 I am aware of my right to OPD my son/daughter out of the trail at any time during the 
course of the trail without having to give the reasons for doing so.  
 I, exercising my free power of choice, hereby give my consent to include my 
son/daughter as a subject in the clinical trial of ―clinical evaluation of Kuruver kudineer 
(internal medicine), Sambrani thuvalai and Mysatchi pugai (external medicine) 
 
Date:      Signature  __________________ 
      Name   __________________ 
      Signature of witness  __________________ 
      Name   __________________ 
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Njrpa rpj;jkUj;Jt epWtdk; 
mNahj;jpjhr gz;bjH kUj;Jt epWtdk; 
Foe;ij kUj;Jtj;Jiw 
gupfupg;Gj; jpwidf; fz;lwpAk; kUj;Jt Ma;T 
xg;Gjy; gbtk; - II 
Ma;thsuhy; rhd;wspf;fg;gl;lJ 
ehd; ,e;j kUj;Jt Ma;itFwpj;j midj;J tpguq;fisAk; Foe;ijapd; 
ngw;NwhUf;F GupAk; tifapy; vLj;Jiuj;Njd; vd cWjp mspf;fpNwd; 
Njjp :                      ifnahg;gk;;: 
,lk ;:                      ngaH : 
Nehahspapd; ngw;Nwhh; xg;Gjy; gbtk; 
vd;dplk; ,e;j kUj;Jt Ma;tpd; fhuzj;ijAk;> kUe;jpd; jd;ik kw;Wk; 
kUj;Jt topKiwg; gw;wpAk;> ,e;j kUj;Jtj;ij njhlu;e;J vdJ 
Foe;ijapd; cly;> ,af;fj;ijf; fz;fhzpf;fTk;> mjid ghJfhf;f 
gad;gLk; kUj;Jt Ma;Tf;$lg; gupNrhjidfs; gw;wpAk; jpUg;jp mspf;Fk; 
Ma;T kUj;Jtuhy; tpsf;fpf; $wg;gl;lJ. 
Ehd; ,e;j kUj;Jt Ma;tpd; NghJ fhuzk; vJTk; $whky; vg;NghJ 
Ntz;LkhdhYk; vd; Foe;ijia tpLtpj;Jf; nfhs;Sk; cupikia 
njupe;jpUf;fpNwd;;;;. 
ehd; vd;Dila Rje;jpukhf Nju;T nra;Ak; cupikiaf; nfhz;L         
ke;j re;ep Neha;f;fhd FUNtH FbePu; (cs; kUe;J) kw;Wk; rhk;gpuhzp 
Jthiy> ikrhl;rp Gif (ntspkUe;J) gupfupg;G jpwidf; fz;lwpAk; 
kUj;Jt Ma;Tf;F vdJ Foe;ijia  cl;gLj;j xg;Gjy; mspf;fpNwd;. 
Njjp:                         ngw;NwhH ngaH  : 
 
,lk;:         ifnahg;gk;   :  
 
                rhl;rpf;fhuH ngau; : 
          ifnahg;gk;    : 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
Clinical Evaluation of  Kuruver Kudineer  (Internal Medicine) , Sambrani Thuvalai 
And Mysatchi Pugai ( External Medicine) For Mantha Sanni In Children. 
FORM  III -  CASE REPORT FORM 
Principle Investigator: Dr.G.Dharshini priya 
Clinical trial registry no: CTRI/2017/05/008698    Serial.No: 
DATE OP.NO / IP.NO NAME DATE OF 
BIRTH 
AGE /SEX 
     
 
FATHER/ 
MOTHER/ 
GAURDIAN 
NAME 
OCCUPATION 
AND INCOME 
RELIGION POSTAL 
ADDRESS AND 
CONTACT NO. 
RELAIBILITY 
     
 
Present Complaints and Duration : 
 
 
 
 
 
H/O of Past Illness : 
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 Medical History :  
Any Medical history      YES                No   
If Yes, Details 
 
Immunisation History : 
Immunisation        Complete      Incomplete        Complete but time Lag  
 
Familial History : 
Any relevant Hereditary /Family History       Yes               No  
If Yes, Details  
 
Food Habits : 
        Vegetarian                       Non vegetarian                         Mixed  
 
Body Measurements : 
PARAMETERS UNIT EXPECTED HEIGHT 
AND WEIGHT 
CALCULATED BY 
WEECH’S FORMULA 
 
Height in cm 
  
 
Weight in Kg 
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Habits : 
1. Picca                              Yes                   No    
2. Nail biting                      Yes                   No    
3. Bowel movements          Yes                  No     
4. Thumb sucking               Yes                 No     
5. Enuresis                          Yes                   No    
 
Vital signs : 
1. Pulse rate              - 
2. Heart rate              - 
3. Respiratory Rate   - 
4. Temperature          - 
 
Examinations: 
GENERAL 
EXAMINATION 
NORMAL ABNORMAL IF ABNORMAL,  PROVIDE 
BREIF DESCRIPTION AND 
RECORD, IF  CLINICALLY 
SIGNIFICAL OR NOT 
General Appearance 
  
 
Skin And Nails 
  
 
Eyes, Ears, Nose and 
Throat   
 
Head and Neck 
  
 
Pedal Oedema 
  
 
Lymphadenopathy 
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SYSTEMIC 
EXAMINATION 
NORMAL ABNORMAL IF ABNORMAL,  PROVIDE 
BREIF DESCRIPTION AND 
RECORD, IF  CLINICALLY 
SIGNIFICAL OR NOT 
Respiratory System 
  
 
Cardiovascular 
System   
 
Gastro intestinal 
System   
 
Musculo skeletal 
System   
 
Central Nervous 
System   
 
Endocrine System 
  
 
If Others , Specify  
 
 
HIGHER 
INTELLECTUALL 
FUNCTIONS 
NORMAL ABNORMAL IF ABNORMAL,  PROVIDE 
BREIF DESCRIPTION AND 
RECORD, IF  CLINICALLY 
SIGNIFICAL OR NOT 
Consciousness 
  
 
Orientation 
  
 
Memory 
  
 
Language 
  
 
Sleep pattern 
  
 
Handedness 
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Haematology : 
Clinical Haematology Laboratory Test Performed?       Yes              No  
                         If not, Explain _________________________________________________ 
Date of the Sample   : 
Time of the Sample   : 
HAEMATOLOGY VALUE UNIT IF  INDICATED AS OUT OF 
NORMAL RANGE ON 
REPORT, PLEASE STATE IF 
CLINICALLY SIGNIFICANT 
WBC   
YES        NO  
RBC   
 YES           NO  
Hb   
YES         NO  
HCT   
YES         NO  
MCV   
YES          NO  
MCH   
YES         NO  
PLT   
YES         NO  
NEUTROPHILS   
YES        NO  
LYMPHOCYTES   
YES         NO  
MONOCYTES   
YES         NO  
EOSINOPHILS   
YES         NO  
BASOPHILS   
YES         NO  
RETICULOCYTES   
YES         NO  
OTHER TEST   
       YES         NO  
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SIDDHA ASSESSMENT 
பருவங்கள் ஆண் குழந்தை பபண் குழந்தை 
இயல்பு பாதிப்பு இயல்பு பாதிப்பு 
1. கா஧்பு   
2. செங்கீரப   
3. தா஬்   
4. ெ஧்஧ாணி   
5. முதத்ந்   
6. வாபார஦   
7. அந்புலி   
8. சிறு஧ர஫/ கழங்கு   
9. சி஫்றி஬்/ 
அந்நார஦ 
  
10. சிறுததப/் ஊஞ்ெ஬்   
 
Nilam:-  
Kurinji        Mullai  Marutham       Neithal       Paalai  
Kaala Iyalbu:-  
            Kaarkalam          Koothirkaalam               Munpanikaalam     
    Pinpanikaalam                Illavenirkaalam            Muthuvenirkaalam  
Yaakai:- 
 Vatham         Vatha Pitham          Vatha Kabam         
 Pitham           Pitha vatham           Pitha Kabam         
 Kabam                       Kaba Vatham                 Kaba Pitham         
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Gunam:-  
 Sathuvam  Rasatham  Thamasam  
 
Pori / Pulangal:- 
  Normal Affected  Normal Affected                  Remarks 
Mei / unarvu        
Vaai / suvai        
Kan / parvai        
Mooku/ natram        
Sevi / olli        
 
 
Kanmendhirium / Kanmavidayam 
           Normal         Affected         Normal            Affected  Remarks 
Kai / dhanam                    
Kaal / ghamanam        
Vaai / vaaku         
Eruvaai / visarkam        
Karuvaai /anantham          
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UYIR THATHUKKAL: 
Vatham: 
   Normal   Affected  Remarks 
Pranan                 
Abanan     
Viyanan     
Uthanan     
Samanan     
Nagan      
Koorman     
Kirukaran     
Devathathan     
Dhanajeyan         
 
Pitham:  
   Normal Affected  Remarks 
Analam     
Ranjagam      
Saathagam     
Alosagam     
Prasagam     
160 
 
Kabam:     
   Normal Affected  Remarks 
Avalambagam       
Kilethagam     
Pothagam     
Tharpagam     
Santhigam     
 
UDALTHATHUKKAL: 
 
           Normal          Affected  Remarks 
Saaram     
Senneer        
Oon       
Kozhuppu     
Enbu      
Moolai      
Sukilam / Suronitham                 
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ENVAGAI THERVUGAL: 
                            Normal  Affected  Remarks 
Naa  
 Niram               
 Thanmai                
 Suvai                      
Niram                                
Mozhi                  
Vizhi                             
     Niram               
   Thanmai       
   Paarvai            
            Sparisam        
 
 
Malam 
 Niram   Normal  Affected  
 Nurai   Normal  Affected  
 Elagal   Normal  Affected  
 Erugal   Normal  Affected  
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Moothiram 
Neerkuri:       Niram   Normal  Affected  
  Edai   Normal  Affected   
  Nurai             Normal   Affected  
  Manam            Normal    Affected  
  Enjal       Normal  Affected   
 
Neikuri: 
  Vatham     
  Pitham      
  Kabam      
  Others     __________________ 
 
Naadi: 
 
End of the Trail: 
Date of trial completion/withdrawal: 
Date last trial medication given: 
 
 Clinical Assessment parameter (0th day, 30th day , 60th day, 90th day) 
          
 
Date:       Signature of Investigator 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
CLINICAL ASSESSMENT PARAMETERS FOR AUTISM SPECTRUM DISORDER 
IN CHILDREN 
(0TH DAY, 30TH DAY, 60TH DAY, 90TH DAY) 
 
 
Principle Investigator : Dr.G.Dharshini priya 
Clinical trial registry no:  CTRI/2017/05/008698         Serial.No: 
 
 
DATE 
 
OP.NO/ 
IP.NO 
 
NAME 
 
AGE/SEX 
 
DATE OF ENROLLMENT AND 
DATE OF COMPLETION 
 
INFORMANT 
 
RELAIABILITY 
       
 
S.NO 
 
SCALE 
 
SKILLS 
(5) 
0 
(10) 
1 
(15) 
2 
(20) 
3 
(25) 
4 
 
1. 
 
SOCIAL 
RELATIONSHIP 
AND RECIPROCITY 
Eye contact      
Social smile      
Solitary and repetitive activities      
 Social interaction      
Peer relationship      
 
2. 
 
EMOTIONAL 
RESPONSIVENESS 
Inappropriate Emotional response      
Exaggerated emotions      
Self-stimulating emotions      
Fear for danger      
Excited for no apparent reasons      
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Severe 
(125-249) 
Moderate to 
severe 
(250-374) 
 
Mild to 
Moderate  
(375-499) 
Mild  
(500-624) 
Normal to 
Mild  
( >625) 
     
 
 
 
3. 
 
SPEECH, 
LANGUAGE AND 
COMMUNICATION 
SKILLS  
 Non-verbal language to communicate the 
others 
     
Stereotyped and repetitive use of language      
Unusual noises      
Meaningless words      
Understand the real meaning of  
communication 
     
 
4.  
 
BEHAVIOURAL 
PATTERNS 
Hyperactivity and restlessness      
Aggressive  behaviour      
Attachment to inanimate objects      
 Self-injurious behaviour      
temper tantrums      
 
5. 
 
SENSORY ASPECTS 
 Unusual visions      
Stares into space for long periods of time      
Insensitive to pain      
Responds to object       
Tracking objects 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANITHAR HOSPITAL, CHENNAI 600 047. 
FORM IV PATIENT INFORMATION SHEET 
Name of Principal Investigator       : _____________________________ 
Name of the institute                        : National Institute of Siddha, 
     Tambaram Sanatorium, 
     Chennai-47. 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN CLINICAL 
TRIAL. 
I, ________________________________________Studying as a PG Scholar at National 
Institute of Siddha, Tambaram Sanatorium, doing a clinical trial entitled on the study 
“Mantha Sanni” (Autism Spectrum Disorder). 
―Mantha sanni (ASD) ―a brain based disorder. It is an important socio behavioural problem 
affecting the children and characterized by difficulties in social interaction, verbal and non 
verbal communication and repetitive behaviour.   
As per the siddha text book Kuzhandhai Maruthuvam (Bala vaagadam), Autism is termed as 
Mantha sanni which is respectively ந஥த்ந் எ஦்஧து அருவ ஥ிர஬யி஬் 
அககக்ருவினாகின ந஦ந் , புதத்ி , அகங்காபந், சிதத்திலுந் ந஥த்ந் & 
ெ஦்஦ி எ஦்஧து  அறிவு க஬கக்ந், வான் பித஫்஫஬், இரை விைாந஬் 
அ஬றுத஬்.  The symptoms of ந஥த் ெ஦்஦ி are about resembled with Autism Spectrum 
Disorder (ASD).we are treating with Brami nei, Amukura tablet, Muthuchipi parpam in our 
OPD.  
So I would like to conduct an open clinical trial on Mantha sanni (ASD) with the Internal 
medicine Kuruver Kudineer which is mentioned in the Siddha literature of  Aathma 
ratchamirthammenum vaithya sarasangiragam- Kandha saami mudhaliyaar Pg.no: 265 
and external therapy  Sambrani Thuvalai & Mysatchi pugai respectively in         
Thanvanthri thylam – 500,Thanvanthri , P.no:29 &  Kuzhandhai Maruthuvam (Bala 
vaagadam) k.s.Murugesha Muthaliyaar, Maru . Pon. Guru.sironmani P.no: 168. 
In this regard, I would like to ask you few questions. I will maintain confidentiality of your 
comments and data obtained. Taking part in the study is voluntary. No compensation will be 
paid to you for taking part in this study. It may be benefit to our community, as it may help us 
to understand the problem of defaulters and potential solutions. 
If you agree your child to be a participant in this study, he/she will be included in the study 
primarily by signing the consent form and then you will be given the internal medicine ― 
clinical evaluation of  kuruver kudineer (internal medicine)  [3 to 6 years - 30 ml,  6 to 9 
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years - 40 ml, 9 to 12 years -50 ml -twice a day]  and Sambrani Thuvalai and Mysatchi pugai 
( external medicine). The medicine will be provided free of cost. Children will attend the 
OPD regularly or admitted IPD for external therapy . If you are not willing to take part of this 
study you will be treated with the medicine available in NIS with full care. 
The trail drug contain the following ingredients such asவவட்டிவவர் (Vettivera zizanoides), 
வியா஫ிச்சு (Plectranthes vettiveroides) , சுக்கு (Zingiber officinalae ) , பற்பைாகம் ( Hedyotis 
corymbosa ) , சிறுவதக்கு ( Clerodendrum seratum  ) 
Most of the ingredients of Mantha sanni possess the anxiolytic activity, antioxidant, analgesic 
and CNS depressant which may be helpful in calming the brain. The raw drugs will be 
purchased from a reputed country shop and after purification; the medicine will be prepared 
in the Gunapadam laboratory of NIS under the proper guidance of the guide. 
The information I am collecting in this study will remain between you and the principal 
investigator (myself). I will ask you few questions through a questionnaire. The questionnaire 
will take approximately 1 hour of your time. 
If you wish to find out more about this study before taking part, you can ask me all the 
questions you want or contact Dr.G.DHARSHINI PRIYA, III yr PG Scholar .principal 
investigator of this study through 9994998821.Till now there is no adverse effect noted with 
this medicine. However if you noticed your child has any illness you can contact through 
phone number at any time. You can also   contact the Member-secretary of Ethics committee, 
National Institute Siddha, Chennai 600047, Tel no: 91-44-22380789, for rights and 
participation in the study. 
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jfty; gbtk; 
         ke;j re;ep Neha;f;fhd rpj;j kUe;Jfspd; FUNtH FbePu;  
(cs; kUe;J) kw;Wk; rhk;gpuhzp Jthiy> ikrhl;rp Gif (ntspkUe;J) 
gupfupg;G jpwidf; fz;lwpAk; kUj;Jt Ma;tpw;fhd jfty; gbtk;. 
 
Kjd;ik Muha;r;rpahsH ngaH : Dr.f.jH\pdp gpupah 
epWtddj;jpd; ngaH         : Njrpa rpj;j kUj;Jt epWtdk;> 
                          jhk;guk; rdl;Nlhupak;> 
                                nrd;id. 
Njrpa rpj;j kUj;Jt epWtdj;jpy; gl;l Nkw;gbg;G gapd;W tUk; ehd; 
ke;j re;ep vd;Dk; Nehapy; kUj;Jt Muha;r;rpapy; <Lgl;Ls;Nsd;. ,e;j 
Muha;r;rp rk;ke;jkhf rpy Nfs;tpfs; Nfl;fTk;> Njitahd Ma;tf 
gupNrhjidf;F jq;fsJ Foe;ijia cl;gLj;jTk; cs;Nsd;. 
ke;j re;ep (ASD) vd;gJ %is rhHe;j FiwghL. ,J For;ijfis 
ghjpf;Fk; xU Kf;fpa r%f elj;ijg; gpur;ridfs; > tha;nkhop njhlHG 
rpf;fy;fs; kw;Wk; r%f Clhly; xNu nraiyj; jpUk;gr; nra;Ak; 
mwpFwpfshFk;. 
Foe;ij kUj;Jtk; (ghy thflk;) rpj;j kUj;Jt ciu Vl;bd;gb ke;jk; 
vd;gJ mUt epiyapy; mff;fUtpahfpa kdk;> Gj;jp> mfq;fhuk;> 
rpj;jjpYk; ke;jk; kw;;Wk; rd;dp vd;gJ mwpT fyf;fk;> tha; gpjw;wy;> 
,il tplhJ myWjy;. NkYk; ,f;FwpFzq;fs; KiwNa Ml;brk; 
vdgLtJld; xj;Js;sd. ,t;tpj FwpFzq;fs; cs;s Foe;ijf;F 
mKf;Fuh nghb> gpukp nea; Nghd;w kUe;jpid ,e;j kUj;Jtkid 
tof;fpy; cs;sJ. 
cq;fs; Foe;ij rk;ge;jkhf ehd; jq;fsplk; rpy Nfs;tpfisf; Nfl;f 
Ntz;Lk;. ,e;j Ma;tpy; gq;Nfw;gJ jq;fspd; nrhe;j tpUg;gj;jpw;FupaJ. 
NkYk; cq;fs; Foe;ijapd; midj;J tptuq;fSk; ufrpakhf 
itf;fg;gLk; vd cWjp mspf;fpNwd;.,jpy; gazg;gb Kjypa ve;j 
cjtp njhifAk; toq;fg;gl khl;lhJ. ,e;j Muha;r;rpapd; NghJ 
jq;fsJ Foe;ijapd; clYf;F NtW ghjpg;G gl;rj;jpy; Njrpa rpj;j 
kUj;Jtkidapy; jf;f rpfpr;ir mspf;fg;gLk;. 
,e;j Muha;r;rpapy; cq;fs; Foe;ij gq;Nfw;ghsuhf ,Ug;gjw;F ePq;fs; 
xg;Gf; nfhz;L ,g;gbtj;jpy; ifnahg;gk; ,Ltjd; %yk; FUNtu; FbePu; 
cs; kUe;jhf 90 ehl;fs; vLf;f Ntz;Lk;  ( 3-6 Mz;Lfs; - 30 kp;.yp.> 
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7-9 Mz;Lfs; - 40 kp;.yp.> 10-12 Mz;Lfs; - 50 kp;.yp.>) NkYk; rhk;gpuhzp 
Jthiy> ikrhl;rp Gif ntspg;Gw rpfpr;irahf 90 ehl;fs; mspf;f 
Ntz;Lk;. jq;fspd; tpUg;gj;jpw;F Vw;g ntsp NehahsH gpupT (m) cs; 
Nehahsh; gphptpy; fye;J rpfpr;ir Nkw;nfhs;syhk;. ,jpy; fye;Js;s 
kUe;Jg;nghUl;fspd; nray;ghL ika euk;G kz;lyj;ij rhptu ,af;fp 
%isia mikjpgLj;Jk;. 
,k;kUe;J nghUl;fis ehl;L kUe;J filapypUe;J thq;fp gpd;G 
Fzghlk; Ma;tfj;jpy; cs;s jf;f kUj;Jt mjpfhupapd; 
topfhl;Ljypd;%yk; kUe;J jahupf;fg;gLk;. 
 ,e;j Muha;r;rpapy; Nehapduhf Nru;e;j gpwF cq;fSf;F tUg;gk; 
,y;iynadpy; vg;NghJ Ntz;LkhdhYk; jq;fsJ Foe;ijia tpyf;fpf; 
nfhs;syhk;. 
 ,e;j Muha;r;rp rk;ke;jkhf kw;w tptuq;fis mwptjw;F Kjd;ik 
Muha;r;rpahsuhd Dr. f.ju;\pdp gpupah (gl;l Nkw;gbg;ghsu; Foe;ij 
kUj;Jt gpupT) ifNgrp vz; : 9994998821 njhlupG nfhs;syhk;. 
 NkYk; ,e;j Muha;r;rpf;F IEC (epWtd ePjpnewpFO) rhd;W 
ngwg;gl;Ls;sJ; ,e;j kUe;J rpwg;ghf ke;j re;ep Neha;f;fhf 
mq;fPfupf;fg;gl;l rpj;j kUj;Jt நூypy; $wg;gl;Ls;sJ. NkYk; czT 
Kiwapy; gj;jpak; fhf;FkhW mwpTWj;jg;gLfpwJ. 
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 NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
Clinical Evaluation Of  Kuruver Kudineer  (Internal Medicine) , Sambrani Thuvalai 
And Mysatchi Pugai ( External Medicine) For Mantha Sanni In Children. 
DRUG COMPLAINCE-VI 
Protocol no:     Principle Investigator: Dr.G.Dharshini priya 
Clinical trial registry no: CTRI/2017/05/008698 Serial.No: 
 
DATE OP.NO / 
IP.NO 
NAME AGE / 
SEX 
DATE OF 
ENROLLMENT 
&DATE OF 
COMPLETION 
INFORMANT 
 
RELIABLITY 
        
 
Internal medicine: 
NAME OF THE DRUG   : kuruver kudineer  
FORM OF THE DRUG   : liquid 
ADMINISTRATION       : PER ORAL 
DOSE & DURATION      : 3 to 6 years - 30 ml(bds) 
                                             6 to 9 years - 40 ml(bds) 
                                             9 to 12 years -50 ml(bds) for 96 days 
NO. OF DRUG PACKETS GIVEN:   ______ 
NO. OF DRUG PACKETS RETURNED: _____   
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External medicine : 
i)NAME OF THE DRUG: Sambrani thuvalai  
ADMINISTRATION: Thuvalai  
DURATION   : Once in a alternate days ( 21 days) 
ii) NAME OF THE DRUG: Mysatchi pugai 
ADMINISTRATION: fumigation 
DURATION   : Every Alternate Week  
 
 
 
 
Date:       Signature of Investigator 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
Clinical Evaluation of  Kuruver Kudineer  (Internal Medicine) , Sambrani Thuvalai 
And Mysatchi Pugai ( External Medicine) For Mantha Sanni In Children. 
FORM  VI– WITHDRAWAL FORM 
 
Principle Investigator:  Dr.G.Dharshini priya 
Clinical trial registry no: CTRI/2017/05/008698    Serial.No: 
 
DATE OP.NO 
/ IP.NO 
NAME AGE / 
SEX 
DATE OF 
ENROLLMENT  
INFORMANT 
 
RELIABLITY 
          
 
Date of trial commencement    : 
Date of withdrawal from trial   : 
Reason(s) for withdrawal   :  
Long absence at reporting   : Yes/ No 
Irregular treatment     : Yes/ No 
Shift of locality      : Yes/ No 
Complication adverse reactions if any : Yes/ No 
Exacerbation of symptoms   : Yes/ No 
 Patient not willing to continue             : Yes/ No 
 
Date:       Signature of Investigator 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
Clinical Evaluation Of  Kuruver Kudineer  (Internal Medicine) , Sambrani Thuvalai 
And Mysatchi Pugai ( External Medicine) For Mantha Sanni In Children.) 
FORM -VII ADVERSE REACTION  FORM 
 
Protocol no:     Principle Investigator: Dr.G.Dharshini priya 
Clinical trial registry no: CTRI/2017/05/008698 Serial.No: 
 
DATE OP.NO / 
IP.NO 
NAME AGE / 
SEX 
DATE OF 
ENROLLMENT 
&DATE OF 
COMPLETION 
INFORMANT 
 
RELIABLITY 
        
 
Date of trial commencement  : 
Date of withdrawal from trial   : 
Description of adverse reaction  : 
 
 
Date:                  Signature of Investigator 
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                                     FORM VIII – PHARMACOVIGILANCE FORM 
1. Patient / consumer identification (please complete or tick boxes below as appropriate) 
        NATIONAL PHARMACOVIGILANCE PROGRAMME FOR SIDDHA DRUGS 
 
 
Please note:  i.All consumers / patients and reporters information will remain confidential. 
         ii. It is requested to report all suspected reactions to the concerned, even 
if it does not have complete data, as soon as possible. 
Peripheral Center code:     State: 
 
Name  Father name Patient / Record 
No. 
Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / 
Age: 
Sex:     M / F  
Weight : 
Degam: 
 
 
2. Description of the suspected Adverse Reactions (please complete boxes below) 
 
Date and time  of 
initial observation 
 Season: 
Description of 
reaction   
 Geographical area: 
 
 
 
Reporting Form for Suspected Adverse Reactions to Siddha 
Drugs 
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3. List of all medicines / Formulations including drugs of other systems used by the 
patient during the reporting period: 
Medicine Daily 
dose 
Route of 
administration 
& Vehicle - 
Adjuvant 
Date  Diagnosis for 
which medicine 
taken  Starting Stopped 
Siddha      
Any other 
system of 
medicines 
     
 
4. Brief details of the Siddha Medicine which seems to be toxic: 
Details Drug – 1 Drug – 2 Drug - 3 
a) Name of the medicine    
b) Manufacturing unit 
and batch No. and date 
   
c) Expiry date    
d) Purchased and 
obtained from 
   
e) Composition of the 
formulation / Part of the 
drug used 
   
 
b) Dietary Restrictions if any 
c) Whether the drug is consumed under institutionally qualified medical supervision or used 
as self medication.  
d) Any other relevant information. 
5. Treatment provided for adverse reaction: 
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6. The result of the adverse reaction / side effect / untoward effects (please complete the 
boxes below) 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   
No. 
Reaction abated after drug stopped or dose reduced: 
Reaction reappeared after re introduction: 
 
 
Was the patient admitted to hospital? 
If yes, give name and address of 
hospital 
 
 
7. Any laboratory investigations done to evaluate other possibilities?  If yes specify:  
 
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition  
 
Any Others  
 
9. H/O previous allergies / Drug reactions:  
 
 
 
10. Other illness (please describe): 
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11. Identification of the reporter: 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / 
Attendant / Manufacturer /                                                                      
                                Distributor / Supplier / Any others (please specify) 
Name: 
 
Address: 
 
Telephone / E – mail if any : 
 
 
 
Signature of the reporter:          Date: 
 
 
Please send the completed form to:  
                              The Director 
                              National Institute of Siddha, 
(Pharmacovigilance Regional Centre For 
Siddha                        Medicine), 
                                                                          Tambaram Sanatorium, Chennai-600 047. 
 (O) 044-22381314  Fax : 044 – 
22381314 
        Website : www.nischennai.org 
Email: nischennaisiddha@yahoo.co.in 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * * * *  
   
 
Name & address of the RRC-
ASU/ PPC-ASU 
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This filled-in ADR report may be sent within one month of observation /occurrence of 
ADR   
 
 
 
 
 
 
 
 
Date:                                                                              
Station:  
Signature of the Investigator: 
Signature of the Lecturer:                                                  Signature of the HOD    
 
 
 
 
 
 
 
 
 
 
 
 
  
Who Can Report? 
 Any Health care professionals like Siddha Doctors /  
Nurses / Siddha Pharmacists / Patients etc.  
What to Report?  
 All reactions,  Drug interactions,  
Confidentiality  
 The patient’s identity will be held in strict confidence 
and protected to the fullest extent.  
 Submission of report will be taken up for remedial 
measures only not for legal claim  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
Clinical evaluation of Kuruverkudineer (internal medicine) ,Sambranithuvalai and 
Mysatchipugai ( external medicine)  for  MANTHA SANNI in children 
                                     FORM IV-DIETARY ADVICE FORM 
 
THINGS TO TAKE 
 
1. Increased intake  of omega 3 fatty acid 
2. Increase intake of vitamins and minerals 
3. Intake  of almond milk,Wallnut 
4. A natural food as organic which is easily digestable and absorbed 
5. Intake of Fresh fruits and Juices 
6. Drink Cumin seeds water 
7. Intake of all types spinaches weekly twice 
 
 
 
THINGS TO AVOID 
 
1. Gluten  like wheat should be avoided 
2. Caisen like dairy products , yoghurts and soy should be avoided 
3. Avoid junk food, pasta, pizza burger and artificial food items etc… 
4. Avoid broiler chicken and white sugar 
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PDF of Trial
CTRI Website URL - http://ctri.nic.in
Clinical Trial Details (PDF Generation Date :- Mon, 09 Jul 2018 09:33:00 GMT)
CTRI Number CTRI/2017/05/008698 [Registered on: 30/05/2017] - Trial Registered Prospectively
Last Modified On 29/05/2017
Post Graduate Thesis Yes
Type of Trial Interventional
Type of Study Siddha
Study Design Single Arm Trial
Public Title of Study Mantha sanni ( Autism Spectrum Disorder) in Children
Scientific Title of
Study
A Clinical Assessment And Evaluation Of Mantha Sanni (Autism Spectrum Disorder) with the
Siddha Therapeutic Management in Children.
Secondary IDs if Any Secondary ID Identifier
NIL NIL
Details of Principal
Investigator or overall
Trial Coordinator
(multi-center study)
Details of Principal Investigator
Name GDharshini priya
Designation Mantha Sanni - Autism Spectrum Disorder-[MS(ASD)]
Affiliation National institute of siddha
Address National institue of siddha , chennai. National institue of siddha ,
chennai.
Chennai
TAMIL NADU
600047
India
Phone 9994998821
Fax 09994998821
Email dharshini874@gmail.com
Details Contact
Person (Scientific
Query)
Details Contact Person (Scientific Query)
Name DrAArul Mozhi
Designation lecturer
Affiliation National institute of siddha
Address National institue of siddha , chennai. National institue of siddha ,
chennai.
Chennai
TAMIL NADU
600047
India
Phone 9500151930
Fax 9500151930
Email drarulmozhi@yahoo.co.in
Details Contact
Person (Public Query)
Details Contact Person (Public Query)
Name DrMMeenakshi sundaram
Designation Associative Professor
Affiliation National institute of Siddha
Address National institue of siddha , chennai. National institue of siddha ,
chennai.
Chennai
TAMIL NADU
600047
India
Phone 9940266442
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Fax 9940266442
Email mmssiddha@rediffmail.com
Source of Monetary or
Material Support
Source of Monetary or Material Support
> National institute of Siddha, Tambaram Sanatorium, Chennai-47
Primary Sponsor Primary Sponsor Details
Name DrGDharshini priya
Address National institute of Siddha, Chennai- 47
Type of Sponsor Research institution and hospital
Details of Secondary
Sponsor
Name Address
NIL NIL
Countries of
Recruitment
List of Countries
India
Sites of Study Name of Principal
Investigator 
Name of Site Site Address Phone/Fax/Email
DrGDharshini priya National institute of
Siddha
Department of
Kuzhandai
maruthuvam, Room no
:9
Chennai
TAMIL NADU
9994998821
9994998821
dharshini874@gmail.co
m
Details of Ethics
Committee
Name of Committee Approval Status Date of Approval Is Independent Ethics
Committee?
Institutional ethical
committee
Approved 14/10/2016 No
Regulatory Clearance
Status from DCGI
Status Date
Not Applicable No Date Specified
Health Condition /
Problems Studied
Health Type Condition
Patients Childern with Autism spectrum disorder
Intervention /
Comparator Agent
Type Name Details
Intervention Internal Medicine vettiver(Vettivera zizanoides)-
1/4 palam Vizhamichi
(Plectranthes vettiveroides ) -
1/4 palam Chukku (Zingiber
officinalae ) - 1/4 palam
Parpadagam( Hedyotis
corymbosa)- 1/4 palam
Siruthaekku ( Clerodendrum
seratum ) - 1/4 palam
Comparator Agent External medicine - Sambirani
Thuvali and Mysatchi Pugai
External therapy - 3 months
SAMBIRANI THUVALAI
-Velerukkan samoolam
(Caloptoria gigantea)
-Sambirani kudineer (Styrax
benzoin) -Vaeppam
ennai(Neem Oil) MYSATCHI
PUGAI -Mysatchi(Shorea
rubusta) -Agirkattai(Aquillaria
achallocha) -Sanni naayagam (
Nigella sativa)
-Sambirani(Styrax benzoin)
-velaiver (Cleome gynandra)
-sathisaaranai (Trianthema
184184 
PDF of Trial
CTRI Website URL - http://ctri.nic.in
decandra)
Inclusion Criteria Inclusion Criteria
Age From 3.00 Year(s)
Age To 12.00 Year(s)
Gender Both
Details • Children of age group under 3- 12 years
• Clinically diagnosed as a ASD
• Impaired social interaction
• Mild aggressive
• Repetitive behaviour
• Lack of eye contact
• Blabble sound
Exclusion Criteria Exclusion Criteria
Details • H/o epilepsy
• H/o severe aggressive with ADHD
• H/o cerebral palsy
• H/o congenital heart disease
• Any other serious illness
Method of Generating
Random Sequence
Not Applicable
Method of
Concealment
Blinding/Masking
Primary Outcome Outcome Timepoints
A Clinical Assessment and Evaluation of
ManthaSanni (Autism Spectrum Disorder) with
Siddha Therapeutic Management in Children
30 patients
Secondary Outcome Outcome Timepoints
To renovate the social impairment, eye contact
and to slow down the behaviour wise emotional,
repetitive hyperactive and blabble unwanted
echoes .
30 patients
Target Sample Size Total Sample Size=30
Sample Size from India=30
Phase of Trial Phase 3
Date of First
Enrollment (India)
05/06/2017
Date of First
Enrollment (Global)
No Date Specified
Estimated Duration of
Trial
Years=2
Months=0
Days=0
Recruitment Status of
Trial (Global)
Not Applicable
Recruitment Status of
Trial (India)
Not Yet Recruiting
Publication Details None yet
Brief Summary A Clinical Assessment and Evaluvation of Mantha Sanni (Autism Spectrum Disorder) with the
Siddha Therapeutic management in Children
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